0001213900-21-057191.txt : 20211108 0001213900-21-057191.hdr.sgml : 20211108 20211108082108 ACCESSION NUMBER: 0001213900-21-057191 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 48 CONFORMED PERIOD OF REPORT: 20210930 FILED AS OF DATE: 20211108 DATE AS OF CHANGE: 20211108 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Joway Health Industries Group Inc CENTRAL INDEX KEY: 0001263364 STANDARD INDUSTRIAL CLASSIFICATION: MISCELLANEOUS FABRICATED TEXTILE PRODUCTS [2390] IRS NUMBER: 980221494 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 333-108715 FILM NUMBER: 211386619 BUSINESS ADDRESS: STREET 1: NO 19 BAOWANG ROAD STREET 2: BAODI ECONOMIC DEVELOPMENT ZONE CITY: TIANJIN, PRC STATE: F4 ZIP: 300180 BUSINESS PHONE: 862258896888 MAIL ADDRESS: STREET 1: NO 19 BAOWANG ROAD STREET 2: BAODI ECONOMIC DEVELOPMENT ZONE CITY: TIANJIN, PRC STATE: F4 ZIP: 300180 FORMER COMPANY: FORMER CONFORMED NAME: G2 VENTURES INC DATE OF NAME CHANGE: 20030911 10-Q 1 f10q0921_jowayhealth.htm QUARTERLY REPORT

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 10-Q

 

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934.

 

For the Quarterly Period Ended September 30, 2021

 

or

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934.

 

Commission File Number: 333-108715

 

Joway Health Industries Group Inc.

(Exact Name of Registrant as Specified in Its Charter)

 

Nevada   98-0221494

(State or other jurisdiction of
incorporation or organization)

 

(I.R.S. Employer
Identification No.)

 

No.2, Baowang Road, Baodi Economic Development Zone

Tianjin, P.R. China 301800

(Address of principal executive offices) (Zip Code)

 

(86) 022-22533666

(Registrant’s telephone number, including area code)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
None   N/A   N/A

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter periods that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes      No  

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File to be submitted posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).     Yes       No   

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company filer. See definition of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer     Accelerated filer
Non-accelerated filer Smaller reporting company      
Emerging growth company 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes      No  

 

As of November 5, 2021, the registrant had 20,054,000 shares of common stock issued and outstanding.

 

 

 

 

 

 

JOWAY HEALTH INDUSTRIES GROUP INC.

 

QUARTERLY REPORT ON FORM 10-Q

 

September 30, 2021

 

TABLE OF CONTENTS

 

  PAGE
PART I - FINANCIAL INFORMATION  
   
Item 1. Financial Statements (unaudited) 1
     
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 2
     
Item 3. Quantitative and Qualitative Disclosures About Market Risk 7
     
Item 4. Controls and Procedures 7
     
PART II - OTHER INFORMATION  
   
Item 1. Legal Proceedings 8
     
Item 1A. Risk Factors 8
     
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 8
     
Item 3. Defaults Upon Senior Securities 8
     
Item 4. Mine Safety Disclosure 8
     
Item 5. Other Information 8
     
Item 6. Exhibits 8
     
SIGNATURES 9

 

i

 

 

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

 

Except for historical information, this report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Such forward-looking statements include, among others, those statements including the words “believes”, “anticipates”, “expects”, “intends”, “estimates”, “plans” and words of similar import. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.

 

Forward-looking statements are based on our current expectations and assumptions regarding our business, potential target businesses, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. We caution you therefore that you should not rely on any of these forward-looking statements as statements of historical fact or as guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements include changes in local, regional, national or global political, economic, business, competitive, market (supply and demand) and regulatory conditions.

 

A description of these and other risks and uncertainties that could affect our business appears in the section captioned “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020 which we filed with the Securities and Exchange Commission (“SEC”) on August 16, 2021 (the “Annual Report”). The risks and uncertainties described under “Risk Factors” are not exhaustive.

 

Given these uncertainties, readers of this Quarterly Report on Form 10-Q (“Quarterly Report”) are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future events or developments.

 

ii

 

 

PART I – FINANCIAL INFORMATION

 

Item 1. Financial Statements.

 

The accompanying unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States and the rules of the SEC, and should be read in conjunction with the audited financial statements and notes thereto contained in our Annual Report, as updated in subsequent filings we have made with the SEC. In the opinion of management, all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of financial position and the results of operations for the periods presented have been reflected herein. The results of operations for the periods presented are not necessarily indicative of the results to be expected for the full year.

 

JOWAY HEALTH INDUSTRIES GROUP INC.

 

CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

September 30, 2021 (UNAUDITED)

 

INDEX TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

Condensed Consolidated Balance Sheets at September 30, 2021 (Unaudited) and December 31, 2020 F-1
   
Condensed Consolidated Statements of Income and Comprehensive Income for the three months and nine months ended September 30, 2021 and 2020 (Unaudited) F-2
   
Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2021 and 2020 (Unaudited) F-3
   
Notes to Condensed Consolidated Financial Statements F-4 - F-13

 

1

 

 

JOWAY HEALTH INDUSTRIES GROUP INC.

 

BALANCE SHEETS

 

   September 30,   December 31, 
   2021   2020 
   (Unaudited)   (Audited) 
ASSETS        
         
CURRENT ASSETS:        
Receivable from related party  $
-
   $119,070 
Total current assets   
-
    119,070 
           
Total assets  $
-
   $119,070 
           
LIABILITIES AND STOCKHOLDERS' EQUITY          
           
CURRENT LIABILITIES:          
Special dividend payable  $
-
   $119,070 
Other payables   90,095    51,344 
Due to related parties   2,610    693,546 
Total current liabilities   92,705    863,960 
           
COMMITMENTS   
-
    
-
 
           
STOCKHOLDERS' EQUITY:          
Preferred stock - par value $0.001; 1,000,000 shares authorized; no shares issued and outstanding   
-
    
-
 
Common stock - par value $0.001; 200,000,000 shares authorized; 20,054,000 shares issued and outstanding at September 30, 2021 and December 31, 2020   20,054    20,054 
Additional paid-in-capital   7,228,862    6,469,236 
Accumulated deficit   (7,341,621)   (7,234,180)
Total stockholders' equity   (92,705)   (744,890)
Total liabilities and stockholders' equity  $
-
   $119,070 

 

The accompanying notes are an integral part of these unaudited consolidated financial statements

 

F-1

 

 

JOWAY HEALTH INDUSTRIES GROUP INC.

 

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

 

   Three Months Ended
September 30,
   Nine months ended
September 30,
 
   2021   2020   2021   2020 
   (Unaudited)   (Unaudited)   (Unaudited)   (Unaudited) 
REVENUES  $
-
   $
-
   $
-
   $
-
 
                     
COST OF REVENUES   
-
    
-
    
-
    
-
 
                     
GROSS PROFIT   
-
    
-
    
-
    
-
 
                     
General and administrative expenses   10,884    25,317    107,441    180,814 
OPERATING EXPENSES   10,884    25,317    107,441    180,814 
                     
LOSS FROM OPERATIONS   (10,884)   (25,317)   (107,441)   (180,814)
                     
Other expenses   
-
    (48)   
-
    (252)
OTHER LOSS, NET   
-
    (48)   
-
    (252)
                     
LOSS BEFORE INCOME TAXES   (10,884)   (25,365)   (107,441)   (181,066)
                     
INCOME TAXES   
-
    
-
    
-
    
-
 
                     
NET LOSS FROM CONTINUING OPERATIONS   (10,884)   (25,365)   (107,441)   (181,066)
                     
Discontinued operations:                    
Loss from operations of discontinued component, net of taxes   
-
    (169,330)   
-
    (548,155)
                     
NET LOSS   (10,884)   (194,695)   (107,441)   (729,221)
                     
OTHER COMPREHENSIVE LOSS:                    
Foreign currency translation adjustments   
-
    103,625    
-
    60,934 
                     
COMPREHENSIVE LOSS  $(10,884)  $(91,070)  $(107,441)  $(668,287)
                     
LOSS PER COMMON SHARE, BASIC AND DILUTED:                    
Continuing operations - Basic & diluted  $(0.00)  $(0.00)  $(0.01)  $(0.01)
Discontinued operations - Basic & diluted  $
-
   $(0.01)  $
-
   $(0.03)
                     
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING, BASIC AND DILUTED   20,054,000    20,054,000    20,054,000    20,054,000 

 

The accompanying notes are an integral part of these unaudited consolidated financial statements

 

F-2

 

 

JOWAY HEALTH INDUSTRIES GROUP INC.

 

CONSOLIDATED STATEMENTS OF CASH FLOWS

 

   Nine months ended
September 30,
 
   2021   2020 
   (Unaudited)   (Unaudited) 
CASH FLOWS FROM OPERATING ACTIVITIES:        
Net loss from continuing operations  $(107,441)  $(181,066)
Adjustments to reconcile net loss to net cash provided by operating activities          
          
Changes in operating assets and liabilities:          
Receivable from disposal of subsidiaries   119,070    
-
 
Special dividend payable   (119,070)   
-
 
Other payables   38,751    28,000 
Net cash used in operating activities   (68,690)   (153,066)
Net cash used in operating activities from discontinued component   
-
    (274,499)
Net cash provided by operating activities   (68,690)   (427,565)
           
CASH FLOWS FROM FINANCING ACTIVITIES:          
Due to related parties   68,690    153,065 
Net cash provided by financing activities   68,690    153,065 
Net cash provided by financing activities from discontinued component   
-
    281,753 
Net cash provided by financing activities   68,690    434,818 
           
EFFECT OF EXCHANGE RATE CHANGES ON CASH   
-
    (7,253)
           
NET INCREASE IN CASH   
-
    
-
 
           
CASH, beginning of period   
-
    
-
 
           
CASH, end of period  $
-
   $
-
 
           
SUPPLEMENTAL DISCLOSURES:          
           
Income taxes paid  $
-
   $
-
 
Interest paid  $
-
   $
-
 
NON-CASH TRANSACTIONS OF INVESTING AND FINANCING ACTIVITIES          
           
Related party loan released by Jinghe Zhang  $295,928   $
-
 
Related party loan released by Joway Shengshi  $463,698   $
-
 

 

The accompanying notes are an integral part of these unaudited consolidated financial statements

 

F-3

 

 

JOWAY HEALTH INDUSTRIES GROUP INC.

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

 

NOTE 1  – ORGANIZATION

 

The unaudited condensed consolidated financial statements include the financial statements of Joway Health Industries Group Inc. (referred to herein as “Joway Health”), its subsidiaries, and variable interest entities (“VIEs”) where Joway Health is deemed the primary beneficiary. Joway Health, its subsidiaries and VIEs are collectively referred to herein as the “Company”, “we” and “us”.

 

Joway Health (formerly G2 Ventures, Inc.) was originally incorporated under the laws of the State of Texas on March 21, 2003. On September 21, 2010, Joway Health entered into a Share Exchange Agreement (the “Share Exchange”) with the sole stockholder of Dynamic Elite International Limited. As a result of the Share Exchange, Dynamic Elite became a wholly-owned subsidiary of Joway Health and the stockholders of Dynamic Elite acquired approximately 76.08% of the issued and outstanding stock of Joway Health. The share exchange transaction resulted in the shareholders of Dynamic Elite acquiring a majority voting interest in Joway Health. Generally accepted accounting principles in the United States of America require that the company whose shareholders retain the majority interest in the combined business be treated as the acquirer for accounting purposes. The reverse acquisition process utilizes the capital structure of Joway Health and the assets and liabilities of Dynamic Elite recorded at historical cost. On December 22, 2010, Joway Health changed its jurisdiction of incorporation from the State of Texas to the State of Nevada.

 

Dynamic Elite International Limited (referred to herein as “Dynamic Elite”) was incorporated under the laws of the British Virgin Islands on June 2, 2010 as a limited liability company (a BVI company). Dynamic Elite engages in manufacturing and distributing tourmaline products in China. Its wholly owned subsidiary, Tianjin Junhe Management Consulting Co., Ltd. was incorporated on September 15, 2010 in Tianjin, People’s Republic of China (“PRC”). Other than the equity interest in Junhe Consulting, Dynamic Elite does not own any assets or conduct any operations.

 

Tianjin Junhe Management Consulting Co., Ltd. (referred to herein as “Junhe Consulting”) conducts its business through Tianjin Joway Shengshi Group Co., Ltd. that is consolidated as a variable interest entity.

 

Tianjin Joway Shengshi Group Co., Ltd. (referred to herein as “Joway Shengshi”) was incorporated in PRC on May 17, 2007. Joway Shengshi is currently owned 99% by Jinghe Zhang, the Company’s current CEO and President and 1% by Song Baogang. Joway Shengshi engages in manufacturing and distributing tourmaline products in China. Shenyang Joway Electronic Technology Co., Ltd., Tianjin Joway Decoration Engineering Co., Ltd. and Tianjin Oriental Shengtang Trading Import & Export Trading Co., Ltd are subsidiaries of Joway Shengshi.

 

Shenyang Joway Electronic Technology Co., Ltd. (referred to herein as “Joway Technology”) was originally named Liaoning Joway Technology Engineering Co., Ltd. which was incorporated on March 28, 2007 in PRC. The name was changed on June 22, 2011. It engages in the distribution of Tourmaline Activated Water Machines and Tourmaline Wellness Houses. Prior to July 25, 2010, Joway Shengshi owned 90.91% of Joway Technology. Joway Shengshi entered into a share acquisition agreement with Jingyun Chen, another stockholder of Joway Technology on July 25, 2010 to acquire the remaining 9.09% of the share of Joway Technology. As a result of the share acquisition, Joway Technology became a wholly-owned subsidiary of Joway Shengshi.

 

Tianjin Joway Decoration Engineering Co., Ltd. (referred to herein as “Joway Decoration”) was incorporated on April 22, 2009 in PRC. It engages in the distribution of Tourmaline Activated Water Machines, Tourmaline Wellness House for family use and Tourmaline Wellness House materials. Prior to July 9, 2010, Joway Shengshi owned 90% of Joway Decoration. Joway Shengshi entered into a share acquisition agreement with Jingyun Chen, another stockholder of Joway Decoration on July 9, 2010 to acquire the remaining 10% of the shares of Joway Decoration. As a result of the share acquisition, Joway Decoration became a wholly-owned subsidiary of Joway Shengshi. Jingyun Chen is currently the General Manager of Joway Decoration.

 

Tianjin Oriental Shengtang Import & Export Trading Co., Ltd. (referred to herein as “Shengtang Trading”) was incorporated on September 18, 2009 in the PRC. It engages in purchasing raw materials which it sells to other companies of the group. Prior to July 28, 2010, Joway Shengshi owned 95% of Shengtang Trading. Joway Shengshi entered into a share acquisition agreement with Wang Aiying, another stockholder of Shengtang Trading on July 28, 2010 to acquire the remaining 5% of the shares of Shengtang Trading. As a result of the share acquisition, Shengtang Trading became a wholly-owned subsidiary of Joway Shengshi.

 

F-4

 

 

The following table lists the Company and its subsidiaries:

 

Name   Domicile and Date of Incorporation   Paid in Capital   Percentage of Effective Ownership   Principal Activities
Joway Health Industries Group Inc.  

March 21, 2003,

Nevada

  USD 20,054  

86.8% owned by Crystal Globe Limited

13.2%owned by other institutional and individual investors

 

Investment

Holding

                 
Dynamic Elite International Limited  

June 2, 2010,

British Virgin Islands

  USD 10,000   100% owned by Joway Health Industries Group Inc.  

Investment

Holding

                 
Tianjin Junhe Management Consulting Co., Ltd.   September 15, 2010, PRC   USD 20,000   100% owned by Dynamic Elite International Limited   Advisory
                 
Tianjin Joway Shengshi Group Co., Ltd.   May 17, 2007, PRC   USD 7,216,140.72   99% owned by Jinghe Zhang,  and 1% owned  by Baogang Song  

Production and

distribution of Healthcare Knit Goods and Daily Healthcare and Personal Care products

                 
Shenyang Joway Electronic Technology Co., Ltd.   March 28, 2007, PRC   USD 142,072.97   100% owned by Tianjin Joway Shengshi Group Co., Ltd   Distribution of Tourmaline Activated Water Machine and construction of Tourmaline Wellness House
                 
Tianjin Joway Decoration Engineering Co., Ltd.   April 22, 2009, PRC   USD 292,367.74   100% owned by Tianjin Joway Shengshi Group Co., Ltd   Distribution of Wellness House for family use and Activated Water Machine and construction of Tourmaline Wellness House
                 
Tianjin Oriental Shengtang Import & Export Trading Co., Ltd.   September 18, 2009, PRC   USD 292,463.75   100% owned by Tianjin Joway Shengshi Group Co., Ltd   Distribution of tourmaline products

 

F-5

 

 

 

On September 16, 2010, prior to the share exchange, Junhe Consulting entered into a series of contractual agreements (the “Contractual Agreements”) with Joway Shengshi and Joway Shengshi’s owners. The following is a brief description of the Contractual Agreements entered into between Junhe Consulting and Joway Shengshi or Joway Shengshi’s owners

 

1. Consulting Services Agreement. Pursuant to the consulting services agreement between Junhe Consulting and Joway Shengshi, Junhe Consulting has the right to advise, consult, manage and operate Joway Shengshi, and collect and own all of the net profits of the Operating Entities.

 

2. Operating Agreement. Under the operating agreement between Junhe Consulting and Joway Shengshi, Junhe Consulting has the right to recommend director candidates and appoint the senior executives of Joway Shengshi, approve any transactions that may materially affect the assets, liabilities, rights or operations of Joway Shengshi, and guarantee the contractual performance by Joway Shengshi of any agreements with third parties, in exchange for a pledge by Joway Shengshi of its accounts receivable and assets.

 

3. Voting Rights Proxy Agreement. Under the voting rights proxy agreement between Joway Shengshi’s owners and Junhe Consulting, the owners of Joway Shengshi have vested their collective voting control over Joway Shengshi to Junhe Consulting and will only transfer their respective equity interests in Joway Shengshi to Junhe Consulting or its designee.

 

4. Option Agreement. Under the option agreement between Joway Shengshi’s owners and Junhe Consulting, the owners of Joway Shengshi have granted Junhe Consulting the irrevocable right and option to acquire all of their equity interests in Joway Shengshi.

 

5. Equity Pledge Agreement. Under the equity pledge agreement between Joway Shengshi’s owners and Junhe Consulting, the owners of Joway Shengshi have pledged all of their rights, titles and interests in Joway Shengshi to Junhe Consulting to guarantee Joway Shengshi’s performance of its obligations under the Consulting Services Agreement.

 

As a result of the Contractual Agreements, Joway Shengshi is effectively a variable interest entity of Junhe Consulting. Accordingly, the Company through its wholly-owned subsidiary Junhe Consulting, consolidates Joway Shengshi’s results of operation, assets and liabilities in its financial statements.

 

In connection with the Share Exchange and as consideration for entering into the VIE Agreements, Jingshe Zhang and Baogang Song, the shareholders of Joway Shengshi (the “Grantees”), entered into a Call Option Agreement, dated July 20,2010 with Lionel Evan Liu (the “Grantor”), the sole shareholder of Crystal Globe (the controlling shareholder of Dynamic Elite), a British Virgin Islands company (the “Call Option Agreement”), pursuant to which the Grantees had the right to purchase up to 100% of the shares of Crystal Globe (the “Call Option”) at an exercise price of $2.00 per share (the “Exercise Price”) for a period of five years. The Call Option vested as to 34% of the shares of Crystal Globe on April 2, 2011 and as to 33% on each of April 2, 2012 and 2013 (the respective “Call Option Effective Date”). On March 28, 2015, the Grantor and Grantees amended the Call Option Agreement, to (i) reduce the Exercise Price to $0.00 per share and (ii) extend the Grantees’ rights to exercise their call option within ten years from the respective Option Effective Date.

 

On November 13, 2016, Jinghe Zhang exercised the Call Option as to 99% of the shares of Crystal Globe and Baogang Song exercised his Call Option as to 1% of the shares of Crystal Globe. As a result of exercising the Call Option, Jinghe Zhang became the controlling shareholder of Crystal Globe and in turn, the controlling shareholder of the Company. On November 20, 2016, Baogang Song transferred 1% of the shares of Crystal Globe to Jinghe Zhang. Consequently, Jinghe Zhang controls 17,408,000 shares, or 86.8%, of the issued and outstanding shares of the Company’s common stock.

 

F-6

 

 

On December 31, 2020, upon the Company completed the Merger Agreement with Crystal Globe, Joway Health becomes a “shell company” (as such term is defined in Rule 12b-2 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”).

 

Going forward, the Company intends to seek, investigate and, if such investigation warrants, engage in a business combination with a private entity whose business presents an opportunity for the Company’s stockholders.

 

NOTE 2 – GOING CONCERN

 

The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the discharge of liabilities in the normal course of business for the foreseeable future.

 

As reflected in the accompanying consolidated financial statements, for the nine months ended September 30, 2021 and 2020, we incurred net losses of $107,441 and $729,221, respectively. As of September 30, 2021, we had an accumulated deficit of $7.3 million. Management believes these factors raise substantial doubt about our ability to continue as a going concern for the next twelve months.

 

The continuation of our company as a going concern through the next twelve months is dependent upon (1) the continued financial support from our stockholders or external financing. Management believes that our existing stockholders will provide the additional cash to meet our obligations as they become due, and (2) that it will be able to implement its business plan to expand our company’s operations and generate sufficient revenues to meet its obligations.

 

These conditions raise substantial doubt about our company’s ability to continue as a going concern. These financial statements do not include any adjustments to reflect the possible future effect on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the outcome of these uncertainties. Management believes that the actions presently being taken to obtain additional funding and implement its strategic plan provides the opportunity for our company to continue as a going concern.

 

NOTE 3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of Presentation

 

The accompanying unaudited consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“US GAAP”). Accordingly, they do not include all of the information and the footnotes required by generally accepted accounting principles for complete financial statements. The Company’s functional currency is the Chinese Renminbi (“RMB”) in 2020; however, the accompanying unaudited consolidated financial statements have been translated and presented in United States Dollars (“USD”). All significant inter-company transactions and balances have been eliminated. The consolidated financial statements include all adjustments that, in the opinion of management, are necessary to make the financial statements not misleading.

 

Operating results for the nine month period ended September 30, 2021 are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2021. The accompanying unaudited consolidated financial statements should be read in conjunction with the Company’s form 10-K for the fiscal year ended December 31, 2020 which was filed on August 16, 2021.

 

Use of Estimates

 

The preparation of the consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Management makes these estimates using the best information available at the time the estimates are made. Actual results could differ from those estimates.

 

F-7

 

 

Reclassification

 

Certain prior year balances were reclassified to conform to the current year’s presentation with consideration of reflecting all of the Company’s subsidiaries and VIEs as discontinued operations. None of these reclassifications had an impact on reported financial position or cash flows for any of the periods presented.

 

Basis of Consolidation

 

For the periods prior to the sale of Dynamic Elite, its subsidiaries, and controlled VIEs, the Company consolidated financial statements include Dynamic Elite, its wholly owned subsidiaries, and controlled VIEs. All significant inter-company accounts and transactions have been eliminated in the consolidation.

 

Foreign Currency Translation

 

The accompanying consolidated financial statements are presented in USD. The functional currency of the Company is RMB in 2020. The consolidated financial statements are translated into United States dollars from RMB at period-end exchange rates as to assets and liabilities and average exchange rates as to revenues and expenses. Equity accounts are translated at their historical exchange rates when the equity transactions occurred. The resulting transaction adjustments are recorded as a component of stockholders’ equity. Gains and losses from foreign currency transactions are included in net income.

 

   For the
nine months ended
September 30,
   For the
year ended
December 31,
 
   2020   2020 
Period ended RMB: USD Exchange rate   6.8101    6.5249 
Average RMB: USD Exchange rate   6.9917    6.8976 

 

The RMB is not freely convertible into foreign currency and all foreign exchange transactions must take place through authorized institutions. No representation is made that the RMB amounts could have been, or could be, converted into USD at the rates used in translation.

 

Foreign currency translation adjustments have been reported as comprehensive income in the consolidated financial statements and totaled $103,625 for the three months ended September 30, 2020, and $60,934 for the nine months ended September 30, 2020. No foreign currency translation adjustments for the three months and nine months ended September 30, 2021.

 

Other Comprehensive Income

 

Other comprehensive income is defined as the change in equity during the period from transactions and other events, excluding the changes resulting from investments by owners and distributions to owners, and is not included in the computation of income tax expense or benefit. Accumulated other comprehensive income represents the accumulated balance of foreign currency translation adjustments.

 

Concentrations of Credit Risk

 

Prior to the Merger Agreement, the Company’s operations are carried out in the PRC. Accordingly, the Company’s business, financial condition, and results of operations may be influenced by the political, economic, and legal environment in the PRC, and by the general state of the PRC’s economy. The Company’s operations in the PRC are subject to specific considerations and significant risks not typically associated with companies in North America. The Company’s results may be adversely affected by changes in governmental policies with respect to laws and regulations, anti-inflationary measures, currency conversion and remittance abroad, and rates and methods of taxation, among other things. Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash and trade accounts receivable. Substantially all of the Company’s cash is maintained with state-owned banks within the PRC, and no deposits are covered by insurance. The Company has not experienced any losses in such accounts and believes it is not exposed to any risks on its cash in bank accounts.

 

F-8

 

 

Fair Value of Financial Instruments

 

Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 820 establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:

 

Level 1—defined as observable inputs such as quoted prices in active markets for identical assets or liabilities;

 

Level 2—defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and

 

Level 3—defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.

 

The carrying amounts reported in the balance sheets for cash, accounts receivable, other receivable, accounts payable, other payable, and amounts due from related parties generally approximate their fair market values based on the short-term maturity of these instruments. ASC 825-10 “Financial Instruments” allows entities to voluntarily choose to measure certain financial assets and liabilities at fair value (fair value option). The fair value option may be elected on an instrument-by-instrument basis and is irrevocable, unless a new election date occurs. If the fair value option is elected for an instrument, unrealized gains and losses for that instrument should be reported in earnings at each subsequent reporting date. The Company did not elect to apply the fair value option to any outstanding instruments.

 

Revenue Recognition

 

The Company recognizes revenue when control of promised goods or services is transferred to the company’s customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services.

 

Prior to the Merger Agreement, with respect to sales of product to both franchisee and non-franchisee customers, the Company transfers control, invoices the customer and recognizes revenue upon shipment to the customer. Sales prices are based on fixed price lists that are different depending on whether the price list is for franchisee customers or for non-franchisee customers. Sales, value add and other taxes collected concurrent with revenue-producing activities are excluded from revenue.

 

Income Taxes

 

The Company accounts for income taxes in accordance with FASB ASC 740 “Income Taxes” (formerly SFAS No. 109 Accounting for Income Taxes), which is an asset and liability approach that requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the Company’s financial statements or tax returns. ASC 740 additionally requires the establishment of a valuation allowance to reflect the likelihood of realization of deferred tax assets. Realization of deferred tax assets is dependent upon future earnings, if any, of which the timing and amount are uncertain.

 

According to ASC 740, the evaluation of a tax position is a two-step process. The first step is to determine whether it is more likely than not that a tax position will be sustained upon examination, including the resolution of any related appeals or litigation based on the technical merits of that position. The second step is to measure a tax position that meets the more-likely-than-not threshold to determine the amount of benefit to be recognized in the financial statements. A tax position is measured at the largest amount of benefit that is greater than 50% likelihood of being realized upon ultimate settlement. Tax positions that previously failed to meet the more-likely-than-not recognition threshold should be recognized in the first subsequent period in which the threshold is met. Previously recognized tax positions that no longer meet the more-likely-than-not criteria should be de-recognized in the first subsequent financial reporting period in which the threshold is no longer met. ASC 740 also provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosures, and transition.

 

F-9

 

 

Basic and Diluted Earnings per Share

 

The Company reports earnings per share in accordance with FASB ASC 260 “Earnings per share”. The Company’s basic earnings per share are computed using the weighted average number of shares outstanding for the periods presented. Diluted earnings per share are computed based on the assumption that any dilutive options or warrants were converted or exercised. Dilution is computed by applying the treasury stock method. Under this method, the Company’s outstanding stock warrants are assumed to be exercised, and funds thus obtained were assumed to be used to purchase common stock at the average market price during the period. There were no dilutive instruments outstanding during the three month and nine month periods ended September 30, 2021 and 2020.

 

Recently Issued Accounting Pronouncements

 

In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”), which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020, with early adoption permitted. The Company adopted the standard in the first quarter of 2021. Adoption of the standard did not have a significant impact on the Company’s consolidated statement of earnings in 2021.

 

Other accounting standards that have been issued or proposed by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on the Company’s consolidated financial statements upon adoption.

 

NOTE 4 – DECONSOLIDATION

 

On November 20, 2020, Joway Health entered into a Merger Agreement (the “Merger Agreement”) with Dynamic Elite International Limited, a British Virgin Islands company and a wholly-owned subsidiary of the Company (“Dynamic Elite”), Crystal Globe Limited, a British Virgin Islands company (“Crystal Globe”) and Joway Merger Subsidiary Limited, a British Virgin Islands company and a wholly-owned subsidiary of Crystal Globe (“Merger Sub”). The Merger Agreement provides that, upon the terms and subject to the satisfaction or waiver of the conditions set forth therein, Merger Sub will be merged with and into Dynamic Elite (the “Merger”), with Dynamic Elite continuing as the surviving corporation as a wholly-owned subsidiary of Crystal Globe.

 

Crystal Globe, as the majority shareholder holding approximately 86.81% of the Company, is also the sole shareholder of Dynamic Elite after the Merger. Mr. Jinghe Zhang, as the President, Chief Executive Officer, Chairman and Director, and the majority beneficial owner of the Company, also serves as sole shareholder and executive director of Crystal Globe. As a result, the Company and Dynamic Elite are under common control of Crystal Globe and Mr. Jinghe Zhang.

 

Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the “Effective Time”) and as a result of the Merger, the ordinary shares of common stock of Dynamic Elite issued and outstanding immediately prior to the Effective Time, all of which are held by the Company, will be cancelled and extinguished. In accordance with the Merger Agreement, Crystal Globe has offered a cash consideration of $0.045 per share for outstanding shares of Joway Health’s common stock (the “Merger Consideration”). As of November 20, 2020, Joway Health reported 20,054,000 shares of common stock outstanding. As a result, Joway Health recognized a loss of $1,340,795 from this transaction.

 

In January 2021, Joway Health had received $119,070 from Crystal Globe and distributed proportionately to the Company’s minority shareholders, other than Crystal Globe, which represents 2,646,000 shares of Joway Health’s common stock. Since the remaining 17,408,000 shares of Joway Health’s common stock is owned by Crystal Globe, the $0.045 per share payment for the 17,408,000 shares is offset.

 

F-10

 

 

The following is a reconciliation of the deconsolidation:

 

   Amount 
Selling price  $902,430 
Disposed assets and liabilities:     
Cash   79,446 
Current assets   1,133,812 
Fixed assets   3,194,533 
Intangible assets   465,007 
Liabilities   (1,977,822)
Accumulated other comprehensive income   (651,751)
    2,243,225 
Loss from disposal of discontinued component, net of income tax  $(1,340,795)

 

NOTE 5 – RECEIVABLE FROM RELATED PARTY

 

Receivable from related party consist of the following:

 

   September 30,   December 31, 
   2021   2020 
Crystal Globe  $
      -
   $119,070 

 

The receivable from Crystal Globe is related to the Merger Agreement which is part of the Merger Consideration for Joway Health’s minority shareholders who hold 2,646,000 shares of Joway Health’s common stock.

 

In January 2021, Joway Health had received $119,070 from Crystal Globe and distributed proportionately to the Company’s minority shareholders.

 

NOTE 6 – SPECIAL DIVIDEND PAYABLE

 

As of September 30, 2021 and December 31, 2020, the Company reported $0 and $119,070 as special dividend payables, respectively. The payables are related to the Merger Agreement which is part of the Merger Consideration for Joway Health’s minority shareholders who hold 2,646,000 shares of Joway Health’s common stock. 

 

On November 20, 2020, Joway Health entered into a Merger Agreement (the “Merger Agreement”) with Dynamic Elite International Limited, a British Virgin Islands company and a wholly-owned subsidiary of the Company (“Dynamic Elite”), Crystal Globe Limited, a British Virgin Islands company (“Crystal Globe”) and Joway Merger Subsidiary Limited, a British Virgin Islands company and a wholly-owned subsidiary of Crystal Globe (“Merger Sub”). The Merger Agreement provides that, upon the terms and subject to the satisfaction or waiver of the conditions set forth therein, Merger Sub will be merged with and into Dynamic Elite (the “Merger”), with Dynamic Elite continuing as the surviving corporation as a wholly-owned subsidiary of Crystal Globe. 

 

Crystal Globe, as the majority shareholder holding approximately 86.81% of the Company, is also the sole shareholder of Dynamic Elite after the Merger. Mr. Jinghe Zhang, as the President, Chief Executive Officer, Chairman and Director, and the majority beneficial owner of the Company, also serves as sole shareholder and executive director of Crystal Globe. As a result, the Company and Dynamic Elite are under common control of Crystal Globe and Mr. Jinghe Zhang. 

 

F-11

 

 

Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the “Effective Time”) and as a result of the Merger, the ordinary shares of common stock of Dynamic Elite issued and outstanding immediately prior to the Effective Time, all of which are held by the Company, will be cancelled and extinguished. In accordance with the Merger Agreement, Crystal Globe has offered a cash consideration of $0.045 per share for outstanding shares of Joway Health’s common stock (the “Merger Consideration”). As of November 20, 2020, Joway Health reported 20,054,000 shares of common stock outstanding. 

 

As a result of the Merger Agreement, Joway Health needs to distribute proportionately the Merger Consideration to the Company’s shareholders. In January 2021, Joway Health had received $119,070 from Crystal Globe and distributed proportionately to the Company’s minority shareholders, other than Crystal Globe, which represents 2,646,000 shares of Joway Health’s common stock. Since the remaining 17,408,000 shares of Joway Health’s common stock is owned by Crystal Globe, the $0.045 per share payment for the 17,408,000 shares is offset.

 

NOTE 7 – RELATED PARTY TRANSACTIONS

 

Payables due to related parties consist of the following:

 

   September 30,   December 31, 
   2021   2020 
Jinghe Zhang  $2,610   $233,693 
Joway Shengshi   
-
    459,853 
Total  $2,610   $693,546 

 

The amounts owed to related parties are non-interest bearing and have no specified repayment terms.

 

Transactions with Jinghe Zhang

 

The Company is a shell company and has no cash, Mr. Jinghe Zhang, our President, Chief Executive Officer and director, agreed to advance operating capital to the Company. For the three months ended September 30, 2021 and 2020, the Company received $1,693 and $19,364 from Mr. Jinghe Zhang, respectively, for its continuing operating component. For the nine months ended September 30, 2021 and 2020, the Company received $68,690 and $153,065 from Mr. Jinghe Zhang, respectively, for its continuing operating component. For the three months and nine months ended September 30, 2021, the Company received $0 from Mr. Jinghe Zhang, respectively, for its discontinued operating component. For the Company’s discontinued operation component, during the three months and nine months ended September 30, 2020, the Company received $161,021 and $281,753 from Mr. Jinghe Zhang, respectively.

 

On April 28, 2021, Mr. Jinghe Zhang released the Company from $295,928.47 of indebtedness owed to him from the Company. As of September 30, 2021, the total unpaid principal balance due to Mr. Jinghe Zhang for advances was $2,610.

 

Transactions with Joway Shengshi

 

Joway Shengshi is a company of the discontinued operations. Mr. Jinghe Zhang owns 99% of the equity interest in Joway Shengshi. For the three months ended September 30, 2021 and 2020, the Company received $0 from Joway Shengshi, respectively, for its continuing and discontinued operating components. For the nine months ended September 30, 2021 and 2020, we received $3,844 and $0 of advances from Joway Shengshi, respectively, for our continuing operation component. For our discontinued operation component, we received $0 from Joway Shengshi for the nine months ended September 30, 2021 and 2020.

 

On April 28, 2021, Joway Shengshi released the Company from $463,697.67 of indebtedness owed to it from the Company. As of September 30, 2021, the total unpaid principal balance due to Joway Shengshi for advances was $0.

 

F-12

 

 

Disposal of all of Joway Health’s subsidiaries and VIEs

 

On November 20, 2020, Joway Health entered into a Merger Agreement (the “Merger Agreement”) with Dynamic Elite International Limited, a British Virgin Islands company and a wholly-owned subsidiary of the Company (“Dynamic Elite”), Crystal Globe Limited, a British Virgin Islands company (“Crystal Globe”) and Joway Merger Subsidiary Limited, a British Virgin Islands company and a wholly-owned subsidiary of Crystal Globe (“Merger Sub”). The Merger Agreement provides that, upon the terms and subject to the satisfaction or waiver of the conditions set forth therein, Merger Sub will be merged with and into Dynamic Elite (the “Merger”), with Dynamic Elite continuing as the surviving corporation as a wholly-owned subsidiary of Crystal Globe.

 

Crystal Globe, as the majority shareholder holding approximately 86.81% of the Company, is also the sole shareholder of Dynamic Elite after the Merger. Mr. Jinghe Zhang, as the President, Chief Executive Officer, Chairman and Director, and the majority beneficial owner of the Company, also serves as sole shareholder and executive director of Crystal Globe. As a result, the Company and Dynamic Elite are under common control of Crystal Globe and Mr. Jinghe Zhang.

 

Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the “Effective Time”) and as a result of the Merger, the ordinary shares of common stock of Dynamic Elite issued and outstanding immediately prior to the Effective Time, all of which are held by the Company, will be cancelled and extinguished. In accordance with the Merger Agreement, Crystal Globe has offered a cash consideration of $0.045 per share for outstanding shares of Joway Health’s common stock (the “Merger Consideration”). As of November 20, 2020, Joway Health reported 20,054,000 shares of common stock outstanding.

 

As a result of the Merger Agreement, Joway Health needs to distribute proportionately the Merger Consideration to the Company’s shareholders. In January 2021, Joway Health had received $119,070 from Crystal Globe and distributed proportionately to the Company’s minority shareholders, other than Crystal Globe, which represents 2,646,000 shares of Joway Health’s common stock. Since the remaining 17,408,000 shares of Joway Health’s common stock is owned by Crystal Globe, the $0.045 per share payment for the 17,408,000 shares is offset.

 

NOTE 8 – INCOME TAXES

 

Upon the Company executed the Merger Agreement on December 31, 2020, no provision was made for federal income taxes since the Company has significant net operating losses.

 

The Company’s income tax returns since inception are subject to audit by regulatory authorities. Changes in tax laws and rates could also affect recorded deferred tax assets and liabilities in the future. Management is not aware of any such changes that would have a material effect on the Company’s results of operations, cash flows or financial position. The calculation of our tax liabilities involves dealing with uncertainties in the application of complex tax laws and regulations. FASB ASC Topic 740, Income Taxes provides that a tax benefit from an uncertain tax position may be recognized when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits. ASC Topic 740 also provides guidance on measurement, derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition.

 

We recognize tax liabilities in accordance with ASC Topic 740 and we adjust these liabilities when our judgment changes as a result of the evaluation of new information not previously available. Due to the complexity of some of these uncertainties, the ultimate resolution may result in a payment that is materially different from our current estimate of the tax liabilities. These differences will be reflected as increases or decreases to income tax expense in the period in which they are determined. 

 

F-13

 

 

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

 

Forward-Looking Statements

 

The following management’s discussion and analysis should be read in conjunction with our historical financial statements and the related notes thereto. The management’s discussion and analysis contain forward-looking statements, such as statements of our plans, objectives, expectations and intentions. Any statements that are not statements of historical fact are forward-looking statements. When used, the words “believe,” “plan,” “intend,” “anticipate,” “target,” “estimate,” “expect” and the like, and/or future tense or conditional constructions (“will,” “may,” “could,” “should,” etc.), or similar expressions, identify certain of these forward-looking statements. These forward-looking statements are subject to risks and uncertainties, including those under “Risk Factors” in our Annual Report filed with the SEC on August 16, 2021, as updated in subsequent filings we have made with the SEC that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. Our actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors. We do not undertake any obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this Quarterly Report.

 

Basis of Presentation

 

The following discussion highlights our results of operations and the principal factors that have affected our financial condition as well as our liquidity and capital resources for the periods described, and provide information that management believes is relevant for an assessment and understanding of the statements of financial condition and results of operations presented herein. The following discussion and analysis are based on our unaudited financial statements contained in this Quarterly Report, which we have prepared in accordance with United States generally accepted accounting principles. You should read the discussion and analysis together with such financial statements and the related notes thereto.

 

Overview

 

We are incorporated in the state of Nevada. Prior to the consummation of the Merger as of December 31, 2020, as more specifically described below, Joway Health Industries Group Inc. (the “Company” or “Joway Health”), through our PRC Operating Entities, were engaged in the manufacture, distribution and sales of tourmaline-related healthcare products. Our principal executive offices were located at No. 19. Baowang Road, Baodi Economic Development Zone, Tianjin City, P.R.China 301800.

 

As of December 31, 2020, we become a shell company as a result of the Merger described below.

 

Entry into a Material Definitive Agreement

 

On November 20, 2020, Joway Health entered into a Merger Agreement (the “Merger Agreement”) with Dynamic Elite International Limited, a British Virgin Islands company and a wholly-owned subsidiary of the Company (“Dynamic Elite”), Crystal Globe Limited, a British Virgin Islands company (“Crystal Globe”) and Joway Merger Subsidiary Limited, a British Virgin Islands company and a wholly-owned subsidiary of Crystal Globe (“Merger Sub”). The Merger Agreement provides that, upon the terms and subject to the satisfaction or waiver of the conditions set forth therein, Merger Sub will be merged with and into Dynamic Elite (the “Merger”), with Dynamic Elite continuing as the surviving corporation as a wholly-owned subsidiary of Crystal Globe. The special committee of the Board of Directors of the Company unanimously approved the Merger Agreement and the transactions contemplated thereby.

 

Crystal Globe, as the majority shareholder holding approximately 86.81% of the Company, is also the sole shareholder of Dynamic Elite. Mr. Jinghe Zhang, as the President, Chief Executive Officer, Chairman and Director, and the majority beneficial owner of the Company, also serves as sole shareholder and executive director of Crystal Globe. As a result, the Company and Dynamic Elite are under common control of Crystal Globe and Mr. Jinghe Zhang.

 

2

 

 

Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the “Effective Time”) and as a result of the Merger, the ordinary shares of common stock of Dynamic Elite issued and outstanding immediately prior to the Effective Time, all of which are held by the Company, were cancelled and extinguished. In accordance with the Merger Agreement, Crystal Globe has offered to pay cash consideration to the Company of $0.045 per share for the outstanding shares of the common stock of the Company (the “Merger Consideration”). At the date of the Merger Agreement, we had 20,054,000 shares of common stock outstanding.

 

Completion of Acquisition or Disposition of Assets

 

Pursuant to the terms of the Merger Agreement dated November 20, 2020, as of December 31, 2020, the Effective Time of the Merger, the 10,000 ordinary shares of common stock of Dynamic Elite issued and outstanding immediately which were held by the Company, were cancelled for $0.045 per share for the outstanding shares of the common stock of the Company as Merger Consideration.

 

In January 2021, the Company had received $119,070 from Crystal Globe and distributed proportionately to the Company’s minority shareholders, other than Crystal Globe, which represents 2,646,000 shares of our common stock. Since the remaining 17,408,000 shares of our common stock is owned by Crystal Globe, the $0.045 per share payment for the 17,408,000 shares was offset and Crystal Globe did not receive any cash payment in connection with the Merger.

 

Change in Shell Company Status

 

As a result of the consummation of the Merger, the Company became a shell company as of December 31, 2020.

 

Going forward, we intend to seek, investigate and, if such investigation warrants, engage in a business combination with a private entity whose business presents an opportunity for our shareholders. Our objectives are extremely general and are not intended to restrict discretion of our Board of Directors to search for and enter into potential business opportunities or to reject any such opportunities. We have no particular business combination in mind and have not entered into any negotiations regarding such a combination. Neither our officers nor any of our affiliates has engaged in any negotiations with any representative of any company regarding the possibility of an acquisition or combination between our company and such other company. We have not yet entered into any agreement, nor do we have any commitment or understanding to enter into or become engaged in a transaction.

 

We will not restrict our potential candidate target companies to any specific business, industry or geographical location and, thus, may acquire any type of business. Further, we may acquire or combine with a venture that is in its preliminary or early stages of development, one that is already in operation or one that is in a more mature stage of its corporate existence. Accordingly, business opportunities may be available in many different industries and at various stages of development, all of which will make the task of comparative investigation and analysis of such business opportunities difficult and complex.

 

The analysis of new business opportunities will be undertaken by or under the supervision of our executive officers and sole director, none of whom is a business analyst. Therefore, it is anticipated that outside consultants or advisors may be utilized to assist us in the search for and analysis of qualified target companies.

 

Results of Operations

 

Three Months Ended September 30, 2021 Compared to Three Months Ended September 30, 2020

 

Operating expenses

 

Operating expenses, consisting entirely of general and administrative expenses (including professional fees) totaled $10,884 for the three-month period ended September 30, 2021, compared to $25,317 for the three-month period ended September 30, 2020. This decrease was mainly due to the decrease of attorney fee, as a result of that we became a shell company in 2021.

 

3

 

 

Loss from operations

 

As a result of the foregoing, our loss from operations was $10,884 for the three-month period ended September 30, 2021, compared to $25,317 for the three-month period ended September 30, 2020.

 

Income taxes

 

We did not have income tax expenses in the three-month period ended September 30, 2021 and 2020.

 

Net Loss from continuing operations

  

We incurred a net loss of $10,884 for the three months ended September 30, 2021, compared to a net loss of $25,365 for the corresponding period ended September 30, 2020.

 

Operating loss from discontinued operations

 

As of December 31, 2020, we sold all of our subsidiaries and VIEs to Crystal Globe, one of our major shareholders. With a result, operating results from our subsidiaries and VIEs for the three-month period ended September 30, 2020 were reported as part of loss from operations of our discontinued component.

 

For the three-month period ended September 30, 2020, revenue from our discontinued operations was $77,289 and cost of goods sold from our discontinued operations was $37,517.

 

Nine Months Ended September 30, 2021 Compared to Nine Months Ended September 30, 2020

 

Operating expenses

  

Operating expenses, consisting entirely of general and administrative expenses (including professional fees) totaled $107,441 for the nine-month period ended September 30, 2021, compared to $180,814 for the nine-month period ended September 30, 2020. This decrease was mainly due to the decrease of attorney fee, as a result of that we became a shell company in 2021.

 

Loss from operations

 

As a result of the foregoing, our loss from operations was $107,441 for the nine-month period ended September 30, 2021, compared to $180,814 for the nine-month period ended September 30, 2020.

 

Income taxes

 

We did not have income tax expenses in the nine-month period ended September 30, 2021 and 2020.

 

Net Loss from continuing operations

  

We incurred a net loss of $107,441 for the nine months ended September 30, 2021, compared to a net loss of $181,066 for the corresponding period ended September 30, 2020.

 

Operating loss from discontinued operations

 

As of December 31, 2020, we sold all of our subsidiaries and VIEs to Crystal Globe, one of our major shareholders. With a result, operating results from our subsidiaries and VIEs for the nine-month period ended September 30, 2020 were reported as part of loss from operations of our discontinued component.

 

For the nine-month period ended September 30, 2020, revenue from our discontinued operations was $159,407 and cost of goods sold from our discontinued operations was $83,268.

 

4

 

 

Liquidity and Capital Resources

 

As of September 30, 2021, we had no cash, liabilities of $92,705, and our working capital deficit was $92,705. Our current liquidity is not sufficient to meet the obligations associated with being a company that is fully reporting with the SEC.

 

To date, we have managed to keep our monthly cash flow requirement low for two reasons.  First, our sole officer does not draw a salary at this time.  Second, we have been able to keep our operating expenses to a minimum by operating in space provided at no expense by one of our shareholders.

 

We currently have no external sources of liquidity such as arrangements with credit institutions or off-balance sheet arrangements that will have or are reasonably likely to have a current or future effect on our financial condition or immediate access to capital.

 

Our directors and officers have made no commitments written or oral, with respect to providing a source of liquidity in the form of cash advances, loans and/or financial guarantees.  

 

We will need to raise funds in order to effectuate our business plan. We anticipate that we will need to seek financing through means such as borrowings from institutions or private individuals. There can be no assurance that we will be able to raise such funds. If we are unsuccessful at raising sufficient funds, for whatever reason, to fund our operations, we may be forced to seek a buyer for our business or another entity with which we could create a joint venture.  If all of these alternatives fail, we expect that we will be required to seek protection from creditors under applicable bankruptcy laws.

 

We have a history of operating losses and negative cash flow. These conditions raise substantial doubt about our ability to meet all of our obligations over the twelve months following the filing of this Form 10-Q. Management has evaluated these conditions and concluded that current plans will alleviate this concern. We currently have no debt other than advances from a shareholder and have no reason to believe that the shareholder will cease advancing the Company operating capital.

 

Our ability to continue as a going concern is dependent on our ability to implement our business plan, raise capital and generate revenues. See Note 2 of our financial statements.

 

Off-Balance Sheet Arrangements

 

We have never entered into any off-balance sheet financing arrangements and have not formed any special purpose entities. We have not guaranteed any debt or commitments of other entities or entered into any options on non-financial assets.

 

Contractual Obligations

 

None.

 

Critical Accounting Policies

 

Management’s discussion and analysis of its financial condition and results of operations are based upon our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. Our financial statements reflect the selection and application of accounting policies which require management to make significant estimates and judgments. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances. Actual results may differ from these estimates under different assumptions or conditions. We believe that the following reflect the more critical accounting policies that currently affect our financial condition and results of operations.

 

5

 

 

Basis of Consolidation

 

The accompanying consolidated financial statements include Joway Health and its wholly owned subsidiaries and controlled VIEs. All significant inter-company accounts and transactions have been eliminated in the consolidation.

 

Pursuant to Accounting Standards Codification Topic 810 “Consolidation” (“ASC 810”), the Company is required to include in its consolidated financial statements the financial statements of its variable interest entities (“VIEs”). ASC 810 requires a VIE to be consolidated by a company if that company is subject to a majority of the risk of loss for the VIE or is entitled to receive a majority of the VIE’s residual returns. VIEs are those entities in which a company, through contractual arrangements, bears the risk of, and enjoys the rewards normally associated with ownership of the entity, and therefore the company is the primary beneficiary of the entity.

 

Based on the various Contractual Agreements, we believe we are able to exercise control over the VIEs, and to obtain the full economic benefits. We believe that the terms of the exclusive option agreement are currently exercisable and legally enforceable under PRC laws and regulations. We also believe that the minimum amount of consideration permitted by the applicable PRC law to exercise the option does not represent a financial barrier or disincentive for us to exercise our rights under the exclusive option agreement. A simple majority vote of our board of directors is required to pass a resolution to exercise our rights under the exclusive option agreement, for which consent of the shareholder of VIEs is not required. Therefore, we believe this gives us the power to direct the activities that most significantly impact VIEs’ economic performance. T We believe that our ability to exercise effective control, together with the consulting service agreements and the equity pledge agreements, give us the rights to receive substantially all of the economic benefits from VIEs in consideration for the services provided by its wholly owned subsidiaries in China. Accordingly, as the primary beneficiary of VIEs and in accordance with U.S. GAAP, Joway Shengshi, Joway Technology, Joway Decoration, and Shengtang Trading, as VIEs of Junhe Consulting, has been consolidated in the Company’s financial statements. Sales from Joway Shengshi, Joway Technology, Joway Decoration, and Shengtang Trading are included in our total sales, their incomes or losses from operations are consolidated with ours, and our net income or loss includes net income or loss from Joway Shengshi, Joway Technology, Joway Decoration, and Shengtang Trading.

 

Revenue Recognition

 

The Company recognizes revenue when control of promised goods or services is transferred to the company’s customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services.

 

Prior to the Merger Agreement, with respect to sales of product to both franchisee and non-franchisee customers, the Company transfers control, invoices the customer and recognizes revenue upon shipment to the customer. Sales prices are based on fixed price lists that are different depending on whether the price list is for franchisee customers or for non-franchisee customers. Sales, value add and other taxes collected concurrent with revenue-producing activities are excluded from revenue.

 

Recent Accounting Pronouncements

 

We do not anticipate that the adoption of recently issued accounting pronouncements to have a material effect on our condensed consolidated financial statements.

 

Going Concern

 

The accompanying unaudited condensed financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates continuity of operations, realization of assets, and liquidation of liabilities in the normal course of business. As reflected in the accompanying unaudited condensed financial statements, the Company had an accumulated deficit of $7,341,621 and a working capital deficit of approximately $92,705 at September 30, 2021, and has incurred losses for all periods presented. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The ability of the Company to continue as a going concern is dependent on the Company’s ability to raise additional capital and implement its business plan, which is now to seek and develop a new sale strategy to enhance our sale force. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. Management intends to provide the Company with additional loans as needed. Management feels these actions provide the opportunity for the Company to continue as a going concern.

 

6

 

 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

 

None.

 

ITEM 4. CONTROLS AND PROCEDURES.

 

Evaluation of Disclosure Controls and Procedures

 

Our management, under the supervision and with the participation of our Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), has evaluated the effectiveness of our disclosure controls and procedures as defined in SEC Rules 13a-15(e) and 15d-15(e) as of the end of the period covered by this quarterly report. The purpose of this evaluation is to determine if, as of September 30, 2021, our disclosure controls and procedures were operating effectively such that the information, required to be disclosed in our Securities and Exchange Commission (“SEC”) reports (i) was recorded, processed, summarized and reported within the time periods specified in SEC rules and forms, and (ii) was accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

 

Based on their evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of September 30, 2021, our disclosure controls and procedures were not effective, based on the material weakness described below:

 

We did not have sufficient skilled accounting personnel that are either qualified as Certified Public Accountants in the U.S. or that have received education from U.S. institutions or other educational programs that would provide enough relevant education relating to U.S. GAAP. The Company’s CFO and Financial Manager have worked for U.S. listed companies but have limited experience with U.S. GAAP and are not U.S. Certified Public Accountants. Further, our operating subsidiaries are based in China, and in accordance with PRC laws and regulations, are required to comply with PRC GAAP, rather than U.S. GAAP. Thus, the accounting skills and understanding necessary to fulfill the requirements of U.S. GAAP-based reporting, including the preparation of financial statements and consolidation, are inadequate, and determined to be a material weakness.

 

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. All internal control systems, no matter how well designed, have inherent limitations. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation.

 

Changes in Internal Control over Financial Reporting

 

There were no changes in our internal control over financial reporting for the three months ended September 30, 2021 that materially affected, or are reasonably likely to materially affect our internal control over financial reporting.

 

7

 

 

PART II – OTHER INFORMATION

 

ITEM 1. LEGAL PROCEEDINGS.

 

We know of no material, active, pending or threatened proceeding against us or our subsidiaries, nor are we, or any subsidiary, involved as a plaintiff or defendant in any material proceeding or pending litigation.

 

ITEM 1A. RISK FACTORS.

 

Not required for smaller reporting companies.

 

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

 

None.

 

ITEM 3. DEFAULTS UPON SENIOR SECURITIES.

 

None.

 

ITEM 4. MINE SAFETY DISCLOSURES.

 

Not applicable.

 

ITEM 5. OTHER INFORMATION.

 

None. 

 

ITEM 6. EXHIBITS.

 

Exhibit No.   Description
     
31.1   Certification of Principal Executive Officer of Joway Health Industries Group Inc. pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2   Certification of Principal Financial Officer of Joway Health Industries Group Inc pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1   Certifications of Principal Executive Officer of Joway Health Industries Group Incpursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2   Certifications of Principal Financial Officer of Joway Health Industries Group Inc pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS   Inline XBRL Instance Document
101.SCH   Inline XBRL Taxonomy Extension Schema Document
101.CAL   Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB   Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE   Inline XBRL Taxonomy Extension Presentation Linkbase Document
104   Cover Page Interactive Data File (formatted as Inline XBRL and contained in exhibit 101)

 

8

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  JOWAY HEALTH INDUSTRIES GROUP INC.
     
Dated: November 8, 2021 By: /s/ JINGHE ZHANG
    Jinghe Zhang
   

President and Chief Executive Officer

(Principal Executive Officer)

     
Dated: November 8, 2021 By: /s/ YUAN HUANG
    Yuan Huang
   

Chief Financial Officer

(Principal Financial and Accounting Officer)

 

 

9

 

 

GTVI NONE false --12-31 Q3 0001263364 0001263364 2021-01-01 2021-09-30 0001263364 2021-11-05 0001263364 2021-09-30 0001263364 2020-12-31 0001263364 2021-07-01 2021-09-30 0001263364 2020-07-01 2020-09-30 0001263364 2020-01-01 2020-09-30 0001263364 2019-12-31 0001263364 2020-09-30 0001263364 gtvi:DynamicEliteMember 2010-09-21 0001263364 gtvi:TianjinJowayShengshiGroupCoLtdMember 2007-05-17 0001263364 gtvi:JowayShengshiToJowayTechnologyMember 2010-07-25 0001263364 gtvi:JowayShengshiToJowayDecorationMember 2010-07-09 0001263364 gtvi:JowayShengshiToShengtangTradingMember 2010-07-28 0001263364 gtvi:CrystalGlobeMember 2010-07-20 0001263364 gtvi:CrystalGlobeMember 2010-07-11 2010-07-20 0001263364 2015-03-20 2015-03-28 0001263364 gtvi:JingheZhangMember gtvi:CrystalGlobeMember 2016-11-13 0001263364 gtvi:BaogangSongMember gtvi:CrystalGlobeMember 2016-11-01 2016-11-13 0001263364 gtvi:CrystalGlobalToJingheZhangMember 2016-11-01 2016-11-20 0001263364 gtvi:JingheZhangMember 2016-11-20 0001263364 gtvi:JingheZhangMember 2016-11-01 2016-11-20 0001263364 gtvi:JowayHealthIndustriesGroupIncMember 2021-01-01 2021-09-30 0001263364 gtvi:JowayHealthIndustriesGroupIncMember 2021-09-30 0001263364 gtvi:DynamicEliteInternationalLimitedMember 2021-01-01 2021-09-30 0001263364 gtvi:DynamicEliteInternationalLimitedMember 2021-09-30 0001263364 gtvi:TianjinJunheManagementConsultingCoLtdMember 2021-01-01 2021-09-30 0001263364 gtvi:TianjinJunheManagementConsultingCoLtdMember 2021-09-30 0001263364 gtvi:TianjinJowayShengshiGroupCoLtdMember 2021-01-01 2021-09-30 0001263364 gtvi:TianjinJowayShengshiGroupCoLtdMember 2021-09-30 0001263364 gtvi:ShenyangJowayElectronicTechnologyCoLtdMember 2021-01-01 2021-09-30 0001263364 gtvi:ShenyangJowayElectronicTechnologyCoLtdMember 2021-09-30 0001263364 gtvi:TianjinJowayDecorationEngineeringCoLtdMember 2021-01-01 2021-09-30 0001263364 gtvi:TianjinJowayDecorationEngineeringCoLtdMember 2021-09-30 0001263364 gtvi:TianjinOrientalShengtangImportAndExportTradingCoLtdMember 2021-01-01 2021-09-30 0001263364 gtvi:TianjinOrientalShengtangImportAndExportTradingCoLtdMember 2021-09-30 0001263364 gtvi:RenminbiUnitedStatesDollarExchangeRateMember 2020-09-30 0001263364 gtvi:RenminbiUnitedStatesDollarExchangeRateMember 2020-12-31 0001263364 gtvi:AverageRenminbiUnitedStatesDollarExchangeRateMember 2020-09-30 0001263364 gtvi:AverageRenminbiUnitedStatesDollarExchangeRateMember 2020-12-31 0001263364 gtvi:MergerAgreementMember 2020-11-20 0001263364 gtvi:MergerAgreementMember 2020-11-02 2020-11-20 0001263364 gtvi:MergerAgreementMember 2021-01-02 2021-01-31 0001263364 gtvi:JowayHealthsMember 2021-01-01 2021-09-30 0001263364 gtvi:CrystalGlobeMember 2021-01-31 0001263364 gtvi:CrystalGlobeMember 2021-09-30 0001263364 gtvi:CrystalGlobeMember 2020-12-31 0001263364 gtvi:JowayHealthsMember 2021-09-30 0001263364 2020-11-20 0001263364 gtvi:JowayHealthsMember 2020-11-20 0001263364 2021-01-01 2021-01-31 0001263364 gtvi:JingheZhangMember 2021-07-01 2021-09-30 0001263364 gtvi:JingheZhangMember 2020-07-01 2020-09-30 0001263364 gtvi:JingheZhangMember 2021-01-01 2021-09-30 0001263364 gtvi:JingheZhangMember 2020-01-01 2020-09-30 0001263364 gtvi:JingheZhangMember 2021-04-28 0001263364 gtvi:JingheZhangMember 2021-09-30 0001263364 gtvi:JowayShengshiMember 2021-07-01 2021-09-30 0001263364 gtvi:JowayShengshiMember 2021-01-01 2021-09-30 0001263364 gtvi:JowayShengshiMember 2020-01-01 2020-09-30 0001263364 gtvi:JowayShengshiMember 2021-09-30 0001263364 gtvi:JowayShengshiMember 2020-09-30 0001263364 gtvi:JowayShengshiMember 2021-04-28 0001263364 gtvi:CrystalGlobeMember 2020-11-20 0001263364 gtvi:MergerAgreementMember 2021-09-30 0001263364 gtvi:JingheZhangMember 2021-09-30 0001263364 gtvi:JingheZhangMember 2020-12-31 0001263364 gtvi:JowayShengshiMember 2021-09-30 0001263364 gtvi:JowayShengshiMember 2020-12-31 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure
EX-31.1 2 f10q0921ex31-1_jowayhealth.htm CERTIFICATION

Exhibit 31.1

 

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

OF REGISTRANT PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

(RULE 13a-14(a) or 15d-14(a) OF THE EXCHANGE ACT)

 

I, Jinghe Zhang, certify that:

 

1. I have reviewed this quarterly report on Form 10-Q of Joway Health Industries Group Inc.;

 

2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;

 

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly for the period in which this quarterly report is being prepared;

 

b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;

 

d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting;

 

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent function):

 

a) all significant deficiencies in the design or operation of internal controls which could adversely affect the registrant’s ability to record, process, summarize and report financial data and have identified for the registrant’s auditors any material weaknesses in internal controls; and

 

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls over financial reporting.

 

  /s/ Jinghe Zhang
Dated: November 8, 2021 Name: Jinghe Zhang
  Title: President and Chief Executive Officer
  (Principal Executive Officer)

 

EX-31.2 3 f10q0921ex31-2_jowayhealth.htm CERTIFICATION

 Exhibit 31.2

 

 CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

OF REGISTRANT PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

(RULE 13a-14(a) or 15d-14(a) OF THE EXCHANGE ACT) 

 

I, Yuan Huang, certify that:

 

1. I have reviewed this quarterly report on Form 10-Q of Joway Health Industries Group Inc.;

 

2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;

 

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly for the period in which this quarterly report is being prepared;

 

b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;

 

d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting;

 

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent function):

 

a) all significant deficiencies in the design or operation of internal controls which could adversely affect the registrant’s ability to record, process, summarize and report financial data and have identified for the registrant’s auditors any material weaknesses in internal controls; and

 

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls over financial reporting.

 

  /s/ Yuan Huang
Dated: November 8, 2021 Name: Yuan Huang
  Title: Chief Financial Officer
  (Principal Financial and Accounting Officer)

 

EX-32.1 4 f10q0921ex32-1_jowayhealth.htm CERTIFICATION

Exhibit 32.1

 

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF

THE SARBANES-OXLEY ACT OF 2002

 

In connection with this quarterly report on Form 10-Q of Joway Health Industries Group Inc. (the “Company”) as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, in the capacity and on the date indicated below, hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:

 

1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company.

 

/s/ Jinghe Zhang
Dated: November 8, 2021 Name: Jinghe Zhang
  Title: President and Chief Executive Officer
  (Principal Executive Officer)
EX-32.2 5 f10q0921ex32-2_jowayhealth.htm CERTIFICATION

Exhibit 32.2

 

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF

THE SARBANES-OXLEY ACT OF 2002

 

In connection with this quarterly report on Form 10-Q of Joway Health Industries Inc. (the “Company”) as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, in the capacity and on the date indicated below, hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:

 

1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company.

 

  /s/ Yuan Huang
Dated: November 8, 2021 Name: Yuan Huang
  Title: Chief Financial Officer
 

(Principal Financial and Accounting Officer)

 

EX-101.SCH 6 gtvi-20210930.xsd XBRL SCHEMA FILE 001 - Statement - Balance Sheets link:presentationLink link:definitionLink link:calculationLink 002 - Statement - Balance Sheets (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 003 - Statement - Consolidated Statements of Operations and Comprehensive Loss link:presentationLink link:definitionLink link:calculationLink 004 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:definitionLink link:calculationLink 005 - Disclosure - Organization link:presentationLink link:definitionLink link:calculationLink 006 - Disclosure - Going Concern link:presentationLink link:definitionLink link:calculationLink 007 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:definitionLink link:calculationLink 008 - Disclosure - Deconsolidation link:presentationLink link:definitionLink link:calculationLink 009 - Disclosure - Receivable from Related Party link:presentationLink link:definitionLink link:calculationLink 010 - Disclosure - Special Dividend Payable link:presentationLink link:definitionLink link:calculationLink 011 - Disclosure - Related Party Transactions link:presentationLink link:definitionLink link:calculationLink 012 - Disclosure - Income Taxes link:presentationLink link:definitionLink link:calculationLink 013 - Disclosure - Accounting Policies, by Policy (Policies) link:presentationLink link:definitionLink link:calculationLink 014 - Disclosure - Organization (Tables) link:presentationLink link:definitionLink link:calculationLink 015 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:definitionLink link:calculationLink 016 - Disclosure - Deconsolidation (Tables) link:presentationLink link:definitionLink link:calculationLink 017 - Disclosure - Receivable from Related Party (Tables) link:presentationLink link:definitionLink link:calculationLink 018 - Disclosure - Related Party Transactions (Tables) link:presentationLink link:definitionLink link:calculationLink 019 - Disclosure - Organization (Details) link:presentationLink link:definitionLink link:calculationLink 020 - Disclosure - Organization (Details) - Schedule of company and its subsidiaries link:presentationLink link:definitionLink link:calculationLink 021 - Disclosure - Going Concern (Details) link:presentationLink link:definitionLink link:calculationLink 022 - Disclosure - Summary of Significant Accounting Policies (Details) link:presentationLink link:definitionLink link:calculationLink 023 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of gains and losses from foreign currency transactions link:presentationLink link:definitionLink link:calculationLink 024 - Disclosure - Deconsolidation (Details) link:presentationLink link:definitionLink link:calculationLink 025 - Disclosure - Deconsolidation (Details) - Schedule of reconciliation of the deconsolidation link:presentationLink link:definitionLink link:calculationLink 026 - Disclosure - Receivable from Related Party (Details) link:presentationLink link:definitionLink link:calculationLink 027 - Disclosure - Receivable from Related Party (Details) - Schedule of receivable from related party link:presentationLink link:definitionLink link:calculationLink 028 - Disclosure - Special Dividend Payable (Details) link:presentationLink link:definitionLink link:calculationLink 029 - Disclosure - Related Party Transactions (Details) link:presentationLink link:definitionLink link:calculationLink 030 - Disclosure - Related Party Transactions (Details) - Schedule of payables due to related parties link:presentationLink link:definitionLink link:calculationLink 000 - Document - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 7 gtvi-20210930_cal.xml XBRL CALCULATION FILE EX-101.DEF 8 gtvi-20210930_def.xml XBRL DEFINITION FILE EX-101.LAB 9 gtvi-20210930_lab.xml XBRL LABEL FILE EX-101.PRE 10 gtvi-20210930_pre.xml XBRL PRESENTATION FILE XML 11 f10q0921_jowayhealth_htm.xml IDEA: XBRL DOCUMENT 0001263364 2021-01-01 2021-09-30 0001263364 2021-11-05 0001263364 2021-09-30 0001263364 2020-12-31 0001263364 2021-07-01 2021-09-30 0001263364 2020-07-01 2020-09-30 0001263364 2020-01-01 2020-09-30 0001263364 2019-12-31 0001263364 2020-09-30 0001263364 gtvi:DynamicEliteMember 2010-09-21 0001263364 gtvi:TianjinJowayShengshiGroupCoLtdMember 2007-05-17 0001263364 gtvi:JowayShengshiToJowayTechnologyMember 2010-07-25 0001263364 gtvi:JowayShengshiToJowayDecorationMember 2010-07-09 0001263364 gtvi:JowayShengshiToShengtangTradingMember 2010-07-28 0001263364 gtvi:CrystalGlobeMember 2010-07-20 0001263364 gtvi:CrystalGlobeMember 2010-07-11 2010-07-20 0001263364 2015-03-20 2015-03-28 0001263364 gtvi:JingheZhangMember gtvi:CrystalGlobeMember 2016-11-13 0001263364 gtvi:BaogangSongMember gtvi:CrystalGlobeMember 2016-11-01 2016-11-13 0001263364 gtvi:CrystalGlobalToJingheZhangMember 2016-11-01 2016-11-20 0001263364 gtvi:JingheZhangMember 2016-11-20 0001263364 gtvi:JingheZhangMember 2016-11-01 2016-11-20 0001263364 gtvi:JowayHealthIndustriesGroupIncMember 2021-01-01 2021-09-30 0001263364 gtvi:JowayHealthIndustriesGroupIncMember 2021-09-30 0001263364 gtvi:DynamicEliteInternationalLimitedMember 2021-01-01 2021-09-30 0001263364 gtvi:DynamicEliteInternationalLimitedMember 2021-09-30 0001263364 gtvi:TianjinJunheManagementConsultingCoLtdMember 2021-01-01 2021-09-30 0001263364 gtvi:TianjinJunheManagementConsultingCoLtdMember 2021-09-30 0001263364 gtvi:TianjinJowayShengshiGroupCoLtdMember 2021-01-01 2021-09-30 0001263364 gtvi:TianjinJowayShengshiGroupCoLtdMember 2021-09-30 0001263364 gtvi:ShenyangJowayElectronicTechnologyCoLtdMember 2021-01-01 2021-09-30 0001263364 gtvi:ShenyangJowayElectronicTechnologyCoLtdMember 2021-09-30 0001263364 gtvi:TianjinJowayDecorationEngineeringCoLtdMember 2021-01-01 2021-09-30 0001263364 gtvi:TianjinJowayDecorationEngineeringCoLtdMember 2021-09-30 0001263364 gtvi:TianjinOrientalShengtangImportAndExportTradingCoLtdMember 2021-01-01 2021-09-30 0001263364 gtvi:TianjinOrientalShengtangImportAndExportTradingCoLtdMember 2021-09-30 0001263364 gtvi:RenminbiUnitedStatesDollarExchangeRateMember 2020-09-30 0001263364 gtvi:RenminbiUnitedStatesDollarExchangeRateMember 2020-12-31 0001263364 gtvi:AverageRenminbiUnitedStatesDollarExchangeRateMember 2020-09-30 0001263364 gtvi:AverageRenminbiUnitedStatesDollarExchangeRateMember 2020-12-31 0001263364 gtvi:MergerAgreementMember 2020-11-20 0001263364 gtvi:MergerAgreementMember 2020-11-02 2020-11-20 0001263364 gtvi:MergerAgreementMember 2021-01-02 2021-01-31 0001263364 gtvi:JowayHealthsMember 2021-01-01 2021-09-30 0001263364 gtvi:CrystalGlobeMember 2021-01-31 0001263364 gtvi:CrystalGlobeMember 2021-09-30 0001263364 gtvi:CrystalGlobeMember 2020-12-31 0001263364 gtvi:JowayHealthsMember 2021-09-30 0001263364 2020-11-20 0001263364 gtvi:JowayHealthsMember 2020-11-20 0001263364 2021-01-01 2021-01-31 0001263364 gtvi:JingheZhangMember 2021-07-01 2021-09-30 0001263364 gtvi:JingheZhangMember 2020-07-01 2020-09-30 0001263364 gtvi:JingheZhangMember 2021-01-01 2021-09-30 0001263364 gtvi:JingheZhangMember 2020-01-01 2020-09-30 0001263364 gtvi:JingheZhangMember 2021-04-28 0001263364 gtvi:JingheZhangMember 2021-09-30 0001263364 gtvi:JowayShengshiMember 2021-07-01 2021-09-30 0001263364 gtvi:JowayShengshiMember 2021-01-01 2021-09-30 0001263364 gtvi:JowayShengshiMember 2020-01-01 2020-09-30 0001263364 gtvi:JowayShengshiMember 2021-09-30 0001263364 gtvi:JowayShengshiMember 2020-09-30 0001263364 gtvi:JowayShengshiMember 2021-04-28 0001263364 gtvi:CrystalGlobeMember 2020-11-20 0001263364 gtvi:MergerAgreementMember 2021-09-30 0001263364 gtvi:JingheZhangMember 2021-09-30 0001263364 gtvi:JingheZhangMember 2020-12-31 0001263364 gtvi:JowayShengshiMember 2021-09-30 0001263364 gtvi:JowayShengshiMember 2020-12-31 shares iso4217:USD iso4217:USD shares pure 10-Q true 2021-09-30 2021 false 333-108715 Joway Health Industries Group Inc. NV 98-0221494 No.2 Baowang Road Baodi Economic Development Zone Tianjin CN 301800 (86) 022-22533666 None Yes Yes Non-accelerated Filer true false true 20054000 119070 119070 119070 119070 90095 51344 2610 693546 92705 863960 0.001 0.001 1000000 1000000 0.001 0.001 200000000 200000000 20054000 20054000 20054000 20054000 20054 20054 7228862 6469236 -7341621 -7234180 -92705 -744890 119070 -10884 -25317 -107441 -180814 10884 25317 107441 180814 -10884 -25317 -107441 -180814 48 252 -48 -252 -10884 -25365 -107441 -181066 -10884 -25365 -107441 -181066 -169330 -548155 -10884 -194695 -107441 -729221 103625 60934 -10884 -91070 -107441 -668287 0 0 -0.01 -0.01 -0.01 -0.03 20054000 20054000 20054000 20054000 -107441 -181066 119070 119070 38751 28000 -68690 -153066 -274499 -68690 -427565 68690 153065 68690 153065 281753 68690 434818 -7253 295928 463698 <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>NOTE 1<span style="font-family: Times New Roman, Times, Serif">  </span>– ORGANIZATION </b></p><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05pt; text-align: justify">The unaudited condensed consolidated financial statements include the financial statements of Joway Health Industries Group Inc. (referred to herein as “Joway Health”), its subsidiaries, and variable interest entities (“VIEs”) where Joway Health is deemed the primary beneficiary. Joway Health, its subsidiaries and VIEs are collectively referred to herein as the “Company”, “we” and “us”.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05pt; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Joway Health (formerly G2 Ventures, Inc.) was originally incorporated under the laws of the State of Texas on March 21, 2003. On September 21, 2010, Joway Health entered into a Share Exchange Agreement (the “Share Exchange”) with the sole stockholder of Dynamic Elite International Limited. As a result of the Share Exchange, Dynamic Elite became a wholly-owned subsidiary of Joway Health and the stockholders of Dynamic Elite acquired approximately 76.08% of the issued and outstanding stock of Joway Health. The share exchange transaction resulted in the shareholders of Dynamic Elite acquiring a majority voting interest in Joway Health. Generally accepted accounting principles in the United States of America require that the company whose shareholders retain the majority interest in the combined business be treated as the acquirer for accounting purposes. The reverse acquisition process utilizes the capital structure of Joway Health and the assets and liabilities of Dynamic Elite recorded at historical cost. On December 22, 2010, Joway Health changed its jurisdiction of incorporation from the State of Texas to the State of Nevada.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dynamic Elite International Limited (referred to herein as “Dynamic Elite”) was incorporated under the laws of the British Virgin Islands on June 2, 2010 as a limited liability company (a BVI company). Dynamic Elite engages in manufacturing and distributing tourmaline products in China. Its wholly owned subsidiary, Tianjin Junhe Management Consulting Co., Ltd. was incorporated on September 15, 2010 in Tianjin, People’s Republic of China (“PRC”). Other than the equity interest in Junhe Consulting, Dynamic Elite does not own any assets or conduct any operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Tianjin Junhe Management Consulting Co., Ltd. (referred to herein as “Junhe Consulting”) conducts its business through Tianjin Joway Shengshi Group Co., Ltd. that is consolidated as a variable interest entity.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Tianjin Joway Shengshi Group Co., Ltd. (referred to herein as “Joway Shengshi”) was incorporated in PRC on May 17, 2007. Joway Shengshi is currently owned 99% by Jinghe Zhang, the Company’s current CEO and President and 1% by Song Baogang. Joway Shengshi engages in manufacturing and distributing tourmaline products in China. Shenyang Joway Electronic Technology Co., Ltd., Tianjin Joway Decoration Engineering Co., Ltd. and Tianjin Oriental Shengtang Trading Import &amp; Export Trading Co., Ltd are subsidiaries of Joway Shengshi.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Shenyang Joway Electronic Technology Co., Ltd. (referred to herein as “Joway Technology”) was originally named Liaoning Joway Technology Engineering Co., Ltd. which was incorporated on March 28, 2007 in PRC. The name was changed on June 22, 2011. It engages in the distribution of Tourmaline Activated Water Machines and Tourmaline Wellness Houses. Prior to July 25, 2010, Joway Shengshi owned 90.91% of Joway Technology. Joway Shengshi entered into a share acquisition agreement with Jingyun Chen, another stockholder of Joway Technology on July 25, 2010 to acquire the remaining 9.09% of the share of Joway Technology. As a result of the share acquisition, Joway Technology became a wholly-owned subsidiary of Joway Shengshi.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Tianjin Joway Decoration Engineering Co., Ltd. (referred to herein as “Joway Decoration”) was incorporated on April 22, 2009 in PRC. It engages in the distribution of Tourmaline Activated Water Machines, Tourmaline Wellness House for family use and Tourmaline Wellness House materials. Prior to July 9, 2010, Joway Shengshi owned 90% of Joway Decoration. Joway Shengshi entered into a share acquisition agreement with Jingyun Chen, another stockholder of Joway Decoration on July 9, 2010 to acquire the remaining 10% of the shares of Joway Decoration. As a result of the share acquisition, Joway Decoration became a wholly-owned subsidiary of Joway Shengshi. Jingyun Chen is currently the General Manager of Joway Decoration.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Tianjin Oriental Shengtang Import &amp; Export Trading Co., Ltd. (referred to herein as “Shengtang Trading”) was incorporated on September 18, 2009 in the PRC. It engages in purchasing raw materials which it sells to other companies of the group. Prior to July 28, 2010, Joway Shengshi owned 95% of Shengtang Trading. Joway Shengshi entered into a share acquisition agreement with Wang Aiying, another stockholder of Shengtang Trading on July 28, 2010 to acquire the remaining 5% of the shares of Shengtang Trading. As a result of the share acquisition, Shengtang Trading became a wholly-owned subsidiary of Joway Shengshi.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table lists the Company and its subsidiaries:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; width: 25%; text-align: center"><span style="font-size: 10pt"><b>Name</b></span></td> <td style="width: 2%; text-align: center"> </td> <td style="border-bottom: Black 1.5pt solid; width: 15%; text-align: center"><span style="font-size: 10pt"><b>Domicile and Date of Incorporation</b></span></td> <td style="width: 2%; text-align: center"> </td> <td style="border-bottom: Black 1.5pt solid; width: 13%; text-align: center"><span style="font-size: 10pt"><b>Paid in Capital</b></span></td> <td style="width: 2%; text-align: center"> </td> <td style="border-bottom: Black 1.5pt solid; width: 18%; text-align: center"><span style="font-size: 10pt"><b>Percentage of Effective Ownership</b></span></td> <td style="width: 2%; text-align: center"> </td> <td style="border-bottom: Black 1.5pt solid; width: 21%; text-align: center"><span style="font-size: 10pt"><b>Principal Activities</b></span></td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">Joway Health Industries Group Inc.</span></td> <td style="vertical-align: top; text-align: center"> </td> <td style="text-align: center; vertical-align: top"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">March 21, 2003,</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Nevada</p></td> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">USD 20,054</span></td> <td style="vertical-align: top; text-align: center"> </td> <td style="text-align: center; vertical-align: top"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">86.8% owned by Crystal Globe Limited</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">13.2%owned by other institutional and individual investors</p></td> <td style="vertical-align: top; text-align: center"> </td> <td style="text-align: center; vertical-align: top"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Investment</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Holding</p></td></tr> <tr> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"> </td> <td style="text-align: center; vertical-align: top"> </td> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"> </td> <td style="text-align: center; vertical-align: top"> </td> <td style="vertical-align: top; text-align: center"> </td> <td style="text-align: center; vertical-align: top"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">Dynamic Elite International Limited</span></td> <td style="vertical-align: top; text-align: center"> </td> <td style="text-align: center; vertical-align: top"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">June 2, 2010,</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">British Virgin Islands</p></td> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">USD 10,000</span></td> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">100% owned by Joway Health Industries Group Inc.</span></td> <td style="vertical-align: top; text-align: center"> </td> <td style="text-align: center; vertical-align: top"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Investment</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Holding</p></td></tr> <tr> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"> </td> <td style="text-align: center; vertical-align: top"> </td> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"> </td> <td style="text-align: center; vertical-align: top"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">Tianjin Junhe Management Consulting Co., Ltd.</span></td> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">September 15, 2010, PRC</span></td> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">USD 20,000</span></td> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">100% owned by Dynamic Elite International Limited</span></td> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">Advisory</span></td></tr> <tr> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">Tianjin Joway Shengshi Group Co., Ltd.</span></td> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">May 17, 2007, PRC</span></td> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">USD 7,216,140.72</span></td> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">99% owned by Jinghe Zhang,  and 1% owned  by Baogang Song</span></td> <td style="vertical-align: top; text-align: center"> </td> <td style="text-align: center; vertical-align: top"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Production and</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">distribution of Healthcare Knit Goods and Daily Healthcare and Personal Care products</p></td></tr> <tr> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"> </td> <td style="text-align: center; vertical-align: top"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">Shenyang Joway Electronic Technology Co., Ltd.</span></td> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">March 28, 2007, PRC</span></td> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">USD 142,072.97</span></td> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">100% owned by Tianjin Joway Shengshi Group Co., Ltd</span></td> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">Distribution of Tourmaline Activated Water Machine and construction of Tourmaline Wellness House</span></td></tr> <tr> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">Tianjin Joway Decoration Engineering Co., Ltd.</span></td> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">April 22, 2009, PRC</span></td> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">USD 292,367.74</span></td> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">100% owned by Tianjin Joway Shengshi Group Co., Ltd</span></td> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">Distribution of Wellness House for family use and Activated Water Machine and construction of Tourmaline Wellness House</span></td></tr> <tr> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">Tianjin Oriental Shengtang Import &amp; Export Trading Co., Ltd.</span></td> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">September 18, 2009, PRC</span></td> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">USD 292,463.75</span></td> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">100% owned by Tianjin Joway Shengshi Group Co., Ltd</span></td> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">Distribution of tourmaline products</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 16, 2010, prior to the share exchange, Junhe Consulting entered into a series of contractual agreements (the “Contractual Agreements”) with Joway Shengshi and Joway Shengshi’s owners. The following is a brief description of the Contractual Agreements entered into between Junhe Consulting and Joway Shengshi or Joway Shengshi’s owners<span style="font-family: Times New Roman, Times, Serif">:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1. <i>Consulting Services Agreement.</i> Pursuant to the consulting services agreement between Junhe Consulting and Joway Shengshi, Junhe Consulting has the right to advise, consult, manage and operate Joway Shengshi, and collect and own all of the net profits of the Operating Entities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2. <i>Operating Agreement.</i> Under the operating agreement between Junhe Consulting and Joway Shengshi, Junhe Consulting has the right to recommend director candidates and appoint the senior executives of Joway Shengshi, approve any transactions that may materially affect the assets, liabilities, rights or operations of Joway Shengshi, and guarantee the contractual performance by Joway Shengshi of any agreements with third parties, in exchange for a pledge by Joway Shengshi of its accounts receivable and assets.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3. <i>Voting Rights Proxy Agreement.</i> Under the voting rights proxy agreement between Joway Shengshi’s owners and Junhe Consulting, the owners of Joway Shengshi have vested their collective voting control over Joway Shengshi to Junhe Consulting and will only transfer their respective equity interests in Joway Shengshi to Junhe Consulting or its designee.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4. <i>Option Agreement.</i> Under the option agreement between Joway Shengshi’s owners and Junhe Consulting, the owners of Joway Shengshi have granted Junhe Consulting the irrevocable right and option to acquire all of their equity interests in Joway Shengshi.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">5. <i>Equity Pledge Agreement.</i> Under the equity pledge agreement between Joway Shengshi’s owners and Junhe Consulting, the owners of Joway Shengshi have pledged all of their rights, titles and interests in Joway Shengshi to Junhe Consulting to guarantee Joway Shengshi’s performance of its obligations under the Consulting Services Agreement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a result of the Contractual Agreements, Joway Shengshi is effectively a variable interest entity of Junhe Consulting. Accordingly, the Company through its wholly-owned subsidiary Junhe Consulting, consolidates Joway Shengshi’s results of operation, assets and liabilities in its financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the Share Exchange and as consideration for entering into the VIE Agreements, Jingshe Zhang and Baogang Song, the shareholders of Joway Shengshi (the “Grantees”), entered into a Call Option Agreement, dated July 20,2010 with Lionel Evan Liu (the “Grantor”), the sole shareholder of Crystal Globe (the controlling shareholder of Dynamic Elite), a British Virgin Islands company (the “Call Option Agreement”), pursuant to which the Grantees had the right to purchase up to 100% of the shares of Crystal Globe (the “Call Option”) at an exercise price of $2.00 per share (the “Exercise Price”) for a period of five years. The Call Option vested as to 34% of the shares of Crystal Globe on April 2, 2011 and as to 33% on each of April 2, 2012 and 2013 (the respective “Call Option Effective Date”). On March 28, 2015, the Grantor and Grantees amended the Call Option Agreement, to (i) reduce the Exercise Price to $0.00 per share and (ii) extend the Grantees’ rights to exercise their call option within ten years from the respective Option Effective Date.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 13, 2016, Jinghe Zhang exercised the Call Option as to 99% of the shares of Crystal Globe and Baogang Song exercised his Call Option as to 1% of the shares of Crystal Globe. As a result of exercising the Call Option, Jinghe Zhang became the controlling shareholder of Crystal Globe and in turn, the controlling shareholder of the Company. On November 20, 2016, Baogang Song transferred 1% of the shares of Crystal Globe to Jinghe Zhang. Consequently, Jinghe Zhang controls 17,408,000 shares, or 86.8%, of the issued and outstanding shares of the Company’s common stock.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 31, 2020, upon the Company completed the Merger Agreement with Crystal Globe, Joway Health becomes a “shell company” (as such term is defined in Rule 12b-2 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Going forward, the Company intends to seek, investigate and, if such investigation warrants, engage in a business combination with a private entity whose business presents an opportunity for the Company’s stockholders.</p> 0.7608 0.99 0.01 0.9091 0.0909 0.90 0.10 0.95 0.05 <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; width: 25%; text-align: center"><span style="font-size: 10pt"><b>Name</b></span></td> <td style="width: 2%; text-align: center"> </td> <td style="border-bottom: Black 1.5pt solid; width: 15%; text-align: center"><span style="font-size: 10pt"><b>Domicile and Date of Incorporation</b></span></td> <td style="width: 2%; text-align: center"> </td> <td style="border-bottom: Black 1.5pt solid; width: 13%; text-align: center"><span style="font-size: 10pt"><b>Paid in Capital</b></span></td> <td style="width: 2%; text-align: center"> </td> <td style="border-bottom: Black 1.5pt solid; width: 18%; text-align: center"><span style="font-size: 10pt"><b>Percentage of Effective Ownership</b></span></td> <td style="width: 2%; text-align: center"> </td> <td style="border-bottom: Black 1.5pt solid; width: 21%; text-align: center"><span style="font-size: 10pt"><b>Principal Activities</b></span></td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">Joway Health Industries Group Inc.</span></td> <td style="vertical-align: top; text-align: center"> </td> <td style="text-align: center; vertical-align: top"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">March 21, 2003,</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Nevada</p></td> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">USD 20,054</span></td> <td style="vertical-align: top; text-align: center"> </td> <td style="text-align: center; vertical-align: top"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">86.8% owned by Crystal Globe Limited</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">13.2%owned by other institutional and individual investors</p></td> <td style="vertical-align: top; text-align: center"> </td> <td style="text-align: center; vertical-align: top"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Investment</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Holding</p></td></tr> <tr> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"> </td> <td style="text-align: center; vertical-align: top"> </td> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"> </td> <td style="text-align: center; vertical-align: top"> </td> <td style="vertical-align: top; text-align: center"> </td> <td style="text-align: center; vertical-align: top"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">Dynamic Elite International Limited</span></td> <td style="vertical-align: top; text-align: center"> </td> <td style="text-align: center; vertical-align: top"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">June 2, 2010,</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">British Virgin Islands</p></td> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">USD 10,000</span></td> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">100% owned by Joway Health Industries Group Inc.</span></td> <td style="vertical-align: top; text-align: center"> </td> <td style="text-align: center; vertical-align: top"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Investment</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Holding</p></td></tr> <tr> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"> </td> <td style="text-align: center; vertical-align: top"> </td> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"> </td> <td style="text-align: center; vertical-align: top"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">Tianjin Junhe Management Consulting Co., Ltd.</span></td> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">September 15, 2010, PRC</span></td> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">USD 20,000</span></td> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">100% owned by Dynamic Elite International Limited</span></td> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">Advisory</span></td></tr> <tr> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">Tianjin Joway Shengshi Group Co., Ltd.</span></td> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">May 17, 2007, PRC</span></td> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">USD 7,216,140.72</span></td> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">99% owned by Jinghe Zhang,  and 1% owned  by Baogang Song</span></td> <td style="vertical-align: top; text-align: center"> </td> <td style="text-align: center; vertical-align: top"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Production and</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">distribution of Healthcare Knit Goods and Daily Healthcare and Personal Care products</p></td></tr> <tr> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"> </td> <td style="text-align: center; vertical-align: top"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">Shenyang Joway Electronic Technology Co., Ltd.</span></td> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">March 28, 2007, PRC</span></td> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">USD 142,072.97</span></td> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">100% owned by Tianjin Joway Shengshi Group Co., Ltd</span></td> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">Distribution of Tourmaline Activated Water Machine and construction of Tourmaline Wellness House</span></td></tr> <tr> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">Tianjin Joway Decoration Engineering Co., Ltd.</span></td> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">April 22, 2009, PRC</span></td> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">USD 292,367.74</span></td> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">100% owned by Tianjin Joway Shengshi Group Co., Ltd</span></td> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">Distribution of Wellness House for family use and Activated Water Machine and construction of Tourmaline Wellness House</span></td></tr> <tr> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">Tianjin Oriental Shengtang Import &amp; Export Trading Co., Ltd.</span></td> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">September 18, 2009, PRC</span></td> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">USD 292,463.75</span></td> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">100% owned by Tianjin Joway Shengshi Group Co., Ltd</span></td> <td style="vertical-align: top; text-align: center"> </td> <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">Distribution of tourmaline products</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> March 21, 2003, Nevada 20054 86.8% owned by Crystal Globe Limited 13.2%owned by other institutional and individual investors Investment Holding June 2, 2010, British Virgin Islands 10000 100% owned by Joway Health Industries Group Inc. Investment Holding September 15, 2010, PRC 20000 100% owned by Dynamic Elite International Limited Advisory May 17, 2007, PRC 7216140.72 99% owned by Jinghe Zhang,  and 1% owned  by Baogang Song Production and distribution of Healthcare Knit Goods and Daily Healthcare and Personal Care products March 28, 2007, PRC 142072.97 100% owned by Tianjin Joway Shengshi Group Co., Ltd Distribution of Tourmaline Activated Water Machine and construction of Tourmaline Wellness House April 22, 2009, PRC 292367.74 100% owned by Tianjin Joway Shengshi Group Co., Ltd Distribution of Wellness House for family use and Activated Water Machine and construction of Tourmaline Wellness House September 18, 2009, PRC 292463.75 100% owned by Tianjin Joway Shengshi Group Co., Ltd Distribution of tourmaline products 1 2 The Call Option vested as to 34% of the shares of Crystal Globe on April 2, 2011 and as to 33% on each of April 2, 2012 and 2013 (the respective “Call Option Effective Date”). 0 0.99 0.01 0.01 17408000 0.868 <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify"><b>NOTE 2 – GOING CONCERN</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the discharge of liabilities in the normal course of business for the foreseeable future.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As reflected in the accompanying consolidated financial statements, for the nine months ended September 30, 2021 and 2020, we incurred net losses of $107,441 and $729,221, respectively. As of September 30, 2021, we had an accumulated deficit of $7.3 million. Management believes these factors raise substantial doubt about our ability to continue as a going concern for the next twelve months.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The continuation of our company as a going concern through the next twelve months is dependent upon (1) the continued financial support from our stockholders or external financing. Management believes that our existing stockholders will provide the additional cash to meet our obligations as they become due, and (2) that it will be able to implement its business plan to expand our company’s operations and generate sufficient revenues to meet its obligations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These conditions raise substantial doubt about our company’s ability to continue as a going concern. These financial statements do not include any adjustments to reflect the possible future effect on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the outcome of these uncertainties. Management believes that the actions presently being taken to obtain additional funding and implement its strategic plan provides the opportunity for our company to continue as a going concern.</p> 107441 729221 7300000 <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify"><b>NOTE 3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Basis of Presentation</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying unaudited consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“US GAAP”). Accordingly, they do not include all of the information and the footnotes required by generally accepted accounting principles for complete financial statements. The Company’s functional currency is the Chinese Renminbi (“RMB”) in 2020; however, the accompanying unaudited consolidated financial statements have been translated and presented in United States Dollars (“USD”). All significant inter-company transactions and balances have been eliminated. The consolidated financial statements include all adjustments that, in the opinion of management, are necessary to make the financial statements not misleading.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Operating results for the nine month period ended September 30, 2021 are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2021. The accompanying unaudited consolidated financial statements should be read in conjunction with the Company’s form 10-K for the fiscal year ended December 31, 2020 which was filed on August 16, 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Use of Estimates</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of the consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Management makes these estimates using the best information available at the time the estimates are made. Actual results could differ from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Reclassification</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain prior year balances were reclassified to conform to the current year’s presentation with consideration of reflecting all of the Company’s subsidiaries and VIEs as discontinued operations. None of these reclassifications had an impact on reported financial position or cash flows for any of the periods presented.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Basis of Consolidation</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the periods prior to the sale of Dynamic Elite, its subsidiaries, and controlled VIEs, the Company consolidated financial statements include Dynamic Elite, its wholly owned subsidiaries, and controlled VIEs. All significant inter-company accounts and transactions have been eliminated in the consolidation.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Foreign Currency Translation</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated financial statements are presented in USD. The functional currency of the Company is RMB in 2020. The consolidated financial statements are translated into United States dollars from RMB at period-end exchange rates as to assets and liabilities and average exchange rates as to revenues and expenses. Equity accounts are translated at their historical exchange rates when the equity transactions occurred. The resulting transaction adjustments are recorded as a component of stockholders’ equity. Gains and losses from foreign currency transactions are included in net income.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: justify"><b> </b></td><td style="white-space: nowrap; padding-bottom: 1.5pt"><b> </b></td> <td colspan="2" style="padding-bottom: 1.5pt; white-space: nowrap; text-align: center"><b>For the <br/> nine months ended<br/> September 30,</b></td><td style="white-space: nowrap; padding-bottom: 1.5pt"><b> </b></td><td style="white-space: nowrap; padding-bottom: 1.5pt"><b> </b></td> <td colspan="2" style="padding-bottom: 1.5pt; white-space: nowrap; text-align: center"><b>For the <br/> year ended<br/> December 31,</b></td><td style="white-space: nowrap; padding-bottom: 1.5pt"><b> </b></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"><b> </b></td><td style="padding-bottom: 1.5pt"><b> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>2020</b></td><td style="padding-bottom: 1.5pt"><b> </b></td><td style="padding-bottom: 1.5pt"><b> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>2020</b></td><td style="padding-bottom: 1.5pt"><b> </b></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: justify">Period ended RMB: USD Exchange rate</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">6.8101</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">6.5249</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">Average RMB: USD Exchange rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6.9917</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6.8976</td><td style="text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The RMB is not freely convertible into foreign currency and all foreign exchange transactions must take place through authorized institutions. No representation is made that the RMB amounts could have been, or could be, converted into USD at the rates used in translation.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Foreign currency translation adjustments have been reported as comprehensive income in the consolidated financial statements and totaled $103,625 for the three months ended September 30, 2020, and $60,934 for the nine months ended September 30, 2020. No foreign currency translation adjustments for the three months and nine months ended September 30, 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Other Comprehensive Income</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other comprehensive income is defined as the change in equity during the period from transactions and other events, excluding the changes resulting from investments by owners and distributions to owners, and is not included in the computation of income tax expense or benefit. Accumulated other comprehensive income represents the accumulated balance of foreign currency translation adjustments.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Concentrations of Credit Risk</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Prior to the Merger Agreement, the Company’s operations are carried out in the PRC. Accordingly, the Company’s business, financial condition, and results of operations may be influenced by the political, economic, and legal environment in the PRC, and by the general state of the PRC’s economy. The Company’s operations in the PRC are subject to specific considerations and significant risks not typically associated with companies in North America. The Company’s results may be adversely affected by changes in governmental policies with respect to laws and regulations, anti-inflationary measures, currency conversion and remittance abroad, and rates and methods of taxation, among other things. Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash and trade accounts receivable. Substantially all of the Company’s cash is maintained with state-owned banks within the PRC, and no deposits are covered by insurance. The Company has not experienced any losses in such accounts and believes it is not exposed to any risks on its cash in bank accounts.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Fair Value of Financial Instruments</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 820 establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">●</td><td style="text-align: justify">Level 1—defined as observable inputs such as quoted prices in active markets for identical assets or liabilities;</td> </tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 26.6pt; text-indent: -5pt"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">●</td><td style="text-align: justify">Level 2—defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and</td> </tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 26.6pt; text-indent: -5pt"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">●</td><td style="text-align: justify">Level 3—defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.</td> </tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 26.6pt; text-indent: -5pt"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The carrying amounts reported in the balance sheets for cash, accounts receivable, other receivable, accounts payable, other payable, and amounts due from related parties generally approximate their fair market values based on the short-term maturity of these instruments. ASC 825-10 “Financial Instruments” allows entities to voluntarily choose to measure certain financial assets and liabilities at fair value (fair value option). The fair value option may be elected on an instrument-by-instrument basis and is irrevocable, unless a new election date occurs. If the fair value option is elected for an instrument, unrealized gains and losses for that instrument should be reported in earnings at each subsequent reporting date. The Company did not elect to apply the fair value option to any outstanding instruments.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Revenue Recognition</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company recognizes revenue when control of promised goods or services is transferred to the company’s customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Prior to the Merger Agreement, with respect to sales of product to both franchisee and non-franchisee customers, the Company transfers control, invoices the customer and recognizes revenue upon shipment to the customer. Sales prices are based on fixed price lists that are different depending on whether the price list is for franchisee customers or for non-franchisee customers. Sales, value add and other taxes collected concurrent with revenue-producing activities are excluded from revenue.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Income Taxes</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for income taxes in accordance with FASB ASC 740 “Income Taxes” (formerly SFAS No. 109 Accounting for Income Taxes), which is an asset and liability approach that requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the Company’s financial statements or tax returns. ASC 740 additionally requires the establishment of a valuation allowance to reflect the likelihood of realization of deferred tax assets. Realization of deferred tax assets is dependent upon future earnings, if any, of which the timing and amount are uncertain.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">According to ASC 740, the evaluation of a tax position is a two-step process. The first step is to determine whether it is more likely than not that a tax position will be sustained upon examination, including the resolution of any related appeals or litigation based on the technical merits of that position. The second step is to measure a tax position that meets the more-likely-than-not threshold to determine the amount of benefit to be recognized in the financial statements. A tax position is measured at the largest amount of benefit that is greater than 50% likelihood of being realized upon ultimate settlement. Tax positions that previously failed to meet the more-likely-than-not recognition threshold should be recognized in the first subsequent period in which the threshold is met. Previously recognized tax positions that no longer meet the more-likely-than-not criteria should be de-recognized in the first subsequent financial reporting period in which the threshold is no longer met. ASC 740 also provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosures, and transition.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Basic and Diluted Earnings per Share</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company reports earnings per share in accordance with FASB ASC 260 “Earnings per share”. The Company’s basic earnings per share are computed using the weighted average number of shares outstanding for the periods presented. Diluted earnings per share are computed based on the assumption that any dilutive options or warrants were converted or exercised. Dilution is computed by applying the treasury stock method. Under this method, the Company’s outstanding stock warrants are assumed to be exercised, and funds thus obtained were assumed to be used to purchase common stock at the average market price during the period. There were no dilutive instruments outstanding during the three month and nine month periods ended September 30, 2021 and 2020.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Recently Issued Accounting Pronouncements</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”), which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020, with early adoption permitted. The Company adopted the standard in the first quarter of 2021. Adoption of the standard did not have a significant impact on the Company’s consolidated statement of earnings in 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other accounting standards that have been issued or proposed by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on the Company’s consolidated financial statements upon adoption.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Basis of Presentation</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying unaudited consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“US GAAP”). Accordingly, they do not include all of the information and the footnotes required by generally accepted accounting principles for complete financial statements. The Company’s functional currency is the Chinese Renminbi (“RMB”) in 2020; however, the accompanying unaudited consolidated financial statements have been translated and presented in United States Dollars (“USD”). All significant inter-company transactions and balances have been eliminated. The consolidated financial statements include all adjustments that, in the opinion of management, are necessary to make the financial statements not misleading.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Operating results for the nine month period ended September 30, 2021 are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2021. The accompanying unaudited consolidated financial statements should be read in conjunction with the Company’s form 10-K for the fiscal year ended December 31, 2020 which was filed on August 16, 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Use of Estimates</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of the consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Management makes these estimates using the best information available at the time the estimates are made. Actual results could differ from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Reclassification</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain prior year balances were reclassified to conform to the current year’s presentation with consideration of reflecting all of the Company’s subsidiaries and VIEs as discontinued operations. None of these reclassifications had an impact on reported financial position or cash flows for any of the periods presented.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Basis of Consolidation</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the periods prior to the sale of Dynamic Elite, its subsidiaries, and controlled VIEs, the Company consolidated financial statements include Dynamic Elite, its wholly owned subsidiaries, and controlled VIEs. All significant inter-company accounts and transactions have been eliminated in the consolidation.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Foreign Currency Translation</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated financial statements are presented in USD. The functional currency of the Company is RMB in 2020. The consolidated financial statements are translated into United States dollars from RMB at period-end exchange rates as to assets and liabilities and average exchange rates as to revenues and expenses. Equity accounts are translated at their historical exchange rates when the equity transactions occurred. The resulting transaction adjustments are recorded as a component of stockholders’ equity. Gains and losses from foreign currency transactions are included in net income.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: justify"><b> </b></td><td style="white-space: nowrap; padding-bottom: 1.5pt"><b> </b></td> <td colspan="2" style="padding-bottom: 1.5pt; white-space: nowrap; text-align: center"><b>For the <br/> nine months ended<br/> September 30,</b></td><td style="white-space: nowrap; padding-bottom: 1.5pt"><b> </b></td><td style="white-space: nowrap; padding-bottom: 1.5pt"><b> </b></td> <td colspan="2" style="padding-bottom: 1.5pt; white-space: nowrap; text-align: center"><b>For the <br/> year ended<br/> December 31,</b></td><td style="white-space: nowrap; padding-bottom: 1.5pt"><b> </b></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"><b> </b></td><td style="padding-bottom: 1.5pt"><b> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>2020</b></td><td style="padding-bottom: 1.5pt"><b> </b></td><td style="padding-bottom: 1.5pt"><b> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>2020</b></td><td style="padding-bottom: 1.5pt"><b> </b></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: justify">Period ended RMB: USD Exchange rate</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">6.8101</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">6.5249</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">Average RMB: USD Exchange rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6.9917</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6.8976</td><td style="text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The RMB is not freely convertible into foreign currency and all foreign exchange transactions must take place through authorized institutions. No representation is made that the RMB amounts could have been, or could be, converted into USD at the rates used in translation.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Foreign currency translation adjustments have been reported as comprehensive income in the consolidated financial statements and totaled $103,625 for the three months ended September 30, 2020, and $60,934 for the nine months ended September 30, 2020. No foreign currency translation adjustments for the three months and nine months ended September 30, 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: justify"><b> </b></td><td style="white-space: nowrap; padding-bottom: 1.5pt"><b> </b></td> <td colspan="2" style="padding-bottom: 1.5pt; white-space: nowrap; text-align: center"><b>For the <br/> nine months ended<br/> September 30,</b></td><td style="white-space: nowrap; padding-bottom: 1.5pt"><b> </b></td><td style="white-space: nowrap; padding-bottom: 1.5pt"><b> </b></td> <td colspan="2" style="padding-bottom: 1.5pt; white-space: nowrap; text-align: center"><b>For the <br/> year ended<br/> December 31,</b></td><td style="white-space: nowrap; padding-bottom: 1.5pt"><b> </b></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"><b> </b></td><td style="padding-bottom: 1.5pt"><b> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>2020</b></td><td style="padding-bottom: 1.5pt"><b> </b></td><td style="padding-bottom: 1.5pt"><b> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>2020</b></td><td style="padding-bottom: 1.5pt"><b> </b></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: justify">Period ended RMB: USD Exchange rate</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">6.8101</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">6.5249</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">Average RMB: USD Exchange rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6.9917</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6.8976</td><td style="text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> 6.8101 6.5249 6.9917 6.8976 103625 60934 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Other Comprehensive Income</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other comprehensive income is defined as the change in equity during the period from transactions and other events, excluding the changes resulting from investments by owners and distributions to owners, and is not included in the computation of income tax expense or benefit. Accumulated other comprehensive income represents the accumulated balance of foreign currency translation adjustments.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Concentrations of Credit Risk</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Prior to the Merger Agreement, the Company’s operations are carried out in the PRC. Accordingly, the Company’s business, financial condition, and results of operations may be influenced by the political, economic, and legal environment in the PRC, and by the general state of the PRC’s economy. The Company’s operations in the PRC are subject to specific considerations and significant risks not typically associated with companies in North America. The Company’s results may be adversely affected by changes in governmental policies with respect to laws and regulations, anti-inflationary measures, currency conversion and remittance abroad, and rates and methods of taxation, among other things. Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash and trade accounts receivable. Substantially all of the Company’s cash is maintained with state-owned banks within the PRC, and no deposits are covered by insurance. The Company has not experienced any losses in such accounts and believes it is not exposed to any risks on its cash in bank accounts.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Fair Value of Financial Instruments</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 820 establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">●</td><td style="text-align: justify">Level 1—defined as observable inputs such as quoted prices in active markets for identical assets or liabilities;</td> </tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 26.6pt; text-indent: -5pt"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">●</td><td style="text-align: justify">Level 2—defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and</td> </tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 26.6pt; text-indent: -5pt"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">●</td><td style="text-align: justify">Level 3—defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.</td> </tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 26.6pt; text-indent: -5pt"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The carrying amounts reported in the balance sheets for cash, accounts receivable, other receivable, accounts payable, other payable, and amounts due from related parties generally approximate their fair market values based on the short-term maturity of these instruments. ASC 825-10 “Financial Instruments” allows entities to voluntarily choose to measure certain financial assets and liabilities at fair value (fair value option). The fair value option may be elected on an instrument-by-instrument basis and is irrevocable, unless a new election date occurs. If the fair value option is elected for an instrument, unrealized gains and losses for that instrument should be reported in earnings at each subsequent reporting date. The Company did not elect to apply the fair value option to any outstanding instruments.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Revenue Recognition</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company recognizes revenue when control of promised goods or services is transferred to the company’s customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Prior to the Merger Agreement, with respect to sales of product to both franchisee and non-franchisee customers, the Company transfers control, invoices the customer and recognizes revenue upon shipment to the customer. Sales prices are based on fixed price lists that are different depending on whether the price list is for franchisee customers or for non-franchisee customers. Sales, value add and other taxes collected concurrent with revenue-producing activities are excluded from revenue.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Income Taxes</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for income taxes in accordance with FASB ASC 740 “Income Taxes” (formerly SFAS No. 109 Accounting for Income Taxes), which is an asset and liability approach that requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the Company’s financial statements or tax returns. ASC 740 additionally requires the establishment of a valuation allowance to reflect the likelihood of realization of deferred tax assets. Realization of deferred tax assets is dependent upon future earnings, if any, of which the timing and amount are uncertain.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">According to ASC 740, the evaluation of a tax position is a two-step process. The first step is to determine whether it is more likely than not that a tax position will be sustained upon examination, including the resolution of any related appeals or litigation based on the technical merits of that position. The second step is to measure a tax position that meets the more-likely-than-not threshold to determine the amount of benefit to be recognized in the financial statements. A tax position is measured at the largest amount of benefit that is greater than 50% likelihood of being realized upon ultimate settlement. Tax positions that previously failed to meet the more-likely-than-not recognition threshold should be recognized in the first subsequent period in which the threshold is met. Previously recognized tax positions that no longer meet the more-likely-than-not criteria should be de-recognized in the first subsequent financial reporting period in which the threshold is no longer met. ASC 740 also provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosures, and transition.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Basic and Diluted Earnings per Share</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company reports earnings per share in accordance with FASB ASC 260 “Earnings per share”. The Company’s basic earnings per share are computed using the weighted average number of shares outstanding for the periods presented. Diluted earnings per share are computed based on the assumption that any dilutive options or warrants were converted or exercised. Dilution is computed by applying the treasury stock method. Under this method, the Company’s outstanding stock warrants are assumed to be exercised, and funds thus obtained were assumed to be used to purchase common stock at the average market price during the period. There were no dilutive instruments outstanding during the three month and nine month periods ended September 30, 2021 and 2020.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Recently Issued Accounting Pronouncements</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”), which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020, with early adoption permitted. The Company adopted the standard in the first quarter of 2021. Adoption of the standard did not have a significant impact on the Company’s consolidated statement of earnings in 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other accounting standards that have been issued or proposed by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on the Company’s consolidated financial statements upon adoption.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify"><b>NOTE 4 – DECONSOLIDATION</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 20, 2020, Joway Health entered into a Merger Agreement (the “Merger Agreement”) with Dynamic Elite International Limited, a British Virgin Islands company and a wholly-owned subsidiary of the Company (“Dynamic Elite”), Crystal Globe Limited, a British Virgin Islands company (“Crystal Globe”) and Joway Merger Subsidiary Limited, a British Virgin Islands company and a wholly-owned subsidiary of Crystal Globe (“Merger Sub”). The Merger Agreement provides that, upon the terms and subject to the satisfaction or waiver of the conditions set forth therein, Merger Sub will be merged with and into Dynamic Elite (the “Merger”), with Dynamic Elite continuing as the surviving corporation as a wholly-owned subsidiary of Crystal Globe.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Crystal Globe, as the majority shareholder holding approximately 86.81% of the Company, is also the sole shareholder of Dynamic Elite after the Merger. Mr. Jinghe Zhang, as the President, Chief Executive Officer, Chairman and Director, and the majority beneficial owner of the Company, also serves as sole shareholder and executive director of Crystal Globe. As a result, the Company and Dynamic Elite are under common control of Crystal Globe and Mr. Jinghe Zhang.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the “Effective Time”) and as a result of the Merger, the ordinary shares of common stock of Dynamic Elite issued and outstanding immediately prior to the Effective Time, all of which are held by the Company, will be cancelled and extinguished. In accordance with the Merger Agreement, Crystal Globe has offered a cash consideration of $0.045 per share for outstanding shares of Joway Health’s common stock (the “Merger Consideration”). As of November 20, 2020, Joway Health reported 20,054,000 shares of common stock outstanding. As a result, Joway Health recognized a loss of $1,340,795 from this transaction.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In January 2021, Joway Health had received $119,070 from Crystal Globe and distributed proportionately to the Company’s minority shareholders, other than Crystal Globe, which represents 2,646,000 shares of Joway Health’s common stock. Since the remaining 17,408,000 shares of Joway Health’s common stock is owned by Crystal Globe, the $0.045 per share payment for the 17,408,000 shares is offset.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following is a reconciliation of the deconsolidation:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: justify; padding-bottom: 4pt">Selling price</td><td style="width: 1%; padding-bottom: 4pt"> </td> <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">902,430</td><td style="width: 1%; padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">Disposed assets and liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Cash</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">79,446</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">Current assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,133,812</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Fixed assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,194,533</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">Intangible assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">465,007</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,977,822</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify; padding-bottom: 1.5pt">Accumulated other comprehensive income</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(651,751</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,243,225</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify; padding-bottom: 4pt">Loss from disposal of discontinued component, net of income tax</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(1,340,795</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr> </table> 0.8681 0.045 20054000 1340795 In January 2021, Joway Health had received $119,070 from Crystal Globe and distributed proportionately to the Company’s minority shareholders, other than Crystal Globe, which represents 2,646,000 shares of Joway Health’s common stock. Since the remaining 17,408,000 shares of Joway Health’s common stock is owned by Crystal Globe, the $0.045 per share payment for the 17,408,000 shares is offset.  <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: justify; padding-bottom: 4pt">Selling price</td><td style="width: 1%; padding-bottom: 4pt"> </td> <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">902,430</td><td style="width: 1%; padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">Disposed assets and liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Cash</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">79,446</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">Current assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,133,812</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Fixed assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,194,533</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">Intangible assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">465,007</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,977,822</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify; padding-bottom: 1.5pt">Accumulated other comprehensive income</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(651,751</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,243,225</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify; padding-bottom: 4pt">Loss from disposal of discontinued component, net of income tax</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(1,340,795</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr> </table> 902430 79446 1133812 3194533 465007 1977822 -651751 2243225 -1340795 <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify"><b>NOTE 5 – RECEIVABLE FROM RELATED PARTY</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Receivable from related party consist of the following:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td><b> </b></td><td><b> </b></td> <td colspan="2" style="text-align: center"><b>September 30,</b></td><td><b> </b></td><td><b> </b></td> <td colspan="2" style="text-align: center"><b>December 31,</b></td><td><b> </b></td></tr> <tr style="vertical-align: bottom"> <td><b> </b></td><td style="padding-bottom: 1.5pt"><b> </b></td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>2021</b></td><td style="padding-bottom: 1.5pt"><b> </b></td><td style="padding-bottom: 1.5pt"><b> </b></td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>2020</b></td><td style="padding-bottom: 1.5pt"><b> </b></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left; padding-bottom: 4pt">Crystal Globe</td><td style="width: 1%; padding-bottom: 4pt"> </td> <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-58">      -</div></td><td style="width: 1%; padding-bottom: 4pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 4pt"> </td> <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">119,070</td><td style="width: 1%; padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The receivable from Crystal Globe is related to the Merger Agreement which is part of the Merger Consideration for Joway Health’s minority shareholders who hold 2,646,000 shares of Joway Health’s common stock.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In January 2021, Joway Health had received $119,070 from Crystal Globe and distributed proportionately to the Company’s minority shareholders.</p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td><b> </b></td><td><b> </b></td> <td colspan="2" style="text-align: center"><b>September 30,</b></td><td><b> </b></td><td><b> </b></td> <td colspan="2" style="text-align: center"><b>December 31,</b></td><td><b> </b></td></tr> <tr style="vertical-align: bottom"> <td><b> </b></td><td style="padding-bottom: 1.5pt"><b> </b></td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>2021</b></td><td style="padding-bottom: 1.5pt"><b> </b></td><td style="padding-bottom: 1.5pt"><b> </b></td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>2020</b></td><td style="padding-bottom: 1.5pt"><b> </b></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left; padding-bottom: 4pt">Crystal Globe</td><td style="width: 1%; padding-bottom: 4pt"> </td> <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-58">      -</div></td><td style="width: 1%; padding-bottom: 4pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 4pt"> </td> <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">119,070</td><td style="width: 1%; padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> 119070 2646000 119070 <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify"><b>NOTE 6 – SPECIAL DIVIDEND PAYABLE</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of September 30, 2021 and December 31, 2020, the Company reported $0 and $119,070 as special dividend payables, respectively. The payables are related to the Merger Agreement which is part of the Merger Consideration for Joway Health’s minority shareholders who hold 2,646,000 shares of Joway Health’s common stock. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 20, 2020, Joway Health entered into a Merger Agreement (the “Merger Agreement”) with Dynamic Elite International Limited, a British Virgin Islands company and a wholly-owned subsidiary of the Company (“Dynamic Elite”), Crystal Globe Limited, a British Virgin Islands company (“Crystal Globe”) and Joway Merger Subsidiary Limited, a British Virgin Islands company and a wholly-owned subsidiary of Crystal Globe (“Merger Sub”). The Merger Agreement provides that, upon the terms and subject to the satisfaction or waiver of the conditions set forth therein, Merger Sub will be merged with and into Dynamic Elite (the “Merger”), with Dynamic Elite continuing as the surviving corporation as a wholly-owned subsidiary of Crystal Globe. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Crystal Globe, as the majority shareholder holding approximately 86.81% of the Company, is also the sole shareholder of Dynamic Elite after the Merger. Mr. Jinghe Zhang, as the President, Chief Executive Officer, Chairman and Director, and the majority beneficial owner of the Company, also serves as sole shareholder and executive director of Crystal Globe. As a result, the Company and Dynamic Elite are under common control of Crystal Globe and Mr. Jinghe Zhang. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the “Effective Time”) and as a result of the Merger, the ordinary shares of common stock of Dynamic Elite issued and outstanding immediately prior to the Effective Time, all of which are held by the Company, will be cancelled and extinguished. In accordance with the Merger Agreement, Crystal Globe has offered a cash consideration of $0.045 per share for outstanding shares of Joway Health’s common stock (the “Merger Consideration”). As of November 20, 2020, Joway Health reported 20,054,000 shares of common stock outstanding. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a result of the Merger Agreement, Joway Health needs to distribute proportionately the Merger Consideration to the Company’s shareholders. In January 2021, Joway Health had received $119,070 from Crystal Globe and distributed proportionately to the Company’s minority shareholders, other than Crystal Globe, which represents 2,646,000 shares of Joway Health’s common stock. Since the remaining 17,408,000 shares of Joway Health’s common stock is owned by Crystal Globe, the $0.045 per share payment for the 17,408,000 shares is offset.</p> 0 119070 2646000 0.8681 0.045 20054000 Joway Health had received $119,070 from Crystal Globe and distributed proportionately to the Company’s minority shareholders, other than Crystal Globe, which represents 2,646,000 shares of Joway Health’s common stock. Since the remaining 17,408,000 shares of Joway Health’s common stock is owned by Crystal Globe, the $0.045 per share payment for the 17,408,000 shares is offset. <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify"><b>NOTE 7 – RELATED PARTY TRANSACTIONS</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05pt; text-align: justify">Payables due to related parties consist of the following:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> </p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"><b> </b></td><td style="white-space: nowrap"><b> </b></td> <td colspan="2" style="white-space: nowrap; text-align: center"><b>September 30,</b></td><td style="white-space: nowrap"><b> </b></td><td style="white-space: nowrap"><b> </b></td> <td colspan="2" style="white-space: nowrap; text-align: center"><b>December 31,</b></td><td style="white-space: nowrap"><b> </b></td></tr> <tr style="vertical-align: bottom"> <td><b> </b></td><td style="padding-bottom: 1.5pt"><b> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>2021</b></td><td style="padding-bottom: 1.5pt"><b> </b></td><td style="padding-bottom: 1.5pt"><b> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>2020</b></td><td style="padding-bottom: 1.5pt"><b> </b></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Jinghe Zhang</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,610</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">233,693</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Joway Shengshi</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-59">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">459,853</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,610</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">693,546</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The amounts owed to related parties are non-interest bearing and have no specified repayment terms.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Transactions with Jinghe Zhang</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is a shell company and has no cash, Mr. Jinghe Zhang, our President, Chief Executive Officer and director, agreed to advance operating capital to the Company. For the three months ended September 30, 2021 and 2020, the Company received $1,693 and $19,364 from Mr. Jinghe Zhang, respectively, for its continuing operating component. For the nine months ended September 30, 2021 and 2020, the Company received $68,690 and $153,065 from Mr. Jinghe Zhang, respectively, for its continuing operating component. For the three months and nine months ended September 30, 2021, the Company received $0 from Mr. Jinghe Zhang, respectively, for its discontinued operating component. For the Company’s discontinued operation component, during the three months and nine months ended September 30, 2020, the Company received $161,021 and $281,753 from Mr. Jinghe Zhang, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 28, 2021, Mr. Jinghe Zhang released the Company from $295,928.47 of indebtedness owed to him from the Company. As of September 30, 2021, the total unpaid principal balance due to Mr. Jinghe Zhang for advances was $2,610.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Transactions with Joway Shengshi</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Joway Shengshi is a company of the discontinued operations. Mr. Jinghe Zhang owns 99% of the equity interest in Joway Shengshi. For the three months ended September 30, 2021 and 2020, the Company received $0 from Joway Shengshi, respectively, for its continuing and discontinued operating components. For the nine months ended September 30, 2021 and 2020, we received $3,844 and $0 of advances from Joway Shengshi, respectively, for our continuing operation component. For our discontinued operation component, we received $0 from Joway Shengshi for the nine months ended September 30, 2021 and 2020.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 28, 2021, Joway Shengshi released the Company from $463,697.67 of indebtedness owed to it from the Company. As of September 30, 2021, the total unpaid principal balance due to Joway Shengshi for advances was $0.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Disposal of all of Joway Health’s subsidiaries and VIEs</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 20, 2020, Joway Health entered into a Merger Agreement (the “Merger Agreement”) with Dynamic Elite International Limited, a British Virgin Islands company and a wholly-owned subsidiary of the Company (“Dynamic Elite”), Crystal Globe Limited, a British Virgin Islands company (“Crystal Globe”) and Joway Merger Subsidiary Limited, a British Virgin Islands company and a wholly-owned subsidiary of Crystal Globe (“Merger Sub”). The Merger Agreement provides that, upon the terms and subject to the satisfaction or waiver of the conditions set forth therein, Merger Sub will be merged with and into Dynamic Elite (the “Merger”), with Dynamic Elite continuing as the surviving corporation as a wholly-owned subsidiary of Crystal Globe.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Crystal Globe, as the majority shareholder holding approximately 86.81% of the Company, is also the sole shareholder of Dynamic Elite after the Merger. Mr. Jinghe Zhang, as the President, Chief Executive Officer, Chairman and Director, and the majority beneficial owner of the Company, also serves as sole shareholder and executive director of Crystal Globe. As a result, the Company and Dynamic Elite are under common control of Crystal Globe and Mr. Jinghe Zhang.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the “Effective Time”) and as a result of the Merger, the ordinary shares of common stock of Dynamic Elite issued and outstanding immediately prior to the Effective Time, all of which are held by the Company, will be cancelled and extinguished. In accordance with the Merger Agreement, Crystal Globe has offered a cash consideration of $0.045 per share for outstanding shares of Joway Health’s common stock (the “Merger Consideration”). As of November 20, 2020, Joway Health reported 20,054,000 shares of common stock outstanding.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a result of the Merger Agreement, Joway Health needs to distribute proportionately the Merger Consideration to the Company’s shareholders. In January 2021, Joway Health had received $119,070 from Crystal Globe and distributed proportionately to the Company’s minority shareholders, other than Crystal Globe, which represents 2,646,000 shares of Joway Health’s common stock. Since the remaining 17,408,000 shares of Joway Health’s common stock is owned by Crystal Globe, the $0.045 per share payment for the 17,408,000 shares is offset.</p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"><b> </b></td><td style="white-space: nowrap"><b> </b></td> <td colspan="2" style="white-space: nowrap; text-align: center"><b>September 30,</b></td><td style="white-space: nowrap"><b> </b></td><td style="white-space: nowrap"><b> </b></td> <td colspan="2" style="white-space: nowrap; text-align: center"><b>December 31,</b></td><td style="white-space: nowrap"><b> </b></td></tr> <tr style="vertical-align: bottom"> <td><b> </b></td><td style="padding-bottom: 1.5pt"><b> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>2021</b></td><td style="padding-bottom: 1.5pt"><b> </b></td><td style="padding-bottom: 1.5pt"><b> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>2020</b></td><td style="padding-bottom: 1.5pt"><b> </b></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Jinghe Zhang</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,610</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">233,693</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Joway Shengshi</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-59">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">459,853</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,610</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">693,546</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> 2610 233693 459853 2610 693546 1693 19364 68690 153065 0 0 161021 281753 295928.47 2610 0.99 0 0 3844 0 0 0 463697.67 0 0.8681 0.045 20054000 Joway Health needs to distribute proportionately the Merger Consideration to the Company’s shareholders. In January 2021, Joway Health had received $119,070 from Crystal Globe and distributed proportionately to the Company’s minority shareholders, other than Crystal Globe, which represents 2,646,000 shares of Joway Health’s common stock. Since the remaining 17,408,000 shares of Joway Health’s common stock is owned by Crystal Globe, the $0.045 per share payment for the 17,408,000 shares is offset. <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify"><b>NOTE 8 – INCOME TAXES</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon the Company executed the Merger Agreement on December 31, 2020, no provision was made for federal income taxes since the Company has significant net operating losses.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company’s income tax returns since inception are subject to audit by regulatory authorities. Changes in tax laws and rates could also affect recorded deferred tax assets and liabilities in the future. Management is not aware of any such changes that would have a material effect on the Company’s results of operations, cash flows or financial position. The calculation of our tax liabilities involves dealing with uncertainties in the application of complex tax laws and regulations. FASB ASC Topic 740, Income Taxes provides that a tax benefit from an uncertain tax position may be recognized when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits. ASC Topic 740 also provides guidance on measurement, derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We recognize tax liabilities in accordance with ASC Topic 740 and we adjust these liabilities when our judgment changes as a result of the evaluation of new information not previously available. Due to the complexity of some of these uncertainties, the ultimate resolution may result in a payment that is materially different from our current estimate of the tax liabilities. These differences will be reflected as increases or decreases to income tax expense in the period in which they are determined. </p> GTVI NONE false --12-31 Q3 0001263364 XML 12 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Document And Entity Information - shares
9 Months Ended
Sep. 30, 2021
Nov. 05, 2021
Document Information Line Items    
Entity Registrant Name Joway Health Industries Group Inc.  
Trading Symbol GTVI  
Document Type 10-Q  
Current Fiscal Year End Date --12-31  
Entity Common Stock, Shares Outstanding   20,054,000
Amendment Flag false  
Entity Central Index Key 0001263364  
Entity Current Reporting Status Yes  
Entity Filer Category Non-accelerated Filer  
Document Period End Date Sep. 30, 2021  
Document Fiscal Year Focus 2021  
Document Fiscal Period Focus Q3  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company true  
Document Quarterly Report true  
Document Transition Report false  
Entity File Number 333-108715  
Entity Incorporation, State or Country Code NV  
Entity Tax Identification Number 98-0221494  
Entity Address, Address Line One No.2  
Entity Address, Address Line Two Baowang Road  
Entity Address, Address Line Three Baodi Economic Development Zone  
Entity Address, City or Town Tianjin  
Entity Address, Country CN  
Entity Address, Postal Zip Code 301800  
City Area Code (86)  
Local Phone Number 022-22533666  
Title of 12(b) Security None  
Security Exchange Name NONE  
Entity Interactive Data Current Yes  
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.21.2
Balance Sheets - USD ($)
Sep. 30, 2021
Dec. 31, 2020
CURRENT ASSETS:    
Receivable from related party $ 119,070
Total current assets 119,070
Total assets 119,070
CURRENT LIABILITIES:    
Special dividend payable 119,070
Other payables 90,095 51,344
Due to related parties 2,610 693,546
Total current liabilities 92,705 863,960
COMMITMENTS
STOCKHOLDERS' EQUITY:    
Preferred stock - par value $0.001; 1,000,000 shares authorized; no shares issued and outstanding
Common stock - par value $0.001; 200,000,000 shares authorized; 20,054,000 shares issued and outstanding at September 30, 2021 and December 31, 2020 20,054 20,054
Additional paid-in-capital 7,228,862 6,469,236
Accumulated deficit (7,341,621) (7,234,180)
Total stockholders' equity (92,705) (744,890)
Total liabilities and stockholders' equity $ 119,070
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.21.2
Balance Sheets (Parentheticals) - $ / shares
Sep. 30, 2021
Dec. 31, 2020
Statement of Financial Position [Abstract]    
Preferred stock, par value (in Dollars per share) $ 0.001 $ 0.001
Preferred stock, shares authorized 1,000,000 1,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value (in Dollars per share) $ 0.001 $ 0.001
Common stock, shares authorized 200,000,000 200,000,000
Common stock, shares issued 20,054,000 20,054,000
Common stock, shares outstanding 20,054,000 20,054,000
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.21.2
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Income Statement [Abstract]        
REVENUES
COST OF REVENUES
GROSS PROFIT
General and administrative expenses 10,884 25,317 107,441 180,814
OPERATING EXPENSES 10,884 25,317 107,441 180,814
LOSS FROM OPERATIONS (10,884) (25,317) (107,441) (180,814)
Other expenses (48) (252)
OTHER LOSS, NET (48) (252)
LOSS BEFORE INCOME TAXES (10,884) (25,365) (107,441) (181,066)
INCOME TAXES
NET LOSS FROM CONTINUING OPERATIONS (10,884) (25,365) (107,441) (181,066)
Discontinued operations:        
Loss from operations of discontinued component, net of taxes (169,330) (548,155)
NET LOSS (10,884) (194,695) (107,441) (729,221)
OTHER COMPREHENSIVE LOSS:        
Foreign currency translation adjustments 103,625 60,934
COMPREHENSIVE LOSS $ (10,884) $ (91,070) $ (107,441) $ (668,287)
LOSS PER COMMON SHARE, BASIC AND DILUTED:        
Continuing operations - Basic & diluted (in Dollars per share) $ 0 $ 0 $ (0.01) $ (0.01)
Discontinued operations - Basic & diluted (in Dollars per share) $ (0.01) $ (0.03)
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING, BASIC AND DILUTED (in Shares) 20,054,000 20,054,000 20,054,000 20,054,000
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.21.2
Consolidated Statements of Cash Flows - USD ($)
9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net loss from continuing operations $ (107,441) $ (181,066)
Changes in operating assets and liabilities:    
Receivable from disposal of subsidiaries 119,070
Special dividend payable (119,070)
Other payables 38,751 28,000
Net cash used in operating activities (68,690) (153,066)
Net cash used in operating activities from discontinued component (274,499)
Net cash provided by operating activities (68,690) (427,565)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Due to related parties 68,690 153,065
Net cash provided by financing activities 68,690 153,065
Net cash provided by financing activities from discontinued component 281,753
Net cash provided by financing activities 68,690 434,818
EFFECT OF EXCHANGE RATE CHANGES ON CASH (7,253)
NET INCREASE IN CASH
CASH, beginning of period
CASH, end of period
SUPPLEMENTAL DISCLOSURES:    
Income taxes paid
Interest paid
NON-CASH TRANSACTIONS OF INVESTING AND FINANCING ACTIVITIES    
Related party loan released by Jinghe Zhang 295,928
Related party loan released by Joway Shengshi $ 463,698
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.21.2
Organization
9 Months Ended
Sep. 30, 2021
Accounting Policies [Abstract]  
ORGANIZATION

NOTE 1  – ORGANIZATION

 

The unaudited condensed consolidated financial statements include the financial statements of Joway Health Industries Group Inc. (referred to herein as “Joway Health”), its subsidiaries, and variable interest entities (“VIEs”) where Joway Health is deemed the primary beneficiary. Joway Health, its subsidiaries and VIEs are collectively referred to herein as the “Company”, “we” and “us”.

 

Joway Health (formerly G2 Ventures, Inc.) was originally incorporated under the laws of the State of Texas on March 21, 2003. On September 21, 2010, Joway Health entered into a Share Exchange Agreement (the “Share Exchange”) with the sole stockholder of Dynamic Elite International Limited. As a result of the Share Exchange, Dynamic Elite became a wholly-owned subsidiary of Joway Health and the stockholders of Dynamic Elite acquired approximately 76.08% of the issued and outstanding stock of Joway Health. The share exchange transaction resulted in the shareholders of Dynamic Elite acquiring a majority voting interest in Joway Health. Generally accepted accounting principles in the United States of America require that the company whose shareholders retain the majority interest in the combined business be treated as the acquirer for accounting purposes. The reverse acquisition process utilizes the capital structure of Joway Health and the assets and liabilities of Dynamic Elite recorded at historical cost. On December 22, 2010, Joway Health changed its jurisdiction of incorporation from the State of Texas to the State of Nevada.

 

Dynamic Elite International Limited (referred to herein as “Dynamic Elite”) was incorporated under the laws of the British Virgin Islands on June 2, 2010 as a limited liability company (a BVI company). Dynamic Elite engages in manufacturing and distributing tourmaline products in China. Its wholly owned subsidiary, Tianjin Junhe Management Consulting Co., Ltd. was incorporated on September 15, 2010 in Tianjin, People’s Republic of China (“PRC”). Other than the equity interest in Junhe Consulting, Dynamic Elite does not own any assets or conduct any operations.

 

Tianjin Junhe Management Consulting Co., Ltd. (referred to herein as “Junhe Consulting”) conducts its business through Tianjin Joway Shengshi Group Co., Ltd. that is consolidated as a variable interest entity.

 

Tianjin Joway Shengshi Group Co., Ltd. (referred to herein as “Joway Shengshi”) was incorporated in PRC on May 17, 2007. Joway Shengshi is currently owned 99% by Jinghe Zhang, the Company’s current CEO and President and 1% by Song Baogang. Joway Shengshi engages in manufacturing and distributing tourmaline products in China. Shenyang Joway Electronic Technology Co., Ltd., Tianjin Joway Decoration Engineering Co., Ltd. and Tianjin Oriental Shengtang Trading Import & Export Trading Co., Ltd are subsidiaries of Joway Shengshi.

 

Shenyang Joway Electronic Technology Co., Ltd. (referred to herein as “Joway Technology”) was originally named Liaoning Joway Technology Engineering Co., Ltd. which was incorporated on March 28, 2007 in PRC. The name was changed on June 22, 2011. It engages in the distribution of Tourmaline Activated Water Machines and Tourmaline Wellness Houses. Prior to July 25, 2010, Joway Shengshi owned 90.91% of Joway Technology. Joway Shengshi entered into a share acquisition agreement with Jingyun Chen, another stockholder of Joway Technology on July 25, 2010 to acquire the remaining 9.09% of the share of Joway Technology. As a result of the share acquisition, Joway Technology became a wholly-owned subsidiary of Joway Shengshi.

 

Tianjin Joway Decoration Engineering Co., Ltd. (referred to herein as “Joway Decoration”) was incorporated on April 22, 2009 in PRC. It engages in the distribution of Tourmaline Activated Water Machines, Tourmaline Wellness House for family use and Tourmaline Wellness House materials. Prior to July 9, 2010, Joway Shengshi owned 90% of Joway Decoration. Joway Shengshi entered into a share acquisition agreement with Jingyun Chen, another stockholder of Joway Decoration on July 9, 2010 to acquire the remaining 10% of the shares of Joway Decoration. As a result of the share acquisition, Joway Decoration became a wholly-owned subsidiary of Joway Shengshi. Jingyun Chen is currently the General Manager of Joway Decoration.

 

Tianjin Oriental Shengtang Import & Export Trading Co., Ltd. (referred to herein as “Shengtang Trading”) was incorporated on September 18, 2009 in the PRC. It engages in purchasing raw materials which it sells to other companies of the group. Prior to July 28, 2010, Joway Shengshi owned 95% of Shengtang Trading. Joway Shengshi entered into a share acquisition agreement with Wang Aiying, another stockholder of Shengtang Trading on July 28, 2010 to acquire the remaining 5% of the shares of Shengtang Trading. As a result of the share acquisition, Shengtang Trading became a wholly-owned subsidiary of Joway Shengshi.

 

The following table lists the Company and its subsidiaries:

 

Name   Domicile and Date of Incorporation   Paid in Capital   Percentage of Effective Ownership   Principal Activities
Joway Health Industries Group Inc.  

March 21, 2003,

Nevada

  USD 20,054  

86.8% owned by Crystal Globe Limited

13.2%owned by other institutional and individual investors

 

Investment

Holding

                 
Dynamic Elite International Limited  

June 2, 2010,

British Virgin Islands

  USD 10,000   100% owned by Joway Health Industries Group Inc.  

Investment

Holding

                 
Tianjin Junhe Management Consulting Co., Ltd.   September 15, 2010, PRC   USD 20,000   100% owned by Dynamic Elite International Limited   Advisory
                 
Tianjin Joway Shengshi Group Co., Ltd.   May 17, 2007, PRC   USD 7,216,140.72   99% owned by Jinghe Zhang,  and 1% owned  by Baogang Song  

Production and

distribution of Healthcare Knit Goods and Daily Healthcare and Personal Care products

                 
Shenyang Joway Electronic Technology Co., Ltd.   March 28, 2007, PRC   USD 142,072.97   100% owned by Tianjin Joway Shengshi Group Co., Ltd   Distribution of Tourmaline Activated Water Machine and construction of Tourmaline Wellness House
                 
Tianjin Joway Decoration Engineering Co., Ltd.   April 22, 2009, PRC   USD 292,367.74   100% owned by Tianjin Joway Shengshi Group Co., Ltd   Distribution of Wellness House for family use and Activated Water Machine and construction of Tourmaline Wellness House
                 
Tianjin Oriental Shengtang Import & Export Trading Co., Ltd.   September 18, 2009, PRC   USD 292,463.75   100% owned by Tianjin Joway Shengshi Group Co., Ltd   Distribution of tourmaline products

 

On September 16, 2010, prior to the share exchange, Junhe Consulting entered into a series of contractual agreements (the “Contractual Agreements”) with Joway Shengshi and Joway Shengshi’s owners. The following is a brief description of the Contractual Agreements entered into between Junhe Consulting and Joway Shengshi or Joway Shengshi’s owners

 

1. Consulting Services Agreement. Pursuant to the consulting services agreement between Junhe Consulting and Joway Shengshi, Junhe Consulting has the right to advise, consult, manage and operate Joway Shengshi, and collect and own all of the net profits of the Operating Entities.

 

2. Operating Agreement. Under the operating agreement between Junhe Consulting and Joway Shengshi, Junhe Consulting has the right to recommend director candidates and appoint the senior executives of Joway Shengshi, approve any transactions that may materially affect the assets, liabilities, rights or operations of Joway Shengshi, and guarantee the contractual performance by Joway Shengshi of any agreements with third parties, in exchange for a pledge by Joway Shengshi of its accounts receivable and assets.

 

3. Voting Rights Proxy Agreement. Under the voting rights proxy agreement between Joway Shengshi’s owners and Junhe Consulting, the owners of Joway Shengshi have vested their collective voting control over Joway Shengshi to Junhe Consulting and will only transfer their respective equity interests in Joway Shengshi to Junhe Consulting or its designee.

 

4. Option Agreement. Under the option agreement between Joway Shengshi’s owners and Junhe Consulting, the owners of Joway Shengshi have granted Junhe Consulting the irrevocable right and option to acquire all of their equity interests in Joway Shengshi.

 

5. Equity Pledge Agreement. Under the equity pledge agreement between Joway Shengshi’s owners and Junhe Consulting, the owners of Joway Shengshi have pledged all of their rights, titles and interests in Joway Shengshi to Junhe Consulting to guarantee Joway Shengshi’s performance of its obligations under the Consulting Services Agreement.

 

As a result of the Contractual Agreements, Joway Shengshi is effectively a variable interest entity of Junhe Consulting. Accordingly, the Company through its wholly-owned subsidiary Junhe Consulting, consolidates Joway Shengshi’s results of operation, assets and liabilities in its financial statements.

 

In connection with the Share Exchange and as consideration for entering into the VIE Agreements, Jingshe Zhang and Baogang Song, the shareholders of Joway Shengshi (the “Grantees”), entered into a Call Option Agreement, dated July 20,2010 with Lionel Evan Liu (the “Grantor”), the sole shareholder of Crystal Globe (the controlling shareholder of Dynamic Elite), a British Virgin Islands company (the “Call Option Agreement”), pursuant to which the Grantees had the right to purchase up to 100% of the shares of Crystal Globe (the “Call Option”) at an exercise price of $2.00 per share (the “Exercise Price”) for a period of five years. The Call Option vested as to 34% of the shares of Crystal Globe on April 2, 2011 and as to 33% on each of April 2, 2012 and 2013 (the respective “Call Option Effective Date”). On March 28, 2015, the Grantor and Grantees amended the Call Option Agreement, to (i) reduce the Exercise Price to $0.00 per share and (ii) extend the Grantees’ rights to exercise their call option within ten years from the respective Option Effective Date.

 

On November 13, 2016, Jinghe Zhang exercised the Call Option as to 99% of the shares of Crystal Globe and Baogang Song exercised his Call Option as to 1% of the shares of Crystal Globe. As a result of exercising the Call Option, Jinghe Zhang became the controlling shareholder of Crystal Globe and in turn, the controlling shareholder of the Company. On November 20, 2016, Baogang Song transferred 1% of the shares of Crystal Globe to Jinghe Zhang. Consequently, Jinghe Zhang controls 17,408,000 shares, or 86.8%, of the issued and outstanding shares of the Company’s common stock.

 

On December 31, 2020, upon the Company completed the Merger Agreement with Crystal Globe, Joway Health becomes a “shell company” (as such term is defined in Rule 12b-2 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”).

 

Going forward, the Company intends to seek, investigate and, if such investigation warrants, engage in a business combination with a private entity whose business presents an opportunity for the Company’s stockholders.

XML 18 R7.htm IDEA: XBRL DOCUMENT v3.21.2
Going Concern
9 Months Ended
Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
GOING CONCERN

NOTE 2 – GOING CONCERN

 

The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the discharge of liabilities in the normal course of business for the foreseeable future.

 

As reflected in the accompanying consolidated financial statements, for the nine months ended September 30, 2021 and 2020, we incurred net losses of $107,441 and $729,221, respectively. As of September 30, 2021, we had an accumulated deficit of $7.3 million. Management believes these factors raise substantial doubt about our ability to continue as a going concern for the next twelve months.

 

The continuation of our company as a going concern through the next twelve months is dependent upon (1) the continued financial support from our stockholders or external financing. Management believes that our existing stockholders will provide the additional cash to meet our obligations as they become due, and (2) that it will be able to implement its business plan to expand our company’s operations and generate sufficient revenues to meet its obligations.

 

These conditions raise substantial doubt about our company’s ability to continue as a going concern. These financial statements do not include any adjustments to reflect the possible future effect on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the outcome of these uncertainties. Management believes that the actions presently being taken to obtain additional funding and implement its strategic plan provides the opportunity for our company to continue as a going concern.

XML 19 R8.htm IDEA: XBRL DOCUMENT v3.21.2
Summary of Significant Accounting Policies
9 Months Ended
Sep. 30, 2021
Accounting Policies [Abstract]  
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of Presentation

 

The accompanying unaudited consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“US GAAP”). Accordingly, they do not include all of the information and the footnotes required by generally accepted accounting principles for complete financial statements. The Company’s functional currency is the Chinese Renminbi (“RMB”) in 2020; however, the accompanying unaudited consolidated financial statements have been translated and presented in United States Dollars (“USD”). All significant inter-company transactions and balances have been eliminated. The consolidated financial statements include all adjustments that, in the opinion of management, are necessary to make the financial statements not misleading.

 

Operating results for the nine month period ended September 30, 2021 are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2021. The accompanying unaudited consolidated financial statements should be read in conjunction with the Company’s form 10-K for the fiscal year ended December 31, 2020 which was filed on August 16, 2021.

 

Use of Estimates

 

The preparation of the consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Management makes these estimates using the best information available at the time the estimates are made. Actual results could differ from those estimates.

 

Reclassification

 

Certain prior year balances were reclassified to conform to the current year’s presentation with consideration of reflecting all of the Company’s subsidiaries and VIEs as discontinued operations. None of these reclassifications had an impact on reported financial position or cash flows for any of the periods presented.

 

Basis of Consolidation

 

For the periods prior to the sale of Dynamic Elite, its subsidiaries, and controlled VIEs, the Company consolidated financial statements include Dynamic Elite, its wholly owned subsidiaries, and controlled VIEs. All significant inter-company accounts and transactions have been eliminated in the consolidation.

 

Foreign Currency Translation

 

The accompanying consolidated financial statements are presented in USD. The functional currency of the Company is RMB in 2020. The consolidated financial statements are translated into United States dollars from RMB at period-end exchange rates as to assets and liabilities and average exchange rates as to revenues and expenses. Equity accounts are translated at their historical exchange rates when the equity transactions occurred. The resulting transaction adjustments are recorded as a component of stockholders’ equity. Gains and losses from foreign currency transactions are included in net income.

 

   For the
nine months ended
September 30,
   For the
year ended
December 31,
 
   2020   2020 
Period ended RMB: USD Exchange rate   6.8101    6.5249 
Average RMB: USD Exchange rate   6.9917    6.8976 

 

The RMB is not freely convertible into foreign currency and all foreign exchange transactions must take place through authorized institutions. No representation is made that the RMB amounts could have been, or could be, converted into USD at the rates used in translation.

 

Foreign currency translation adjustments have been reported as comprehensive income in the consolidated financial statements and totaled $103,625 for the three months ended September 30, 2020, and $60,934 for the nine months ended September 30, 2020. No foreign currency translation adjustments for the three months and nine months ended September 30, 2021.

 

Other Comprehensive Income

 

Other comprehensive income is defined as the change in equity during the period from transactions and other events, excluding the changes resulting from investments by owners and distributions to owners, and is not included in the computation of income tax expense or benefit. Accumulated other comprehensive income represents the accumulated balance of foreign currency translation adjustments.

 

Concentrations of Credit Risk

 

Prior to the Merger Agreement, the Company’s operations are carried out in the PRC. Accordingly, the Company’s business, financial condition, and results of operations may be influenced by the political, economic, and legal environment in the PRC, and by the general state of the PRC’s economy. The Company’s operations in the PRC are subject to specific considerations and significant risks not typically associated with companies in North America. The Company’s results may be adversely affected by changes in governmental policies with respect to laws and regulations, anti-inflationary measures, currency conversion and remittance abroad, and rates and methods of taxation, among other things. Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash and trade accounts receivable. Substantially all of the Company’s cash is maintained with state-owned banks within the PRC, and no deposits are covered by insurance. The Company has not experienced any losses in such accounts and believes it is not exposed to any risks on its cash in bank accounts.

 

Fair Value of Financial Instruments

 

Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 820 establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:

 

Level 1—defined as observable inputs such as quoted prices in active markets for identical assets or liabilities;

 

Level 2—defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and

 

Level 3—defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.

 

The carrying amounts reported in the balance sheets for cash, accounts receivable, other receivable, accounts payable, other payable, and amounts due from related parties generally approximate their fair market values based on the short-term maturity of these instruments. ASC 825-10 “Financial Instruments” allows entities to voluntarily choose to measure certain financial assets and liabilities at fair value (fair value option). The fair value option may be elected on an instrument-by-instrument basis and is irrevocable, unless a new election date occurs. If the fair value option is elected for an instrument, unrealized gains and losses for that instrument should be reported in earnings at each subsequent reporting date. The Company did not elect to apply the fair value option to any outstanding instruments.

 

Revenue Recognition

 

The Company recognizes revenue when control of promised goods or services is transferred to the company’s customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services.

 

Prior to the Merger Agreement, with respect to sales of product to both franchisee and non-franchisee customers, the Company transfers control, invoices the customer and recognizes revenue upon shipment to the customer. Sales prices are based on fixed price lists that are different depending on whether the price list is for franchisee customers or for non-franchisee customers. Sales, value add and other taxes collected concurrent with revenue-producing activities are excluded from revenue.

 

Income Taxes

 

The Company accounts for income taxes in accordance with FASB ASC 740 “Income Taxes” (formerly SFAS No. 109 Accounting for Income Taxes), which is an asset and liability approach that requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the Company’s financial statements or tax returns. ASC 740 additionally requires the establishment of a valuation allowance to reflect the likelihood of realization of deferred tax assets. Realization of deferred tax assets is dependent upon future earnings, if any, of which the timing and amount are uncertain.

 

According to ASC 740, the evaluation of a tax position is a two-step process. The first step is to determine whether it is more likely than not that a tax position will be sustained upon examination, including the resolution of any related appeals or litigation based on the technical merits of that position. The second step is to measure a tax position that meets the more-likely-than-not threshold to determine the amount of benefit to be recognized in the financial statements. A tax position is measured at the largest amount of benefit that is greater than 50% likelihood of being realized upon ultimate settlement. Tax positions that previously failed to meet the more-likely-than-not recognition threshold should be recognized in the first subsequent period in which the threshold is met. Previously recognized tax positions that no longer meet the more-likely-than-not criteria should be de-recognized in the first subsequent financial reporting period in which the threshold is no longer met. ASC 740 also provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosures, and transition.

 

Basic and Diluted Earnings per Share

 

The Company reports earnings per share in accordance with FASB ASC 260 “Earnings per share”. The Company’s basic earnings per share are computed using the weighted average number of shares outstanding for the periods presented. Diluted earnings per share are computed based on the assumption that any dilutive options or warrants were converted or exercised. Dilution is computed by applying the treasury stock method. Under this method, the Company’s outstanding stock warrants are assumed to be exercised, and funds thus obtained were assumed to be used to purchase common stock at the average market price during the period. There were no dilutive instruments outstanding during the three month and nine month periods ended September 30, 2021 and 2020.

 

Recently Issued Accounting Pronouncements

 

In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”), which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020, with early adoption permitted. The Company adopted the standard in the first quarter of 2021. Adoption of the standard did not have a significant impact on the Company’s consolidated statement of earnings in 2021.

 

Other accounting standards that have been issued or proposed by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on the Company’s consolidated financial statements upon adoption.

XML 20 R9.htm IDEA: XBRL DOCUMENT v3.21.2
Deconsolidation
9 Months Ended
Sep. 30, 2021
Deconsolidation [Abstract]  
DECONSOLIDATION

NOTE 4 – DECONSOLIDATION

 

On November 20, 2020, Joway Health entered into a Merger Agreement (the “Merger Agreement”) with Dynamic Elite International Limited, a British Virgin Islands company and a wholly-owned subsidiary of the Company (“Dynamic Elite”), Crystal Globe Limited, a British Virgin Islands company (“Crystal Globe”) and Joway Merger Subsidiary Limited, a British Virgin Islands company and a wholly-owned subsidiary of Crystal Globe (“Merger Sub”). The Merger Agreement provides that, upon the terms and subject to the satisfaction or waiver of the conditions set forth therein, Merger Sub will be merged with and into Dynamic Elite (the “Merger”), with Dynamic Elite continuing as the surviving corporation as a wholly-owned subsidiary of Crystal Globe.

 

Crystal Globe, as the majority shareholder holding approximately 86.81% of the Company, is also the sole shareholder of Dynamic Elite after the Merger. Mr. Jinghe Zhang, as the President, Chief Executive Officer, Chairman and Director, and the majority beneficial owner of the Company, also serves as sole shareholder and executive director of Crystal Globe. As a result, the Company and Dynamic Elite are under common control of Crystal Globe and Mr. Jinghe Zhang.

 

Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the “Effective Time”) and as a result of the Merger, the ordinary shares of common stock of Dynamic Elite issued and outstanding immediately prior to the Effective Time, all of which are held by the Company, will be cancelled and extinguished. In accordance with the Merger Agreement, Crystal Globe has offered a cash consideration of $0.045 per share for outstanding shares of Joway Health’s common stock (the “Merger Consideration”). As of November 20, 2020, Joway Health reported 20,054,000 shares of common stock outstanding. As a result, Joway Health recognized a loss of $1,340,795 from this transaction.

 

In January 2021, Joway Health had received $119,070 from Crystal Globe and distributed proportionately to the Company’s minority shareholders, other than Crystal Globe, which represents 2,646,000 shares of Joway Health’s common stock. Since the remaining 17,408,000 shares of Joway Health’s common stock is owned by Crystal Globe, the $0.045 per share payment for the 17,408,000 shares is offset.

 

The following is a reconciliation of the deconsolidation:

 

   Amount 
Selling price  $902,430 
Disposed assets and liabilities:     
Cash   79,446 
Current assets   1,133,812 
Fixed assets   3,194,533 
Intangible assets   465,007 
Liabilities   (1,977,822)
Accumulated other comprehensive income   (651,751)
    2,243,225 
Loss from disposal of discontinued component, net of income tax  $(1,340,795)
XML 21 R10.htm IDEA: XBRL DOCUMENT v3.21.2
Receivable from Related Party
9 Months Ended
Sep. 30, 2021
Receivable From Related Party Disclosure [Abstract]  
RECEIVABLE FROM RELATED PARTY

NOTE 5 – RECEIVABLE FROM RELATED PARTY

 

Receivable from related party consist of the following:

 

   September 30,   December 31, 
   2021   2020 
Crystal Globe  $
      -
   $119,070 

 

The receivable from Crystal Globe is related to the Merger Agreement which is part of the Merger Consideration for Joway Health’s minority shareholders who hold 2,646,000 shares of Joway Health’s common stock.

 

In January 2021, Joway Health had received $119,070 from Crystal Globe and distributed proportionately to the Company’s minority shareholders.

XML 22 R11.htm IDEA: XBRL DOCUMENT v3.21.2
Special Dividend Payable
9 Months Ended
Sep. 30, 2021
Disclosure of Restrictions on Dividends, Loans and Advances Disclosure [Abstract]  
SPECIAL DIVIDEND PAYABLE

NOTE 6 – SPECIAL DIVIDEND PAYABLE

 

As of September 30, 2021 and December 31, 2020, the Company reported $0 and $119,070 as special dividend payables, respectively. The payables are related to the Merger Agreement which is part of the Merger Consideration for Joway Health’s minority shareholders who hold 2,646,000 shares of Joway Health’s common stock. 

 

On November 20, 2020, Joway Health entered into a Merger Agreement (the “Merger Agreement”) with Dynamic Elite International Limited, a British Virgin Islands company and a wholly-owned subsidiary of the Company (“Dynamic Elite”), Crystal Globe Limited, a British Virgin Islands company (“Crystal Globe”) and Joway Merger Subsidiary Limited, a British Virgin Islands company and a wholly-owned subsidiary of Crystal Globe (“Merger Sub”). The Merger Agreement provides that, upon the terms and subject to the satisfaction or waiver of the conditions set forth therein, Merger Sub will be merged with and into Dynamic Elite (the “Merger”), with Dynamic Elite continuing as the surviving corporation as a wholly-owned subsidiary of Crystal Globe. 

 

Crystal Globe, as the majority shareholder holding approximately 86.81% of the Company, is also the sole shareholder of Dynamic Elite after the Merger. Mr. Jinghe Zhang, as the President, Chief Executive Officer, Chairman and Director, and the majority beneficial owner of the Company, also serves as sole shareholder and executive director of Crystal Globe. As a result, the Company and Dynamic Elite are under common control of Crystal Globe and Mr. Jinghe Zhang. 

 

Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the “Effective Time”) and as a result of the Merger, the ordinary shares of common stock of Dynamic Elite issued and outstanding immediately prior to the Effective Time, all of which are held by the Company, will be cancelled and extinguished. In accordance with the Merger Agreement, Crystal Globe has offered a cash consideration of $0.045 per share for outstanding shares of Joway Health’s common stock (the “Merger Consideration”). As of November 20, 2020, Joway Health reported 20,054,000 shares of common stock outstanding. 

 

As a result of the Merger Agreement, Joway Health needs to distribute proportionately the Merger Consideration to the Company’s shareholders. In January 2021, Joway Health had received $119,070 from Crystal Globe and distributed proportionately to the Company’s minority shareholders, other than Crystal Globe, which represents 2,646,000 shares of Joway Health’s common stock. Since the remaining 17,408,000 shares of Joway Health’s common stock is owned by Crystal Globe, the $0.045 per share payment for the 17,408,000 shares is offset.

XML 23 R12.htm IDEA: XBRL DOCUMENT v3.21.2
Related Party Transactions
9 Months Ended
Sep. 30, 2021
Related Party Transactions [Abstract]  
RELATED PARTY TRANSACTIONS

NOTE 7 – RELATED PARTY TRANSACTIONS

 

Payables due to related parties consist of the following:

 

   September 30,   December 31, 
   2021   2020 
Jinghe Zhang  $2,610   $233,693 
Joway Shengshi   
-
    459,853 
Total  $2,610   $693,546 

 

The amounts owed to related parties are non-interest bearing and have no specified repayment terms.

 

Transactions with Jinghe Zhang

 

The Company is a shell company and has no cash, Mr. Jinghe Zhang, our President, Chief Executive Officer and director, agreed to advance operating capital to the Company. For the three months ended September 30, 2021 and 2020, the Company received $1,693 and $19,364 from Mr. Jinghe Zhang, respectively, for its continuing operating component. For the nine months ended September 30, 2021 and 2020, the Company received $68,690 and $153,065 from Mr. Jinghe Zhang, respectively, for its continuing operating component. For the three months and nine months ended September 30, 2021, the Company received $0 from Mr. Jinghe Zhang, respectively, for its discontinued operating component. For the Company’s discontinued operation component, during the three months and nine months ended September 30, 2020, the Company received $161,021 and $281,753 from Mr. Jinghe Zhang, respectively.

 

On April 28, 2021, Mr. Jinghe Zhang released the Company from $295,928.47 of indebtedness owed to him from the Company. As of September 30, 2021, the total unpaid principal balance due to Mr. Jinghe Zhang for advances was $2,610.

 

Transactions with Joway Shengshi

 

Joway Shengshi is a company of the discontinued operations. Mr. Jinghe Zhang owns 99% of the equity interest in Joway Shengshi. For the three months ended September 30, 2021 and 2020, the Company received $0 from Joway Shengshi, respectively, for its continuing and discontinued operating components. For the nine months ended September 30, 2021 and 2020, we received $3,844 and $0 of advances from Joway Shengshi, respectively, for our continuing operation component. For our discontinued operation component, we received $0 from Joway Shengshi for the nine months ended September 30, 2021 and 2020.

 

On April 28, 2021, Joway Shengshi released the Company from $463,697.67 of indebtedness owed to it from the Company. As of September 30, 2021, the total unpaid principal balance due to Joway Shengshi for advances was $0.

 

Disposal of all of Joway Health’s subsidiaries and VIEs

 

On November 20, 2020, Joway Health entered into a Merger Agreement (the “Merger Agreement”) with Dynamic Elite International Limited, a British Virgin Islands company and a wholly-owned subsidiary of the Company (“Dynamic Elite”), Crystal Globe Limited, a British Virgin Islands company (“Crystal Globe”) and Joway Merger Subsidiary Limited, a British Virgin Islands company and a wholly-owned subsidiary of Crystal Globe (“Merger Sub”). The Merger Agreement provides that, upon the terms and subject to the satisfaction or waiver of the conditions set forth therein, Merger Sub will be merged with and into Dynamic Elite (the “Merger”), with Dynamic Elite continuing as the surviving corporation as a wholly-owned subsidiary of Crystal Globe.

 

Crystal Globe, as the majority shareholder holding approximately 86.81% of the Company, is also the sole shareholder of Dynamic Elite after the Merger. Mr. Jinghe Zhang, as the President, Chief Executive Officer, Chairman and Director, and the majority beneficial owner of the Company, also serves as sole shareholder and executive director of Crystal Globe. As a result, the Company and Dynamic Elite are under common control of Crystal Globe and Mr. Jinghe Zhang.

 

Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the “Effective Time”) and as a result of the Merger, the ordinary shares of common stock of Dynamic Elite issued and outstanding immediately prior to the Effective Time, all of which are held by the Company, will be cancelled and extinguished. In accordance with the Merger Agreement, Crystal Globe has offered a cash consideration of $0.045 per share for outstanding shares of Joway Health’s common stock (the “Merger Consideration”). As of November 20, 2020, Joway Health reported 20,054,000 shares of common stock outstanding.

 

As a result of the Merger Agreement, Joway Health needs to distribute proportionately the Merger Consideration to the Company’s shareholders. In January 2021, Joway Health had received $119,070 from Crystal Globe and distributed proportionately to the Company’s minority shareholders, other than Crystal Globe, which represents 2,646,000 shares of Joway Health’s common stock. Since the remaining 17,408,000 shares of Joway Health’s common stock is owned by Crystal Globe, the $0.045 per share payment for the 17,408,000 shares is offset.

XML 24 R13.htm IDEA: XBRL DOCUMENT v3.21.2
Income Taxes
9 Months Ended
Sep. 30, 2021
Income Tax Disclosure [Abstract]  
INCOME TAXES

NOTE 8 – INCOME TAXES

 

Upon the Company executed the Merger Agreement on December 31, 2020, no provision was made for federal income taxes since the Company has significant net operating losses.

 

The Company’s income tax returns since inception are subject to audit by regulatory authorities. Changes in tax laws and rates could also affect recorded deferred tax assets and liabilities in the future. Management is not aware of any such changes that would have a material effect on the Company’s results of operations, cash flows or financial position. The calculation of our tax liabilities involves dealing with uncertainties in the application of complex tax laws and regulations. FASB ASC Topic 740, Income Taxes provides that a tax benefit from an uncertain tax position may be recognized when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits. ASC Topic 740 also provides guidance on measurement, derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition.

 

We recognize tax liabilities in accordance with ASC Topic 740 and we adjust these liabilities when our judgment changes as a result of the evaluation of new information not previously available. Due to the complexity of some of these uncertainties, the ultimate resolution may result in a payment that is materially different from our current estimate of the tax liabilities. These differences will be reflected as increases or decreases to income tax expense in the period in which they are determined. 

XML 25 R14.htm IDEA: XBRL DOCUMENT v3.21.2
Accounting Policies, by Policy (Policies)
9 Months Ended
Sep. 30, 2021
Accounting Policies [Abstract]  
Basis of Presentation

Basis of Presentation

 

The accompanying unaudited consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“US GAAP”). Accordingly, they do not include all of the information and the footnotes required by generally accepted accounting principles for complete financial statements. The Company’s functional currency is the Chinese Renminbi (“RMB”) in 2020; however, the accompanying unaudited consolidated financial statements have been translated and presented in United States Dollars (“USD”). All significant inter-company transactions and balances have been eliminated. The consolidated financial statements include all adjustments that, in the opinion of management, are necessary to make the financial statements not misleading.

 

Operating results for the nine month period ended September 30, 2021 are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2021. The accompanying unaudited consolidated financial statements should be read in conjunction with the Company’s form 10-K for the fiscal year ended December 31, 2020 which was filed on August 16, 2021.

 

Use of Estimates

Use of Estimates

 

The preparation of the consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Management makes these estimates using the best information available at the time the estimates are made. Actual results could differ from those estimates.

 

Reclassification

Reclassification

 

Certain prior year balances were reclassified to conform to the current year’s presentation with consideration of reflecting all of the Company’s subsidiaries and VIEs as discontinued operations. None of these reclassifications had an impact on reported financial position or cash flows for any of the periods presented.

 

Basis of Consolidation

Basis of Consolidation

 

For the periods prior to the sale of Dynamic Elite, its subsidiaries, and controlled VIEs, the Company consolidated financial statements include Dynamic Elite, its wholly owned subsidiaries, and controlled VIEs. All significant inter-company accounts and transactions have been eliminated in the consolidation.

 

Foreign Currency Translation

Foreign Currency Translation

 

The accompanying consolidated financial statements are presented in USD. The functional currency of the Company is RMB in 2020. The consolidated financial statements are translated into United States dollars from RMB at period-end exchange rates as to assets and liabilities and average exchange rates as to revenues and expenses. Equity accounts are translated at their historical exchange rates when the equity transactions occurred. The resulting transaction adjustments are recorded as a component of stockholders’ equity. Gains and losses from foreign currency transactions are included in net income.

 

   For the
nine months ended
September 30,
   For the
year ended
December 31,
 
   2020   2020 
Period ended RMB: USD Exchange rate   6.8101    6.5249 
Average RMB: USD Exchange rate   6.9917    6.8976 

 

The RMB is not freely convertible into foreign currency and all foreign exchange transactions must take place through authorized institutions. No representation is made that the RMB amounts could have been, or could be, converted into USD at the rates used in translation.

 

Foreign currency translation adjustments have been reported as comprehensive income in the consolidated financial statements and totaled $103,625 for the three months ended September 30, 2020, and $60,934 for the nine months ended September 30, 2020. No foreign currency translation adjustments for the three months and nine months ended September 30, 2021.

 

Other Comprehensive Income

Other Comprehensive Income

 

Other comprehensive income is defined as the change in equity during the period from transactions and other events, excluding the changes resulting from investments by owners and distributions to owners, and is not included in the computation of income tax expense or benefit. Accumulated other comprehensive income represents the accumulated balance of foreign currency translation adjustments.

 

Concentrations of Credit Risk

Concentrations of Credit Risk

 

Prior to the Merger Agreement, the Company’s operations are carried out in the PRC. Accordingly, the Company’s business, financial condition, and results of operations may be influenced by the political, economic, and legal environment in the PRC, and by the general state of the PRC’s economy. The Company’s operations in the PRC are subject to specific considerations and significant risks not typically associated with companies in North America. The Company’s results may be adversely affected by changes in governmental policies with respect to laws and regulations, anti-inflationary measures, currency conversion and remittance abroad, and rates and methods of taxation, among other things. Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash and trade accounts receivable. Substantially all of the Company’s cash is maintained with state-owned banks within the PRC, and no deposits are covered by insurance. The Company has not experienced any losses in such accounts and believes it is not exposed to any risks on its cash in bank accounts.

 

Fair Value of Financial Instruments

Fair Value of Financial Instruments

 

Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 820 establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:

 

Level 1—defined as observable inputs such as quoted prices in active markets for identical assets or liabilities;

 

Level 2—defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and

 

Level 3—defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.

 

The carrying amounts reported in the balance sheets for cash, accounts receivable, other receivable, accounts payable, other payable, and amounts due from related parties generally approximate their fair market values based on the short-term maturity of these instruments. ASC 825-10 “Financial Instruments” allows entities to voluntarily choose to measure certain financial assets and liabilities at fair value (fair value option). The fair value option may be elected on an instrument-by-instrument basis and is irrevocable, unless a new election date occurs. If the fair value option is elected for an instrument, unrealized gains and losses for that instrument should be reported in earnings at each subsequent reporting date. The Company did not elect to apply the fair value option to any outstanding instruments.

 

Revenue Recognition

Revenue Recognition

 

The Company recognizes revenue when control of promised goods or services is transferred to the company’s customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services.

 

Prior to the Merger Agreement, with respect to sales of product to both franchisee and non-franchisee customers, the Company transfers control, invoices the customer and recognizes revenue upon shipment to the customer. Sales prices are based on fixed price lists that are different depending on whether the price list is for franchisee customers or for non-franchisee customers. Sales, value add and other taxes collected concurrent with revenue-producing activities are excluded from revenue.

 

Income Taxes

Income Taxes

 

The Company accounts for income taxes in accordance with FASB ASC 740 “Income Taxes” (formerly SFAS No. 109 Accounting for Income Taxes), which is an asset and liability approach that requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the Company’s financial statements or tax returns. ASC 740 additionally requires the establishment of a valuation allowance to reflect the likelihood of realization of deferred tax assets. Realization of deferred tax assets is dependent upon future earnings, if any, of which the timing and amount are uncertain.

 

According to ASC 740, the evaluation of a tax position is a two-step process. The first step is to determine whether it is more likely than not that a tax position will be sustained upon examination, including the resolution of any related appeals or litigation based on the technical merits of that position. The second step is to measure a tax position that meets the more-likely-than-not threshold to determine the amount of benefit to be recognized in the financial statements. A tax position is measured at the largest amount of benefit that is greater than 50% likelihood of being realized upon ultimate settlement. Tax positions that previously failed to meet the more-likely-than-not recognition threshold should be recognized in the first subsequent period in which the threshold is met. Previously recognized tax positions that no longer meet the more-likely-than-not criteria should be de-recognized in the first subsequent financial reporting period in which the threshold is no longer met. ASC 740 also provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosures, and transition.

 

Basic and Diluted Earnings per Share

Basic and Diluted Earnings per Share

 

The Company reports earnings per share in accordance with FASB ASC 260 “Earnings per share”. The Company’s basic earnings per share are computed using the weighted average number of shares outstanding for the periods presented. Diluted earnings per share are computed based on the assumption that any dilutive options or warrants were converted or exercised. Dilution is computed by applying the treasury stock method. Under this method, the Company’s outstanding stock warrants are assumed to be exercised, and funds thus obtained were assumed to be used to purchase common stock at the average market price during the period. There were no dilutive instruments outstanding during the three month and nine month periods ended September 30, 2021 and 2020.

 

Recently Issued Accounting Pronouncements

Recently Issued Accounting Pronouncements

 

In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”), which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020, with early adoption permitted. The Company adopted the standard in the first quarter of 2021. Adoption of the standard did not have a significant impact on the Company’s consolidated statement of earnings in 2021.

 

Other accounting standards that have been issued or proposed by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on the Company’s consolidated financial statements upon adoption.

XML 26 R15.htm IDEA: XBRL DOCUMENT v3.21.2
Organization (Tables)
9 Months Ended
Sep. 30, 2021
Accounting Policies [Abstract]  
Schedule of company and its subsidiaries
Name   Domicile and Date of Incorporation   Paid in Capital   Percentage of Effective Ownership   Principal Activities
Joway Health Industries Group Inc.  

March 21, 2003,

Nevada

  USD 20,054  

86.8% owned by Crystal Globe Limited

13.2%owned by other institutional and individual investors

 

Investment

Holding

                 
Dynamic Elite International Limited  

June 2, 2010,

British Virgin Islands

  USD 10,000   100% owned by Joway Health Industries Group Inc.  

Investment

Holding

                 
Tianjin Junhe Management Consulting Co., Ltd.   September 15, 2010, PRC   USD 20,000   100% owned by Dynamic Elite International Limited   Advisory
                 
Tianjin Joway Shengshi Group Co., Ltd.   May 17, 2007, PRC   USD 7,216,140.72   99% owned by Jinghe Zhang,  and 1% owned  by Baogang Song  

Production and

distribution of Healthcare Knit Goods and Daily Healthcare and Personal Care products

                 
Shenyang Joway Electronic Technology Co., Ltd.   March 28, 2007, PRC   USD 142,072.97   100% owned by Tianjin Joway Shengshi Group Co., Ltd   Distribution of Tourmaline Activated Water Machine and construction of Tourmaline Wellness House
                 
Tianjin Joway Decoration Engineering Co., Ltd.   April 22, 2009, PRC   USD 292,367.74   100% owned by Tianjin Joway Shengshi Group Co., Ltd   Distribution of Wellness House for family use and Activated Water Machine and construction of Tourmaline Wellness House
                 
Tianjin Oriental Shengtang Import & Export Trading Co., Ltd.   September 18, 2009, PRC   USD 292,463.75   100% owned by Tianjin Joway Shengshi Group Co., Ltd   Distribution of tourmaline products

 

XML 27 R16.htm IDEA: XBRL DOCUMENT v3.21.2
Summary of Significant Accounting Policies (Tables)
9 Months Ended
Sep. 30, 2021
Accounting Policies [Abstract]  
Schedule of gains and losses from foreign currency transactions
   For the
nine months ended
September 30,
   For the
year ended
December 31,
 
   2020   2020 
Period ended RMB: USD Exchange rate   6.8101    6.5249 
Average RMB: USD Exchange rate   6.9917    6.8976 

 

XML 28 R17.htm IDEA: XBRL DOCUMENT v3.21.2
Deconsolidation (Tables)
9 Months Ended
Sep. 30, 2021
Deconsolidation [Abstract]  
Schedule of reconciliation of the deconsolidation
   Amount 
Selling price  $902,430 
Disposed assets and liabilities:     
Cash   79,446 
Current assets   1,133,812 
Fixed assets   3,194,533 
Intangible assets   465,007 
Liabilities   (1,977,822)
Accumulated other comprehensive income   (651,751)
    2,243,225 
Loss from disposal of discontinued component, net of income tax  $(1,340,795)
XML 29 R18.htm IDEA: XBRL DOCUMENT v3.21.2
Receivable from Related Party (Tables)
9 Months Ended
Sep. 30, 2021
Receivable From Related Party Disclosure [Abstract]  
Schedule of receivable from related party
   September 30,   December 31, 
   2021   2020 
Crystal Globe  $
      -
   $119,070 

 

XML 30 R19.htm IDEA: XBRL DOCUMENT v3.21.2
Related Party Transactions (Tables)
9 Months Ended
Sep. 30, 2021
Related Party Transactions [Abstract]  
Schedule of payables due to related parties
   September 30,   December 31, 
   2021   2020 
Jinghe Zhang  $2,610   $233,693 
Joway Shengshi   
-
    459,853 
Total  $2,610   $693,546 

 

XML 31 R20.htm IDEA: XBRL DOCUMENT v3.21.2
Organization (Details) - $ / shares
1 Months Ended
Nov. 13, 2016
Mar. 28, 2015
Jul. 20, 2010
Nov. 20, 2016
Sep. 21, 2010
Jul. 28, 2010
Jul. 25, 2010
Jul. 09, 2010
May 17, 2007
Organization (Details) [Line Items]                  
Exercise price (in Dollars per share)   $ 0              
Dynamic Elite [Member]                  
Organization (Details) [Line Items]                  
Ownership percentage         76.08%        
Tianjin Joway Shengshi Group Co., Ltd. [Member]                  
Organization (Details) [Line Items]                  
Ownership percentage                 99.00%
Business acquisition percentage of remaining voting interests acquired                 1.00%
Joway Shengshi owned of Joway Technology [Member]                  
Organization (Details) [Line Items]                  
Ownership percentage             90.91%    
Business acquisition percentage of remaining voting interests acquired             9.09%    
Joway Shengshi owned of Joway Decoration [Member]                  
Organization (Details) [Line Items]                  
Ownership percentage               90.00%  
Business acquisition percentage of remaining voting interests acquired               10.00%  
Joway Shengshi To Shengtang Trading [Member]                  
Organization (Details) [Line Items]                  
Ownership percentage           95.00%      
Business acquisition percentage of remaining voting interests acquired           5.00%      
Crystal Globe [Member]                  
Organization (Details) [Line Items]                  
Right to purchase call option percentage     100.00%            
Exercise price per share (in Dollars per share)     $ 2            
Call option, description     The Call Option vested as to 34% of the shares of Crystal Globe on April 2, 2011 and as to 33% on each of April 2, 2012 and 2013 (the respective “Call Option Effective Date”).            
Crystal Global to Jinghe Zhang [Member]                  
Organization (Details) [Line Items]                  
Percentage of shares transferred       1.00%          
Jinghe Zhang [Member]                  
Organization (Details) [Line Items]                  
Common stock shares (in Shares)       17,408,000          
Issued and outstanding shares percentage       86.80%          
Jinghe Zhang [Member] | Crystal Globe [Member]                  
Organization (Details) [Line Items]                  
Percentage of right to purchase of shares 99.00%                
Baogang Song [Member] | Crystal Globe [Member]                  
Organization (Details) [Line Items]                  
Percentage of shares transferred 1.00%                
XML 32 R21.htm IDEA: XBRL DOCUMENT v3.21.2
Organization (Details) - Schedule of company and its subsidiaries
9 Months Ended
Sep. 30, 2021
USD ($)
Joway Health Industries Group Inc. [Member]  
Organization (Details) - Schedule of company and its subsidiaries [Line Items]  
Domicile and Date of Incorporation March 21, 2003, Nevada
Paid in Capital $ 20,054
Percentage of Effective Ownership 86.8% owned by Crystal Globe Limited 13.2%owned by other institutional and individual investors
Principal Activities Investment Holding
Dynamic Elite International Limited [Member]  
Organization (Details) - Schedule of company and its subsidiaries [Line Items]  
Domicile and Date of Incorporation June 2, 2010, British Virgin Islands
Paid in Capital $ 10,000
Percentage of Effective Ownership 100% owned by Joway Health Industries Group Inc.
Principal Activities Investment Holding
Tianjin Junhe Management Consulting Co., Ltd. [Member]  
Organization (Details) - Schedule of company and its subsidiaries [Line Items]  
Domicile and Date of Incorporation September 15, 2010, PRC
Paid in Capital $ 20,000
Percentage of Effective Ownership 100% owned by Dynamic Elite International Limited
Principal Activities Advisory
Tianjin Joway Shengshi Group Co., Ltd. [Member]  
Organization (Details) - Schedule of company and its subsidiaries [Line Items]  
Domicile and Date of Incorporation May 17, 2007, PRC
Paid in Capital $ 7,216,140.72
Percentage of Effective Ownership 99% owned by Jinghe Zhang,  and 1% owned  by Baogang Song
Principal Activities Production and distribution of Healthcare Knit Goods and Daily Healthcare and Personal Care products
Shenyang Joway Electronic Technology Co., Ltd. [Member]  
Organization (Details) - Schedule of company and its subsidiaries [Line Items]  
Domicile and Date of Incorporation March 28, 2007, PRC
Paid in Capital $ 142,072.97
Percentage of Effective Ownership 100% owned by Tianjin Joway Shengshi Group Co., Ltd
Principal Activities Distribution of Tourmaline Activated Water Machine and construction of Tourmaline Wellness House
Tianjin Joway Decoration Engineering Co., Ltd. [Member]  
Organization (Details) - Schedule of company and its subsidiaries [Line Items]  
Domicile and Date of Incorporation April 22, 2009, PRC
Paid in Capital $ 292,367.74
Percentage of Effective Ownership 100% owned by Tianjin Joway Shengshi Group Co., Ltd
Principal Activities Distribution of Wellness House for family use and Activated Water Machine and construction of Tourmaline Wellness House
Tianjin Oriental Shengtang Import & Export Trading Co., Ltd. [Member]  
Organization (Details) - Schedule of company and its subsidiaries [Line Items]  
Domicile and Date of Incorporation September 18, 2009, PRC
Paid in Capital $ 292,463.75
Percentage of Effective Ownership 100% owned by Tianjin Joway Shengshi Group Co., Ltd
Principal Activities Distribution of tourmaline products
XML 33 R22.htm IDEA: XBRL DOCUMENT v3.21.2
Going Concern (Details) - USD ($)
9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Incurred net losses $ 107,441 $ 729,221
Accumulated deficit $ 7,300,000  
XML 34 R23.htm IDEA: XBRL DOCUMENT v3.21.2
Summary of Significant Accounting Policies (Details) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2021
Accounting Policies [Abstract]    
Foreign currency translation adjustments $ 103,625 $ 60,934
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.21.2
Summary of Significant Accounting Policies (Details) - Schedule of gains and losses from foreign currency transactions
Dec. 31, 2020
Sep. 30, 2020
Period ended RMB: USD Exchange rate [Member]    
Summary of Significant Accounting Policies (Details) - Schedule of gains and losses from foreign currency transactions [Line Items]    
Gains and losses from foreign currency transactions 6.5249 6.8101
Average RMB: USD Exchange rate [Member]    
Summary of Significant Accounting Policies (Details) - Schedule of gains and losses from foreign currency transactions [Line Items]    
Gains and losses from foreign currency transactions 6.8976 6.9917
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.21.2
Deconsolidation (Details) - Merger Agreement [Member] - USD ($)
1 Months Ended
Jan. 31, 2021
Nov. 20, 2020
Deconsolidation (Details) [Line Items]    
Percentage of majority shareholder   86.81%
Purchase price   $ 0.045
Common stock outstanding   20,054,000
Transaction of loss value   $ 1,340,795
Description of common stock In January 2021, Joway Health had received $119,070 from Crystal Globe and distributed proportionately to the Company’s minority shareholders, other than Crystal Globe, which represents 2,646,000 shares of Joway Health’s common stock. Since the remaining 17,408,000 shares of Joway Health’s common stock is owned by Crystal Globe, the $0.045 per share payment for the 17,408,000 shares is offset.   
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.21.2
Deconsolidation (Details) - Schedule of reconciliation of the deconsolidation
Sep. 30, 2021
USD ($)
Schedule of reconciliation of the deconsolidation [Abstract]  
Selling price $ 902,430
Disposed assets and liabilities:  
Cash 79,446
Current assets 1,133,812
Fixed assets 3,194,533
Intangible assets 465,007
Liabilities (1,977,822)
Accumulated other comprehensive income (651,751)
Total 2,243,225
Loss from disposal of discontinued component, net of income tax $ (1,340,795)
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.21.2
Receivable from Related Party (Details) - USD ($)
9 Months Ended
Sep. 30, 2021
Jan. 31, 2021
Joway Health's [Member]    
Receivable from Related Party (Details) [Line Items]    
Shares on hold 2,646,000  
Crystal Globe [Member]    
Receivable from Related Party (Details) [Line Items]    
Due from related party   $ 119,070
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.21.2
Receivable from Related Party (Details) - Schedule of receivable from related party - USD ($)
Sep. 30, 2021
Dec. 31, 2020
Crystal Globe [Member]    
Receivable from Related Party (Details) - Schedule of receivable from related party [Line Items]    
Due from related party $ 119,070
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.21.2
Special Dividend Payable (Details) - USD ($)
1 Months Ended
Jan. 31, 2021
Sep. 30, 2021
Dec. 31, 2020
Nov. 20, 2020
Special Dividend Payable (Details) [Line Items]        
Dividend payables   $ 0 $ 119,070  
Percentage of shares held by shareholder       86.81%
Cash consideration per share       $ 0.045
Merger agreement, description Joway Health had received $119,070 from Crystal Globe and distributed proportionately to the Company’s minority shareholders, other than Crystal Globe, which represents 2,646,000 shares of Joway Health’s common stock. Since the remaining 17,408,000 shares of Joway Health’s common stock is owned by Crystal Globe, the $0.045 per share payment for the 17,408,000 shares is offset.      
Joway Health's [Member]        
Special Dividend Payable (Details) [Line Items]        
Shares available to shareholders   2,646,000    
Common stock, shares outstanding       20,054,000
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.21.2
Related Party Transactions (Details) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Apr. 28, 2021
Nov. 20, 2020
Related Party Transactions (Details) [Line Items]            
Due from related parties for discontinued operating component       $ 0    
Cash consideration per share (in Dollars per share)           $ 0.045
Sale of stock, description     Joway Health needs to distribute proportionately the Merger Consideration to the Company’s shareholders. In January 2021, Joway Health had received $119,070 from Crystal Globe and distributed proportionately to the Company’s minority shareholders, other than Crystal Globe, which represents 2,646,000 shares of Joway Health’s common stock. Since the remaining 17,408,000 shares of Joway Health’s common stock is owned by Crystal Globe, the $0.045 per share payment for the 17,408,000 shares is offset.      
Jinghe Zhang [Member]            
Related Party Transactions (Details) [Line Items]            
Due from related parties for continuing operating component $ 1,693 $ 19,364 $ 68,690 153,065    
Due from related parties for discontinued operating component 0 161,021 0 281,753    
Amount of indebtedness         $ 295,928.47  
Unpaid principle amount advance $ 2,610   $ 2,610      
Equity interest 99.00%   99.00%      
Joway Shengshi [Member]            
Related Party Transactions (Details) [Line Items]            
Due from related parties for continuing operating component     $ 3,844 0    
Due from related parties for discontinued operating component $ 0          
Amount of indebtedness         $ 463,697.67  
Unpaid principle amount 0 $ 0 0 $ 0    
Unpaid principal balance in advance $ 0   $ 0      
Crystal Globe [Member]            
Related Party Transactions (Details) [Line Items]            
Equity interest           86.81%
Merger Agreement [Member]            
Related Party Transactions (Details) [Line Items]            
Cash consideration per share (in Dollars per share) $ 0.045   $ 0.045      
Common stock, shares outstanding (in Shares) 20,054,000   20,054,000      
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.21.2
Related Party Transactions (Details) - Schedule of payables due to related parties - USD ($)
Sep. 30, 2021
Dec. 31, 2020
Related Party Transaction [Line Items]    
Total $ 2,610 $ 693,546
Jinghe Zhang [Member]    
Related Party Transaction [Line Items]    
Total 2,610 233,693
Joway Shengshi [Member]    
Related Party Transaction [Line Items]    
Total $ 459,853
EXCEL 43 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 44 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 45 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 46 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 69 222 1 false 24 0 false 4 false false R1.htm 000 - Document - Document And Entity Information Sheet http://jowayhealth.com/role/DocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 001 - Statement - Balance Sheets Sheet http://jowayhealth.com/role/ConsolidatedBalanceSheet Balance Sheets Statements 2 false false R3.htm 002 - Statement - Balance Sheets (Parentheticals) Sheet http://jowayhealth.com/role/ConsolidatedBalanceSheet_Parentheticals Balance Sheets (Parentheticals) Statements 3 false false R4.htm 003 - Statement - Consolidated Statements of Operations and Comprehensive Loss Sheet http://jowayhealth.com/role/ConsolidatedIncomeStatement Consolidated Statements of Operations and Comprehensive Loss Statements 4 false false R5.htm 004 - Statement - Consolidated Statements of Cash Flows Sheet http://jowayhealth.com/role/ConsolidatedCashFlow Consolidated Statements of Cash Flows Statements 5 false false R6.htm 005 - Disclosure - Organization Sheet http://jowayhealth.com/role/Organization Organization Notes 6 false false R7.htm 006 - Disclosure - Going Concern Sheet http://jowayhealth.com/role/GoingConcern Going Concern Notes 7 false false R8.htm 007 - Disclosure - Summary of Significant Accounting Policies Sheet http://jowayhealth.com/role/SummaryofSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 8 false false R9.htm 008 - Disclosure - Deconsolidation Sheet http://jowayhealth.com/role/Deconsolidation Deconsolidation Notes 9 false false R10.htm 009 - Disclosure - Receivable from Related Party Sheet http://jowayhealth.com/role/ReceivablefromRelatedParty Receivable from Related Party Notes 10 false false R11.htm 010 - Disclosure - Special Dividend Payable Sheet http://jowayhealth.com/role/SpecialDividendPayable Special Dividend Payable Notes 11 false false R12.htm 011 - Disclosure - Related Party Transactions Sheet http://jowayhealth.com/role/RelatedPartyTransactions Related Party Transactions Notes 12 false false R13.htm 012 - Disclosure - Income Taxes Sheet http://jowayhealth.com/role/IncomeTaxes Income Taxes Notes 13 false false R14.htm 013 - Disclosure - Accounting Policies, by Policy (Policies) Sheet http://jowayhealth.com/role/AccountingPoliciesByPolicy Accounting Policies, by Policy (Policies) Policies http://jowayhealth.com/role/SummaryofSignificantAccountingPolicies 14 false false R15.htm 014 - Disclosure - Organization (Tables) Sheet http://jowayhealth.com/role/OrganizationTables Organization (Tables) Tables http://jowayhealth.com/role/Organization 15 false false R16.htm 015 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://jowayhealth.com/role/SummaryofSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://jowayhealth.com/role/SummaryofSignificantAccountingPolicies 16 false false R17.htm 016 - Disclosure - Deconsolidation (Tables) Sheet http://jowayhealth.com/role/DeconsolidationTables Deconsolidation (Tables) Tables http://jowayhealth.com/role/Deconsolidation 17 false false R18.htm 017 - Disclosure - Receivable from Related Party (Tables) Sheet http://jowayhealth.com/role/ReceivablefromRelatedPartyTables Receivable from Related Party (Tables) Tables http://jowayhealth.com/role/ReceivablefromRelatedParty 18 false false R19.htm 018 - Disclosure - Related Party Transactions (Tables) Sheet http://jowayhealth.com/role/RelatedPartyTransactionsTables Related Party Transactions (Tables) Tables http://jowayhealth.com/role/RelatedPartyTransactions 19 false false R20.htm 019 - Disclosure - Organization (Details) Sheet http://jowayhealth.com/role/OrganizationDetails Organization (Details) Details http://jowayhealth.com/role/OrganizationTables 20 false false R21.htm 020 - Disclosure - Organization (Details) - Schedule of company and its subsidiaries Sheet http://jowayhealth.com/role/ScheduleofcompanyanditssubsidiariesTable Organization (Details) - Schedule of company and its subsidiaries Details http://jowayhealth.com/role/OrganizationTables 21 false false R22.htm 021 - Disclosure - Going Concern (Details) Sheet http://jowayhealth.com/role/GoingConcernDetails Going Concern (Details) Details http://jowayhealth.com/role/GoingConcern 22 false false R23.htm 022 - Disclosure - Summary of Significant Accounting Policies (Details) Sheet http://jowayhealth.com/role/SummaryofSignificantAccountingPoliciesDetails Summary of Significant Accounting Policies (Details) Details http://jowayhealth.com/role/SummaryofSignificantAccountingPoliciesTables 23 false false R24.htm 023 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of gains and losses from foreign currency transactions Sheet http://jowayhealth.com/role/ScheduleofgainsandlossesfromforeigncurrencytransactionsTable Summary of Significant Accounting Policies (Details) - Schedule of gains and losses from foreign currency transactions Details http://jowayhealth.com/role/SummaryofSignificantAccountingPoliciesTables 24 false false R25.htm 024 - Disclosure - Deconsolidation (Details) Sheet http://jowayhealth.com/role/DeconsolidationDetails Deconsolidation (Details) Details http://jowayhealth.com/role/DeconsolidationTables 25 false false R26.htm 025 - Disclosure - Deconsolidation (Details) - Schedule of reconciliation of the deconsolidation Sheet http://jowayhealth.com/role/ScheduleofreconciliationofthedeconsolidationTable Deconsolidation (Details) - Schedule of reconciliation of the deconsolidation Details http://jowayhealth.com/role/DeconsolidationTables 26 false false R27.htm 026 - Disclosure - Receivable from Related Party (Details) Sheet http://jowayhealth.com/role/ReceivablefromRelatedPartyDetails Receivable from Related Party (Details) Details http://jowayhealth.com/role/ReceivablefromRelatedPartyTables 27 false false R28.htm 027 - Disclosure - Receivable from Related Party (Details) - Schedule of receivable from related party Sheet http://jowayhealth.com/role/ScheduleofreceivablefromrelatedpartyTable Receivable from Related Party (Details) - Schedule of receivable from related party Details http://jowayhealth.com/role/ReceivablefromRelatedPartyTables 28 false false R29.htm 028 - Disclosure - Special Dividend Payable (Details) Sheet http://jowayhealth.com/role/SpecialDividendPayableDetails Special Dividend Payable (Details) Details http://jowayhealth.com/role/SpecialDividendPayable 29 false false R30.htm 029 - Disclosure - Related Party Transactions (Details) Sheet http://jowayhealth.com/role/RelatedPartyTransactionsDetails Related Party Transactions (Details) Details http://jowayhealth.com/role/RelatedPartyTransactionsTables 30 false false R31.htm 030 - Disclosure - Related Party Transactions (Details) - Schedule of payables due to related parties Sheet http://jowayhealth.com/role/ScheduleofpayablesduetorelatedpartiesTable Related Party Transactions (Details) - Schedule of payables due to related parties Details http://jowayhealth.com/role/RelatedPartyTransactionsTables 31 false false All Reports Book All Reports f10q0921_jowayhealth.htm f10q0921ex31-1_jowayhealth.htm f10q0921ex31-2_jowayhealth.htm f10q0921ex32-1_jowayhealth.htm f10q0921ex32-2_jowayhealth.htm gtvi-20210930.xsd gtvi-20210930_cal.xml gtvi-20210930_def.xml gtvi-20210930_lab.xml gtvi-20210930_pre.xml http://xbrl.sec.gov/dei/2021 http://fasb.org/us-gaap/2021-01-31 true true JSON 49 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "f10q0921_jowayhealth.htm": { "axisCustom": 1, "axisStandard": 4, "contextCount": 69, "dts": { "calculationLink": { "local": [ "gtvi-20210930_cal.xml" ] }, "definitionLink": { "local": [ "gtvi-20210930_def.xml" ] }, "inline": { "local": [ "f10q0921_jowayhealth.htm" ] }, "labelLink": { "local": [ "gtvi-20210930_lab.xml" ] }, "presentationLink": { "local": [ "gtvi-20210930_pre.xml" ] }, "schema": { "local": [ "gtvi-20210930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd" ] } }, "elementCount": 236, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2021-01-31": 54, "http://jowayhealth.com/20210930": 4, "http://xbrl.sec.gov/dei/2021": 6, "total": 64 }, "keyCustom": 39, "keyStandard": 183, "memberCustom": 20, "memberStandard": 0, "nsprefix": "gtvi", "nsuri": "http://jowayhealth.com/20210930", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "body", "html" ], "baseRef": "f10q0921_jowayhealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000 - Document - Document And Entity Information", "role": "http://jowayhealth.com/role/DocumentAndEntityInformation", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "body", "html" ], "baseRef": "f10q0921_jowayhealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0921_jowayhealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "gtvi:ReceivableFromRelatedPartyDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "009 - Disclosure - Receivable from Related Party", "role": "http://jowayhealth.com/role/ReceivablefromRelatedParty", "shortName": "Receivable from Related Party", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0921_jowayhealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "gtvi:ReceivableFromRelatedPartyDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0921_jowayhealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDividendPaymentRestrictionsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "010 - Disclosure - Special Dividend Payable", "role": "http://jowayhealth.com/role/SpecialDividendPayable", "shortName": "Special Dividend Payable", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0921_jowayhealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDividendPaymentRestrictionsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0921_jowayhealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "011 - Disclosure - Related Party Transactions", "role": "http://jowayhealth.com/role/RelatedPartyTransactions", "shortName": "Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0921_jowayhealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0921_jowayhealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "012 - Disclosure - Income Taxes", "role": "http://jowayhealth.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0921_jowayhealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_jowayhealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "013 - Disclosure - Accounting Policies, by Policy (Policies)", "role": "http://jowayhealth.com/role/AccountingPoliciesByPolicy", "shortName": "Accounting Policies, by Policy (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_jowayhealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_jowayhealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "gtvi:ListsOfCompanyAndItsSubsidiariesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "014 - Disclosure - Organization (Tables)", "role": "http://jowayhealth.com/role/OrganizationTables", "shortName": "Organization (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_jowayhealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "gtvi:ListsOfCompanyAndItsSubsidiariesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_jowayhealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "gtvi:ForeignCurrencyDisclosureTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "015 - Disclosure - Summary of Significant Accounting Policies (Tables)", "role": "http://jowayhealth.com/role/SummaryofSignificantAccountingPoliciesTables", "shortName": "Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_jowayhealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "gtvi:ForeignCurrencyDisclosureTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_jowayhealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "gtvi:ScheduleOfReconciliationOfTheDeconsolidationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "016 - Disclosure - Deconsolidation (Tables)", "role": "http://jowayhealth.com/role/DeconsolidationTables", "shortName": "Deconsolidation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_jowayhealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "gtvi:ScheduleOfReconciliationOfTheDeconsolidationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_jowayhealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "gtvi:ScheduleOfReceivableFromRelatedPartyTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "017 - Disclosure - Receivable from Related Party (Tables)", "role": "http://jowayhealth.com/role/ReceivablefromRelatedPartyTables", "shortName": "Receivable from Related Party (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_jowayhealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "gtvi:ScheduleOfReceivableFromRelatedPartyTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_jowayhealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "018 - Disclosure - Related Party Transactions (Tables)", "role": "http://jowayhealth.com/role/RelatedPartyTransactionsTables", "shortName": "Related Party Transactions (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_jowayhealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0921_jowayhealth.htm", "contextRef": "c3", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OtherReceivablesNetCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "001 - Statement - Balance Sheets", "role": "http://jowayhealth.com/role/ConsolidatedBalanceSheet", "shortName": "Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0921_jowayhealth.htm", "contextRef": "c3", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OtherReceivablesNetCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_jowayhealth.htm", "contextRef": "c16", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:WarrantExercisePriceDecrease", "reportCount": 1, "unique": true, "unitRef": "usdPershares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "019 - Disclosure - Organization (Details)", "role": "http://jowayhealth.com/role/OrganizationDetails", "shortName": "Organization (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_jowayhealth.htm", "contextRef": "c16", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:WarrantExercisePriceDecrease", "reportCount": 1, "unique": true, "unitRef": "usdPershares", "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "gtvi:ListsOfCompanyAndItsSubsidiariesTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_jowayhealth.htm", "contextRef": "c22", "decimals": null, "first": true, "lang": "en-US", "name": "gtvi:EntityIncorporationDomicileAndDatesOfIncorporation", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "020 - Disclosure - Organization (Details) - Schedule of company and its subsidiaries", "role": "http://jowayhealth.com/role/ScheduleofcompanyanditssubsidiariesTable", "shortName": "Organization (Details) - Schedule of company and its subsidiaries", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "gtvi:ListsOfCompanyAndItsSubsidiariesTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_jowayhealth.htm", "contextRef": "c22", "decimals": null, "first": true, "lang": "en-US", "name": "gtvi:EntityIncorporationDomicileAndDatesOfIncorporation", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_jowayhealth.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "gtvi:IncurredNetLosses", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "021 - Disclosure - Going Concern (Details)", "role": "http://jowayhealth.com/role/GoingConcernDetails", "shortName": "Going Concern (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_jowayhealth.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "gtvi:IncurredNetLosses", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_jowayhealth.htm", "contextRef": "c4", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:TemporaryEquityForeignCurrencyTranslationAdjustments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "022 - Disclosure - Summary of Significant Accounting Policies (Details)", "role": "http://jowayhealth.com/role/SummaryofSignificantAccountingPoliciesDetails", "shortName": "Summary of Significant Accounting Policies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_jowayhealth.htm", "contextRef": "c4", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:TemporaryEquityForeignCurrencyTranslationAdjustments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "gtvi:ForeignCurrencyDisclosureTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_jowayhealth.htm", "contextRef": "c37", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:ForeignCurrencyExchangeRateTranslation1", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "023 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of gains and losses from foreign currency transactions", "role": "http://jowayhealth.com/role/ScheduleofgainsandlossesfromforeigncurrencytransactionsTable", "shortName": "Summary of Significant Accounting Policies (Details) - Schedule of gains and losses from foreign currency transactions", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "gtvi:ForeignCurrencyDisclosureTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_jowayhealth.htm", "contextRef": "c37", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:ForeignCurrencyExchangeRateTranslation1", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_jowayhealth.htm", "contextRef": "c40", "decimals": "4", "first": true, "lang": null, "name": "gtvi:PercentageOfMajorityShareholder", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "024 - Disclosure - Deconsolidation (Details)", "role": "http://jowayhealth.com/role/DeconsolidationDetails", "shortName": "Deconsolidation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_jowayhealth.htm", "contextRef": "c40", "decimals": "4", "first": true, "lang": null, "name": "gtvi:PercentageOfMajorityShareholder", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "gtvi:ScheduleOfReconciliationOfTheDeconsolidationTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_jowayhealth.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "gtvi:DisposedSellingPrice", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "025 - Disclosure - Deconsolidation (Details) - Schedule of reconciliation of the deconsolidation", "role": "http://jowayhealth.com/role/ScheduleofreconciliationofthedeconsolidationTable", "shortName": "Deconsolidation (Details) - Schedule of reconciliation of the deconsolidation", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "gtvi:ScheduleOfReconciliationOfTheDeconsolidationTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_jowayhealth.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "gtvi:DisposedSellingPrice", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_jowayhealth.htm", "contextRef": "c43", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "026 - Disclosure - Receivable from Related Party (Details)", "role": "http://jowayhealth.com/role/ReceivablefromRelatedPartyDetails", "shortName": "Receivable from Related Party (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_jowayhealth.htm", "contextRef": "c43", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "gtvi:ScheduleOfReceivableFromRelatedPartyTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_jowayhealth.htm", "contextRef": "c46", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DueToRelatedPartiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "027 - Disclosure - Receivable from Related Party (Details) - Schedule of receivable from related party", "role": "http://jowayhealth.com/role/ScheduleofreceivablefromrelatedpartyTable", "shortName": "Receivable from Related Party (Details) - Schedule of receivable from related party", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "gtvi:ScheduleOfReceivableFromRelatedPartyTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_jowayhealth.htm", "contextRef": "c46", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DueToRelatedPartiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_jowayhealth.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DividendPaymentsRestrictionsScheduleStatutoryCapitalAndSurplus1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "028 - Disclosure - Special Dividend Payable (Details)", "role": "http://jowayhealth.com/role/SpecialDividendPayableDetails", "shortName": "Special Dividend Payable (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_jowayhealth.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DividendPaymentsRestrictionsScheduleStatutoryCapitalAndSurplus1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0921_jowayhealth.htm", "contextRef": "c2", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPershares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "002 - Statement - Balance Sheets (Parentheticals)", "role": "http://jowayhealth.com/role/ConsolidatedBalanceSheet_Parentheticals", "shortName": "Balance Sheets (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0921_jowayhealth.htm", "contextRef": "c2", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPershares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "gtvi:DueFromRelatedPartiesForDiscontinuedOperatingComponent", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_jowayhealth.htm", "contextRef": "c6", "decimals": "0", "first": true, "lang": null, "name": "gtvi:DueFromRelatedPartiesForDiscontinuedOperatingComponent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "029 - Disclosure - Related Party Transactions (Details)", "role": "http://jowayhealth.com/role/RelatedPartyTransactionsDetails", "shortName": "Related Party Transactions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "gtvi:DueFromRelatedPartiesForDiscontinuedOperatingComponent", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_jowayhealth.htm", "contextRef": "c6", "decimals": "0", "first": true, "lang": null, "name": "gtvi:DueFromRelatedPartiesForDiscontinuedOperatingComponent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0921_jowayhealth.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DueToRelatedPartiesCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "030 - Disclosure - Related Party Transactions (Details) - Schedule of payables due to related parties", "role": "http://jowayhealth.com/role/ScheduleofpayablesduetorelatedpartiesTable", "shortName": "Related Party Transactions (Details) - Schedule of payables due to related parties", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_jowayhealth.htm", "contextRef": "c65", "decimals": "0", "lang": null, "name": "us-gaap:DueToRelatedPartiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0921_jowayhealth.htm", "contextRef": "c4", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "003 - Statement - Consolidated Statements of Operations and Comprehensive Loss", "role": "http://jowayhealth.com/role/ConsolidatedIncomeStatement", "shortName": "Consolidated Statements of Operations and Comprehensive Loss", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0921_jowayhealth.htm", "contextRef": "c4", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0921_jowayhealth.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperations", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "004 - Statement - Consolidated Statements of Cash Flows", "role": "http://jowayhealth.com/role/ConsolidatedCashFlow", "shortName": "Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0921_jowayhealth.htm", "contextRef": "c0", "decimals": "0", "lang": null, "name": "gtvi:ReceivableFromDisposalOfSubsidiaries", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0921_jowayhealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "005 - Disclosure - Organization", "role": "http://jowayhealth.com/role/Organization", "shortName": "Organization", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0921_jowayhealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0921_jowayhealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "006 - Disclosure - Going Concern", "role": "http://jowayhealth.com/role/GoingConcern", "shortName": "Going Concern", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0921_jowayhealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0921_jowayhealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "007 - Disclosure - Summary of Significant Accounting Policies", "role": "http://jowayhealth.com/role/SummaryofSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0921_jowayhealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0921_jowayhealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "gtvi:DeconsolidationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "008 - Disclosure - Deconsolidation", "role": "http://jowayhealth.com/role/Deconsolidation", "shortName": "Deconsolidation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0921_jowayhealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "gtvi:DeconsolidationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 24, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://jowayhealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://jowayhealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://jowayhealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://jowayhealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://jowayhealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://jowayhealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://jowayhealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://jowayhealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r217" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://jowayhealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r218" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://jowayhealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://jowayhealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://jowayhealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://jowayhealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three", "terseLabel": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://jowayhealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://jowayhealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country", "terseLabel": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://jowayhealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://jowayhealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r219" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://jowayhealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://jowayhealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://jowayhealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://jowayhealth.com/role/OrganizationDetails" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r219" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://jowayhealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://jowayhealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r219" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://jowayhealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://jowayhealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r220" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://jowayhealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r219" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://jowayhealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r219" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://jowayhealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r219" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://jowayhealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r219" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://jowayhealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://jowayhealth.com/role/OrganizationDetails", "http://jowayhealth.com/role/ScheduleofcompanyanditssubsidiariesTable" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://jowayhealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r215" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://jowayhealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r216" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://jowayhealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://jowayhealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "gtvi_AccumulatedDeficit": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated deficit.", "label": "AccumulatedDeficit", "terseLabel": "Accumulated deficit" } } }, "localname": "AccumulatedDeficit", "nsuri": "http://jowayhealth.com/20210930", "presentation": [ "http://jowayhealth.com/role/GoingConcernDetails" ], "xbrltype": "monetaryItemType" }, "gtvi_AccumulatedOtherComprehensiveIncome": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive income.", "label": "AccumulatedOtherComprehensiveIncome", "terseLabel": "Accumulated other comprehensive income" } } }, "localname": "AccumulatedOtherComprehensiveIncome", "nsuri": "http://jowayhealth.com/20210930", "presentation": [ "http://jowayhealth.com/role/ScheduleofreconciliationofthedeconsolidationTable" ], "xbrltype": "monetaryItemType" }, "gtvi_AggregateIndebtednessAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of aggregate indebtedness.", "label": "AggregateIndebtednessAmount", "terseLabel": "Amount of indebtedness" } } }, "localname": "AggregateIndebtednessAmount", "nsuri": "http://jowayhealth.com/20210930", "presentation": [ "http://jowayhealth.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "gtvi_AverageRenminbiUnitedStatesDollarExchangeRateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Average renminbi united states dollar exchange rate.", "label": "AverageRenminbiUnitedStatesDollarExchangeRateMember", "terseLabel": "Average RMB: USD Exchange rate [Member]" } } }, "localname": "AverageRenminbiUnitedStatesDollarExchangeRateMember", "nsuri": "http://jowayhealth.com/20210930", "presentation": [ "http://jowayhealth.com/role/ScheduleofgainsandlossesfromforeigncurrencytransactionsTable" ], "xbrltype": "domainItemType" }, "gtvi_BaogangSongMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "BaogangSongMember", "terseLabel": "Baogang Song [Member]" } } }, "localname": "BaogangSongMember", "nsuri": "http://jowayhealth.com/20210930", "presentation": [ "http://jowayhealth.com/role/OrganizationDetails" ], "xbrltype": "domainItemType" }, "gtvi_BusinessAcquisitionPercentageOfRemainingVotingInterestsAcquired": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Business acquisition percentage of remaining voting interests acquired.", "label": "BusinessAcquisitionPercentageOfRemainingVotingInterestsAcquired", "terseLabel": "Business acquisition percentage of remaining voting interests acquired" } } }, "localname": "BusinessAcquisitionPercentageOfRemainingVotingInterestsAcquired", "nsuri": "http://jowayhealth.com/20210930", "presentation": [ "http://jowayhealth.com/role/OrganizationDetails" ], "xbrltype": "percentItemType" }, "gtvi_CallOptionDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of call option.", "label": "CallOptionDescription", "terseLabel": "Call option, description" } } }, "localname": "CallOptionDescription", "nsuri": "http://jowayhealth.com/20210930", "presentation": [ "http://jowayhealth.com/role/OrganizationDetails" ], "xbrltype": "stringItemType" }, "gtvi_CashConsiderationPerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cash consideration per share.", "label": "CashConsiderationPerShare", "terseLabel": "Cash consideration per share", "verboseLabel": "Cash consideration per share (in Dollars per share)" } } }, "localname": "CashConsiderationPerShare", "nsuri": "http://jowayhealth.com/20210930", "presentation": [ "http://jowayhealth.com/role/RelatedPartyTransactionsDetails", "http://jowayhealth.com/role/SpecialDividendPayableDetails" ], "xbrltype": "perShareItemType" }, "gtvi_CrystalGlobalToJingheZhangMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CrystalGlobalToJingheZhangMember", "terseLabel": "Crystal Global to Jinghe Zhang [Member]" } } }, "localname": "CrystalGlobalToJingheZhangMember", "nsuri": "http://jowayhealth.com/20210930", "presentation": [ "http://jowayhealth.com/role/OrganizationDetails" ], "xbrltype": "domainItemType" }, "gtvi_CrystalGlobeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Crystal globe.", "label": "CrystalGlobeMember", "terseLabel": "Crystal Globe [Member]" } } }, "localname": "CrystalGlobeMember", "nsuri": "http://jowayhealth.com/20210930", "presentation": [ "http://jowayhealth.com/role/OrganizationDetails", "http://jowayhealth.com/role/ReceivablefromRelatedPartyDetails", "http://jowayhealth.com/role/RelatedPartyTransactionsDetails", "http://jowayhealth.com/role/ScheduleofreceivablefromrelatedpartyTable" ], "xbrltype": "domainItemType" }, "gtvi_DeconsolidationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deconsolidation [Abstract]" } } }, "localname": "DeconsolidationAbstract", "nsuri": "http://jowayhealth.com/20210930", "xbrltype": "stringItemType" }, "gtvi_DeconsolidationDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deconsolidation (Details) [Line Items]" } } }, "localname": "DeconsolidationDetailsLineItems", "nsuri": "http://jowayhealth.com/20210930", "presentation": [ "http://jowayhealth.com/role/DeconsolidationDetails" ], "xbrltype": "stringItemType" }, "gtvi_DeconsolidationDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deconsolidation (Details) [Table]" } } }, "localname": "DeconsolidationDetailsTable", "nsuri": "http://jowayhealth.com/20210930", "presentation": [ "http://jowayhealth.com/role/DeconsolidationDetails" ], "xbrltype": "stringItemType" }, "gtvi_DeconsolidationTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "DeconsolidationTextBlock", "terseLabel": "DECONSOLIDATION" } } }, "localname": "DeconsolidationTextBlock", "nsuri": "http://jowayhealth.com/20210930", "presentation": [ "http://jowayhealth.com/role/Deconsolidation" ], "xbrltype": "textBlockItemType" }, "gtvi_DescriptionOfCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of common stock.", "label": "DescriptionOfCommonStock", "terseLabel": "Description of common stock" } } }, "localname": "DescriptionOfCommonStock", "nsuri": "http://jowayhealth.com/20210930", "presentation": [ "http://jowayhealth.com/role/DeconsolidationDetails" ], "xbrltype": "stringItemType" }, "gtvi_DisposedAssetsAndLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "DisposedAssetsAndLiabilitiesAbstract", "terseLabel": "Disposed assets and liabilities:" } } }, "localname": "DisposedAssetsAndLiabilitiesAbstract", "nsuri": "http://jowayhealth.com/20210930", "presentation": [ "http://jowayhealth.com/role/ScheduleofreconciliationofthedeconsolidationTable" ], "xbrltype": "stringItemType" }, "gtvi_DisposedFixedAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fixed assets.", "label": "DisposedFixedAssets", "terseLabel": "Fixed assets" } } }, "localname": "DisposedFixedAssets", "nsuri": "http://jowayhealth.com/20210930", "presentation": [ "http://jowayhealth.com/role/ScheduleofreconciliationofthedeconsolidationTable" ], "xbrltype": "monetaryItemType" }, "gtvi_DisposedSellingPrice": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Selling price.", "label": "DisposedSellingPrice", "terseLabel": "Selling price" } } }, "localname": "DisposedSellingPrice", "nsuri": "http://jowayhealth.com/20210930", "presentation": [ "http://jowayhealth.com/role/ScheduleofreconciliationofthedeconsolidationTable" ], "xbrltype": "monetaryItemType" }, "gtvi_DisposedTotal": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "DisposedTotal", "terseLabel": "Total" } } }, "localname": "DisposedTotal", "nsuri": "http://jowayhealth.com/20210930", "presentation": [ "http://jowayhealth.com/role/ScheduleofreconciliationofthedeconsolidationTable" ], "xbrltype": "monetaryItemType" }, "gtvi_DocumentAndEntityInformationAbstract": { "auth_ref": [], "localname": "DocumentAndEntityInformationAbstract", "nsuri": "http://jowayhealth.com/20210930", "xbrltype": "stringItemType" }, "gtvi_DueFromRelatedPartiesForContinuingOperatingComponent": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Due from related parties for continuing operating component.", "label": "DueFromRelatedPartiesForContinuingOperatingComponent", "terseLabel": "Due from related parties for continuing operating component" } } }, "localname": "DueFromRelatedPartiesForContinuingOperatingComponent", "nsuri": "http://jowayhealth.com/20210930", "presentation": [ "http://jowayhealth.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "gtvi_DueFromRelatedPartiesForDiscontinuedOperatingComponent": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Due from related parties for discontinued operating component.", "label": "DueFromRelatedPartiesForDiscontinuedOperatingComponent", "terseLabel": "Due from related parties for discontinued operating component" } } }, "localname": "DueFromRelatedPartiesForDiscontinuedOperatingComponent", "nsuri": "http://jowayhealth.com/20210930", "presentation": [ "http://jowayhealth.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "gtvi_DynamicEliteInternationalLimitedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Dynamic elite international limited.", "label": "DynamicEliteInternationalLimitedMember", "terseLabel": "Dynamic Elite International Limited [Member]" } } }, "localname": "DynamicEliteInternationalLimitedMember", "nsuri": "http://jowayhealth.com/20210930", "presentation": [ "http://jowayhealth.com/role/ScheduleofcompanyanditssubsidiariesTable" ], "xbrltype": "domainItemType" }, "gtvi_DynamicEliteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "DynamicEliteMember", "terseLabel": "Dynamic Elite [Member]" } } }, "localname": "DynamicEliteMember", "nsuri": "http://jowayhealth.com/20210930", "presentation": [ "http://jowayhealth.com/role/OrganizationDetails" ], "xbrltype": "domainItemType" }, "gtvi_EntityIncorporationDomicileAndDatesOfIncorporation": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Entity incorporation domicile and date of incorporation.", "label": "EntityIncorporationDomicileAndDatesOfIncorporation", "terseLabel": "Domicile and Date of Incorporation" } } }, "localname": "EntityIncorporationDomicileAndDatesOfIncorporation", "nsuri": "http://jowayhealth.com/20210930", "presentation": [ "http://jowayhealth.com/role/ScheduleofcompanyanditssubsidiariesTable" ], "xbrltype": "stringItemType" }, "gtvi_ForeignCurrencyDisclosureTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for foreign currency.", "label": "ForeignCurrencyDisclosureTableTextBlock", "terseLabel": "Schedule of gains and losses from foreign currency transactions" } } }, "localname": "ForeignCurrencyDisclosureTableTextBlock", "nsuri": "http://jowayhealth.com/20210930", "presentation": [ "http://jowayhealth.com/role/SummaryofSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "gtvi_IncreaseDecreaseInOtherPayable": { "auth_ref": [], "calculation": { "http://jowayhealth.com/role/ConsolidatedCashFlow": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "IncreaseDecreaseInOtherPayable", "terseLabel": "Other payables" } } }, "localname": "IncreaseDecreaseInOtherPayable", "nsuri": "http://jowayhealth.com/20210930", "presentation": [ "http://jowayhealth.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "gtvi_IncreaseDecreaseInSpecialDividendPayables": { "auth_ref": [], "calculation": { "http://jowayhealth.com/role/ConsolidatedCashFlow": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Special dividend payable.", "label": "IncreaseDecreaseInSpecialDividendPayables", "negatedLabel": "Special dividend payable" } } }, "localname": "IncreaseDecreaseInSpecialDividendPayables", "nsuri": "http://jowayhealth.com/20210930", "presentation": [ "http://jowayhealth.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "gtvi_IncurredNetLosses": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Incurred net losses.", "label": "IncurredNetLosses", "terseLabel": "Incurred net losses" } } }, "localname": "IncurredNetLosses", "nsuri": "http://jowayhealth.com/20210930", "presentation": [ "http://jowayhealth.com/role/GoingConcernDetails" ], "xbrltype": "monetaryItemType" }, "gtvi_IssuedAndOutstandingShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Issued and outstanding shares", "label": "IssuedAndOutstandingShares", "terseLabel": "Issued and outstanding shares percentage" } } }, "localname": "IssuedAndOutstandingShares", "nsuri": "http://jowayhealth.com/20210930", "presentation": [ "http://jowayhealth.com/role/OrganizationDetails" ], "xbrltype": "percentItemType" }, "gtvi_JingheZhangMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Jinghe zhang.", "label": "JingheZhangMember", "terseLabel": "Jinghe Zhang [Member]" } } }, "localname": "JingheZhangMember", "nsuri": "http://jowayhealth.com/20210930", "presentation": [ "http://jowayhealth.com/role/OrganizationDetails", "http://jowayhealth.com/role/RelatedPartyTransactionsDetails", "http://jowayhealth.com/role/ScheduleofpayablesduetorelatedpartiesTable" ], "xbrltype": "domainItemType" }, "gtvi_JowayHealthIndustriesGroupIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "JowayHealthIndustriesGroupIncMember", "terseLabel": "Joway Health Industries Group Inc. [Member]" } } }, "localname": "JowayHealthIndustriesGroupIncMember", "nsuri": "http://jowayhealth.com/20210930", "presentation": [ "http://jowayhealth.com/role/ScheduleofcompanyanditssubsidiariesTable" ], "xbrltype": "domainItemType" }, "gtvi_JowayHealthsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "JowayHealthsMember", "terseLabel": "Joway Health's [Member]" } } }, "localname": "JowayHealthsMember", "nsuri": "http://jowayhealth.com/20210930", "presentation": [ "http://jowayhealth.com/role/ReceivablefromRelatedPartyDetails", "http://jowayhealth.com/role/SpecialDividendPayableDetails" ], "xbrltype": "domainItemType" }, "gtvi_JowayShengshiMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "JowayShengshiMember", "terseLabel": "Joway Shengshi [Member]" } } }, "localname": "JowayShengshiMember", "nsuri": "http://jowayhealth.com/20210930", "presentation": [ "http://jowayhealth.com/role/RelatedPartyTransactionsDetails", "http://jowayhealth.com/role/ScheduleofpayablesduetorelatedpartiesTable" ], "xbrltype": "domainItemType" }, "gtvi_JowayShengshiToJowayDecorationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Joway shengshi to joway decoration.", "label": "JowayShengshiToJowayDecorationMember", "terseLabel": "Joway Shengshi to Joway Decoration [Member]", "verboseLabel": "Joway Shengshi owned of Joway Decoration [Member]" } } }, "localname": "JowayShengshiToJowayDecorationMember", "nsuri": "http://jowayhealth.com/20210930", "presentation": [ "http://jowayhealth.com/role/OrganizationDetails" ], "xbrltype": "domainItemType" }, "gtvi_JowayShengshiToJowayTechnologyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Joway shengshi to joway technology.", "label": "JowayShengshiToJowayTechnologyMember", "terseLabel": "Joway Shengshi to Joway Technology [Member]", "verboseLabel": "Joway Shengshi owned of Joway Technology [Member]" } } }, "localname": "JowayShengshiToJowayTechnologyMember", "nsuri": "http://jowayhealth.com/20210930", "presentation": [ "http://jowayhealth.com/role/OrganizationDetails" ], "xbrltype": "domainItemType" }, "gtvi_JowayShengshiToShengtangTradingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Joway shengshi to shengtang trading.", "label": "JowayShengshiToShengtangTradingMember", "terseLabel": "Joway Shengshi To Shengtang Trading [Member]" } } }, "localname": "JowayShengshiToShengtangTradingMember", "nsuri": "http://jowayhealth.com/20210930", "presentation": [ "http://jowayhealth.com/role/OrganizationDetails" ], "xbrltype": "domainItemType" }, "gtvi_ListsOfCompanyAndItsSubsidiariesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lists of company and its subsidiaries.", "label": "ListsOfCompanyAndItsSubsidiariesTableTextBlock", "terseLabel": "Schedule of company and its subsidiaries" } } }, "localname": "ListsOfCompanyAndItsSubsidiariesTableTextBlock", "nsuri": "http://jowayhealth.com/20210930", "presentation": [ "http://jowayhealth.com/role/OrganizationTables" ], "xbrltype": "textBlockItemType" }, "gtvi_LossFromDisposalOfDiscontinuedComponentNetOfIncomeTax": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Loss from disposal of discontinued component, net of income tax.", "label": "LossFromDisposalOfDiscontinuedComponentNetOfIncomeTax", "terseLabel": "Loss from disposal of discontinued component, net of income tax" } } }, "localname": "LossFromDisposalOfDiscontinuedComponentNetOfIncomeTax", "nsuri": "http://jowayhealth.com/20210930", "presentation": [ "http://jowayhealth.com/role/ScheduleofreconciliationofthedeconsolidationTable" ], "xbrltype": "monetaryItemType" }, "gtvi_MergerAgreementDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Merger agreement, description.", "label": "MergerAgreementDescription", "terseLabel": "Merger agreement, description" } } }, "localname": "MergerAgreementDescription", "nsuri": "http://jowayhealth.com/20210930", "presentation": [ "http://jowayhealth.com/role/SpecialDividendPayableDetails" ], "xbrltype": "stringItemType" }, "gtvi_MergerAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "MergerAgreementMember", "terseLabel": "Merger Agreement [Member]" } } }, "localname": "MergerAgreementMember", "nsuri": "http://jowayhealth.com/20210930", "presentation": [ "http://jowayhealth.com/role/DeconsolidationDetails", "http://jowayhealth.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "gtvi_OrganizationDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization (Details) [Line Items]" } } }, "localname": "OrganizationDetailsLineItems", "nsuri": "http://jowayhealth.com/20210930", "presentation": [ "http://jowayhealth.com/role/OrganizationDetails" ], "xbrltype": "stringItemType" }, "gtvi_OrganizationDetailsScheduleofcompanyanditssubsidiariesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization (Details) - Schedule of company and its subsidiaries [Line Items]" } } }, "localname": "OrganizationDetailsScheduleofcompanyanditssubsidiariesLineItems", "nsuri": "http://jowayhealth.com/20210930", "presentation": [ "http://jowayhealth.com/role/ScheduleofcompanyanditssubsidiariesTable" ], "xbrltype": "stringItemType" }, "gtvi_OrganizationDetailsScheduleofcompanyanditssubsidiariesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization (Details) - Schedule of company and its subsidiaries [Table]" } } }, "localname": "OrganizationDetailsScheduleofcompanyanditssubsidiariesTable", "nsuri": "http://jowayhealth.com/20210930", "presentation": [ "http://jowayhealth.com/role/ScheduleofcompanyanditssubsidiariesTable" ], "xbrltype": "stringItemType" }, "gtvi_OrganizationDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization (Details) [Table]" } } }, "localname": "OrganizationDetailsTable", "nsuri": "http://jowayhealth.com/20210930", "presentation": [ "http://jowayhealth.com/role/OrganizationDetails" ], "xbrltype": "stringItemType" }, "gtvi_PercentageOfEffectiveOwnership": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of effective ownership.", "label": "PercentageOfEffectiveOwnership", "terseLabel": "Percentage of Effective Ownership" } } }, "localname": "PercentageOfEffectiveOwnership", "nsuri": "http://jowayhealth.com/20210930", "presentation": [ "http://jowayhealth.com/role/ScheduleofcompanyanditssubsidiariesTable" ], "xbrltype": "stringItemType" }, "gtvi_PercentageOfMajorityShareholder": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of majority shareholder.", "label": "PercentageOfMajorityShareholder", "terseLabel": "Percentage of majority shareholder" } } }, "localname": "PercentageOfMajorityShareholder", "nsuri": "http://jowayhealth.com/20210930", "presentation": [ "http://jowayhealth.com/role/DeconsolidationDetails" ], "xbrltype": "percentItemType" }, "gtvi_PercentageOfRightToPurchaseOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of right to purchase of shares.", "label": "PercentageOfRightToPurchaseOfShares", "terseLabel": "Percentage of right to purchase of shares" } } }, "localname": "PercentageOfRightToPurchaseOfShares", "nsuri": "http://jowayhealth.com/20210930", "presentation": [ "http://jowayhealth.com/role/OrganizationDetails" ], "xbrltype": "percentItemType" }, "gtvi_PercentageOfSharesHeldByShareholders": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of shares held by shareholders.", "label": "PercentageOfSharesHeldByShareholders", "terseLabel": "Percentage of shares held by shareholder" } } }, "localname": "PercentageOfSharesHeldByShareholders", "nsuri": "http://jowayhealth.com/20210930", "presentation": [ "http://jowayhealth.com/role/SpecialDividendPayableDetails" ], "xbrltype": "percentItemType" }, "gtvi_PercentageOfSharesTransferred": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of shares transferred.", "label": "PercentageOfSharesTransferred", "terseLabel": "Percentage of shares transferred" } } }, "localname": "PercentageOfSharesTransferred", "nsuri": "http://jowayhealth.com/20210930", "presentation": [ "http://jowayhealth.com/role/OrganizationDetails" ], "xbrltype": "percentItemType" }, "gtvi_PurchasePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchase price.", "label": "PurchasePrice", "terseLabel": "Purchase price" } } }, "localname": "PurchasePrice", "nsuri": "http://jowayhealth.com/20210930", "presentation": [ "http://jowayhealth.com/role/DeconsolidationDetails" ], "xbrltype": "perShareItemType" }, "gtvi_ReceivableFromDisposalOfSubsidiaries": { "auth_ref": [], "calculation": { "http://jowayhealth.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Receivable from disposal of subsidiaries.", "label": "ReceivableFromDisposalOfSubsidiaries", "terseLabel": "Receivable from disposal of subsidiaries" } } }, "localname": "ReceivableFromDisposalOfSubsidiaries", "nsuri": "http://jowayhealth.com/20210930", "presentation": [ "http://jowayhealth.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "gtvi_ReceivableFromRelatedPartyDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Receivable From Related Party Disclosure [Abstract]" } } }, "localname": "ReceivableFromRelatedPartyDisclosureAbstract", "nsuri": "http://jowayhealth.com/20210930", "xbrltype": "stringItemType" }, "gtvi_ReceivableFromRelatedPartyDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of receivable from related party.", "label": "ReceivableFromRelatedPartyDisclosureTextBlock", "terseLabel": "RECEIVABLE FROM RELATED PARTY" } } }, "localname": "ReceivableFromRelatedPartyDisclosureTextBlock", "nsuri": "http://jowayhealth.com/20210930", "presentation": [ "http://jowayhealth.com/role/ReceivablefromRelatedParty" ], "xbrltype": "textBlockItemType" }, "gtvi_ReceivablefromRelatedPartyDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Receivable from Related Party (Details) [Line Items]" } } }, "localname": "ReceivablefromRelatedPartyDetailsLineItems", "nsuri": "http://jowayhealth.com/20210930", "presentation": [ "http://jowayhealth.com/role/ReceivablefromRelatedPartyDetails" ], "xbrltype": "stringItemType" }, "gtvi_ReceivablefromRelatedPartyDetailsScheduleofreceivablefromrelatedpartyLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Receivable from Related Party (Details) - Schedule of receivable from related party [Line Items]" } } }, "localname": "ReceivablefromRelatedPartyDetailsScheduleofreceivablefromrelatedpartyLineItems", "nsuri": "http://jowayhealth.com/20210930", "presentation": [ "http://jowayhealth.com/role/ScheduleofreceivablefromrelatedpartyTable" ], "xbrltype": "stringItemType" }, "gtvi_ReceivablefromRelatedPartyDetailsScheduleofreceivablefromrelatedpartyTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Receivable from Related Party (Details) - Schedule of receivable from related party [Table]" } } }, "localname": "ReceivablefromRelatedPartyDetailsScheduleofreceivablefromrelatedpartyTable", "nsuri": "http://jowayhealth.com/20210930", "presentation": [ "http://jowayhealth.com/role/ScheduleofreceivablefromrelatedpartyTable" ], "xbrltype": "stringItemType" }, "gtvi_ReceivablefromRelatedPartyDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Receivable from Related Party (Details) [Table]" } } }, "localname": "ReceivablefromRelatedPartyDetailsTable", "nsuri": "http://jowayhealth.com/20210930", "presentation": [ "http://jowayhealth.com/role/ReceivablefromRelatedPartyDetails" ], "xbrltype": "stringItemType" }, "gtvi_ReclassificationPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ReclassificationPolicyTextBlock", "terseLabel": "Reclassification" } } }, "localname": "ReclassificationPolicyTextBlock", "nsuri": "http://jowayhealth.com/20210930", "presentation": [ "http://jowayhealth.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "gtvi_RelatedPartyLoanReleasedByJingheZhang": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Related party loan released by jinghe zhang.", "label": "RelatedPartyLoanReleasedByJingheZhang", "terseLabel": "Related party loan released by Jinghe Zhang" } } }, "localname": "RelatedPartyLoanReleasedByJingheZhang", "nsuri": "http://jowayhealth.com/20210930", "presentation": [ "http://jowayhealth.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "gtvi_RelatedPartyLoanReleasedByJowayShengshi": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Related party loan released by joway shengsh.", "label": "RelatedPartyLoanReleasedByJowayShengshi", "terseLabel": "Related party loan released by Joway Shengshi" } } }, "localname": "RelatedPartyLoanReleasedByJowayShengshi", "nsuri": "http://jowayhealth.com/20210930", "presentation": [ "http://jowayhealth.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "gtvi_RelatedPartyTransactionsDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions (Details) [Line Items]" } } }, "localname": "RelatedPartyTransactionsDetailsLineItems", "nsuri": "http://jowayhealth.com/20210930", "presentation": [ "http://jowayhealth.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "gtvi_RelatedPartyTransactionsDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions (Details) [Table]" } } }, "localname": "RelatedPartyTransactionsDetailsTable", "nsuri": "http://jowayhealth.com/20210930", "presentation": [ "http://jowayhealth.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "gtvi_RenminbiUnitedStatesDollarExchangeRateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Definition :Year ended renminbi united states dollar exchange rate.", "label": "RenminbiUnitedStatesDollarExchangeRateMember", "terseLabel": "Period ended RMB: USD Exchange rate [Member]" } } }, "localname": "RenminbiUnitedStatesDollarExchangeRateMember", "nsuri": "http://jowayhealth.com/20210930", "presentation": [ "http://jowayhealth.com/role/ScheduleofgainsandlossesfromforeigncurrencytransactionsTable" ], "xbrltype": "domainItemType" }, "gtvi_RightToPurchaseCallOptionPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Right to purchase call option percentage.", "label": "RightToPurchaseCallOptionPercentage", "terseLabel": "Right to purchase call option percentage" } } }, "localname": "RightToPurchaseCallOptionPercentage", "nsuri": "http://jowayhealth.com/20210930", "presentation": [ "http://jowayhealth.com/role/OrganizationDetails" ], "xbrltype": "percentItemType" }, "gtvi_ScheduleOfCompanyAndItsSubsidiariesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of company and its subsidiaries [Abstract]" } } }, "localname": "ScheduleOfCompanyAndItsSubsidiariesAbstract", "nsuri": "http://jowayhealth.com/20210930", "xbrltype": "stringItemType" }, "gtvi_ScheduleOfGainsAndLossesFromForeignCurrencyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of gains and losses from foreign currency transactions [Abstract]" } } }, "localname": "ScheduleOfGainsAndLossesFromForeignCurrencyTransactionsAbstract", "nsuri": "http://jowayhealth.com/20210930", "xbrltype": "stringItemType" }, "gtvi_ScheduleOfPayablesDueToRelatedPartiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of payables due to related parties [Abstract]" } } }, "localname": "ScheduleOfPayablesDueToRelatedPartiesAbstract", "nsuri": "http://jowayhealth.com/20210930", "xbrltype": "stringItemType" }, "gtvi_ScheduleOfReceivableFromRelatedPartyAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of receivable from related party [Abstract]" } } }, "localname": "ScheduleOfReceivableFromRelatedPartyAbstract", "nsuri": "http://jowayhealth.com/20210930", "xbrltype": "stringItemType" }, "gtvi_ScheduleOfReceivableFromRelatedPartyTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ScheduleOfReceivableFromRelatedPartyTableTextBlock", "terseLabel": "Schedule of receivable from related party" } } }, "localname": "ScheduleOfReceivableFromRelatedPartyTableTextBlock", "nsuri": "http://jowayhealth.com/20210930", "presentation": [ "http://jowayhealth.com/role/ReceivablefromRelatedPartyTables" ], "xbrltype": "textBlockItemType" }, "gtvi_ScheduleOfReconciliationOfTheDeconsolidationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of reconciliation of the deconsolidation [Abstract]" } } }, "localname": "ScheduleOfReconciliationOfTheDeconsolidationAbstract", "nsuri": "http://jowayhealth.com/20210930", "xbrltype": "stringItemType" }, "gtvi_ScheduleOfReconciliationOfTheDeconsolidationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ScheduleOfReconciliationOfTheDeconsolidationTableTextBlock", "terseLabel": "Schedule of reconciliation of the deconsolidation" } } }, "localname": "ScheduleOfReconciliationOfTheDeconsolidationTableTextBlock", "nsuri": "http://jowayhealth.com/20210930", "presentation": [ "http://jowayhealth.com/role/DeconsolidationTables" ], "xbrltype": "textBlockItemType" }, "gtvi_ShenyangJowayElectronicTechnologyCoLtdMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shenyang joway electronic technology co., ltd.", "label": "ShenyangJowayElectronicTechnologyCoLtdMember", "terseLabel": "Shenyang Joway Electronic Technology Co., Ltd. [Member]" } } }, "localname": "ShenyangJowayElectronicTechnologyCoLtdMember", "nsuri": "http://jowayhealth.com/20210930", "presentation": [ "http://jowayhealth.com/role/ScheduleofcompanyanditssubsidiariesTable" ], "xbrltype": "domainItemType" }, "gtvi_SpecialDividendPayableDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Special Dividend Payable (Details) [Line Items]" } } }, "localname": "SpecialDividendPayableDetailsLineItems", "nsuri": "http://jowayhealth.com/20210930", "presentation": [ "http://jowayhealth.com/role/SpecialDividendPayableDetails" ], "xbrltype": "stringItemType" }, "gtvi_SpecialDividendPayableDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Special Dividend Payable (Details) [Table]" } } }, "localname": "SpecialDividendPayableDetailsTable", "nsuri": "http://jowayhealth.com/20210930", "presentation": [ "http://jowayhealth.com/role/SpecialDividendPayableDetails" ], "xbrltype": "stringItemType" }, "gtvi_SummaryofSignificantAccountingPoliciesDetailsScheduleofgainsandlossesfromforeigncurrencytransactionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies (Details) - Schedule of gains and losses from foreign currency transactions [Line Items]" } } }, "localname": "SummaryofSignificantAccountingPoliciesDetailsScheduleofgainsandlossesfromforeigncurrencytransactionsLineItems", "nsuri": "http://jowayhealth.com/20210930", "presentation": [ "http://jowayhealth.com/role/ScheduleofgainsandlossesfromforeigncurrencytransactionsTable" ], "xbrltype": "stringItemType" }, "gtvi_SummaryofSignificantAccountingPoliciesDetailsScheduleofgainsandlossesfromforeigncurrencytransactionsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies (Details) - Schedule of gains and losses from foreign currency transactions [Table]" } } }, "localname": "SummaryofSignificantAccountingPoliciesDetailsScheduleofgainsandlossesfromforeigncurrencytransactionsTable", "nsuri": "http://jowayhealth.com/20210930", "presentation": [ "http://jowayhealth.com/role/ScheduleofgainsandlossesfromforeigncurrencytransactionsTable" ], "xbrltype": "stringItemType" }, "gtvi_TianjinJowayDecorationEngineeringCoLtdMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tianjin joway decoration engineering co., ltd.", "label": "TianjinJowayDecorationEngineeringCoLtdMember", "terseLabel": "Tianjin Joway Decoration Engineering Co., Ltd. [Member]" } } }, "localname": "TianjinJowayDecorationEngineeringCoLtdMember", "nsuri": "http://jowayhealth.com/20210930", "presentation": [ "http://jowayhealth.com/role/ScheduleofcompanyanditssubsidiariesTable" ], "xbrltype": "domainItemType" }, "gtvi_TianjinJowayShengshiGroupCoLtdMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tianjin joway shengshi group co., ltd.", "label": "TianjinJowayShengshiGroupCoLtdMember", "terseLabel": "Tianjin Joway Shengshi Group Co., Ltd. [Member]" } } }, "localname": "TianjinJowayShengshiGroupCoLtdMember", "nsuri": "http://jowayhealth.com/20210930", "presentation": [ "http://jowayhealth.com/role/OrganizationDetails", "http://jowayhealth.com/role/ScheduleofcompanyanditssubsidiariesTable" ], "xbrltype": "domainItemType" }, "gtvi_TianjinJunheManagementConsultingCoLtdMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tianjin junhe management consulting co., ltd.", "label": "TianjinJunheManagementConsultingCoLtdMember", "terseLabel": "Tianjin Junhe Management Consulting Co., Ltd. [Member]" } } }, "localname": "TianjinJunheManagementConsultingCoLtdMember", "nsuri": "http://jowayhealth.com/20210930", "presentation": [ "http://jowayhealth.com/role/ScheduleofcompanyanditssubsidiariesTable" ], "xbrltype": "domainItemType" }, "gtvi_TianjinOrientalShengtangImportAndExportTradingCoLtdMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tianjin oriental shengtang import and export trading co., ltd.", "label": "TianjinOrientalShengtangImportAndExportTradingCoLtdMember", "terseLabel": "Tianjin Oriental Shengtang Import & Export Trading Co., Ltd. [Member]" } } }, "localname": "TianjinOrientalShengtangImportAndExportTradingCoLtdMember", "nsuri": "http://jowayhealth.com/20210930", "presentation": [ "http://jowayhealth.com/role/ScheduleofcompanyanditssubsidiariesTable" ], "xbrltype": "domainItemType" }, "gtvi_TransactionOfLossValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Transaction of loss value.", "label": "TransactionOfLossValue", "terseLabel": "Transaction of loss value" } } }, "localname": "TransactionOfLossValue", "nsuri": "http://jowayhealth.com/20210930", "presentation": [ "http://jowayhealth.com/role/DeconsolidationDetails" ], "xbrltype": "monetaryItemType" }, "gtvi_TypeOfAgreementAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "TypeOfAgreementAxis", "terseLabel": "Type of Agreement [Axis]" } } }, "localname": "TypeOfAgreementAxis", "nsuri": "http://jowayhealth.com/20210930", "presentation": [ "http://jowayhealth.com/role/DeconsolidationDetails", "http://jowayhealth.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "gtvi_TypeOfAgreementDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "TypeOfAgreement [Domain]" } } }, "localname": "TypeOfAgreementDomain", "nsuri": "http://jowayhealth.com/20210930", "presentation": [ "http://jowayhealth.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "gtvi_UnpaidPrincipleAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Unpaid principle amount.", "label": "UnpaidPrincipleAmount", "terseLabel": "Unpaid principle amount" } } }, "localname": "UnpaidPrincipleAmount", "nsuri": "http://jowayhealth.com/20210930", "presentation": [ "http://jowayhealth.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "gtvi_UnpaidPrincipleAmountAdvance": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Unpaid principle amount advance", "label": "UnpaidPrincipleAmountAdvance", "terseLabel": "Unpaid principle amount advance" } } }, "localname": "UnpaidPrincipleAmountAdvance", "nsuri": "http://jowayhealth.com/20210930", "presentation": [ "http://jowayhealth.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r27", "r175" ], "calculation": { "http://jowayhealth.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Special dividend payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r21", "r128", "r175" ], "calculation": { "http://jowayhealth.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in-capital", "verboseLabel": "Paid in Capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedBalanceSheet", "http://jowayhealth.com/role/ScheduleofcompanyanditssubsidiariesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r62", "r90", "r93", "r98", "r105", "r110", "r111", "r112", "r114", "r115", "r116", "r117", "r118", "r119", "r121", "r122", "r148", "r153", "r159", "r173", "r175", "r190", "r200" ], "calculation": { "http://jowayhealth.com/role/ConsolidatedBalanceSheet": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r15", "r16", "r31", "r62", "r105", "r110", "r111", "r112", "r114", "r115", "r116", "r117", "r118", "r119", "r121", "r122", "r148", "r153", "r159", "r173", "r175" ], "calculation": { "http://jowayhealth.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "CURRENT ASSETS:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent": { "auth_ref": [ "r0", "r1", "r8", "r9", "r11", "r107", "r108" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Assets, Current", "terseLabel": "Current assets" } } }, "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ScheduleofreconciliationofthedeconsolidationTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r14", "r26", "r56" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "periodEndLabel": "CASH, end of period", "periodStartLabel": "CASH, beginning of period" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r50", "r160" ], "calculation": { "http://jowayhealth.com/role/ConsolidatedCashFlow": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "NET INCREASE IN CASH" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]", "terseLabel": "NON-CASH TRANSACTIONS OF INVESTING AND FINANCING ACTIVITIES" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_CashIncludingDiscontinuedOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash, Including Discontinued Operations [Abstract]", "terseLabel": "Discontinued operations:" } } }, "localname": "CashIncludingDiscontinuedOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "stringItemType" }, "us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations": { "auth_ref": [ "r50" ], "calculation": { "http://jowayhealth.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) of financing activities of discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Cash Provided by (Used in) Financing Activities, Discontinued Operations", "terseLabel": "Net cash provided by financing activities from discontinued component" } } }, "localname": "CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations": { "auth_ref": [ "r7", "r50" ], "calculation": { "http://jowayhealth.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Cash Provided by (Used in) Operating Activities, Discontinued Operations", "terseLabel": "Net cash used in operating activities from discontinued component" } } }, "localname": "CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r125" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "terseLabel": "Exercise price per share (in Dollars per share)" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/OrganizationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r30", "r109", "r194", "r203" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "COMMITMENTS" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommonStockOtherSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Total number of shares of other common stock instruments held by shareholders, such as exchangeable shares. May be all or portion of the number of common shares authorized.", "label": "Common Stock, Other Shares, Outstanding", "netLabel": "Common stock, shares outstanding (in Shares)", "terseLabel": "Common stock shares (in Shares)", "verboseLabel": "Common stock, shares outstanding" } } }, "localname": "CommonStockOtherSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/OrganizationDetails", "http://jowayhealth.com/role/RelatedPartyTransactionsDetails", "http://jowayhealth.com/role/SpecialDividendPayableDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r20" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in Dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r20" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r20" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r20", "r124" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding", "verboseLabel": "Common stock outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://jowayhealth.com/role/DeconsolidationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r20", "r175" ], "calculation": { "http://jowayhealth.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock - par value $0.001; 200,000,000 shares authorized; 20,054,000 shares issued and outstanding at September 30, 2021 and December 31, 2020" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r34", "r36", "r37", "r43", "r197", "r208" ], "calculation": { "http://jowayhealth.com/role/ConsolidatedIncomeStatement": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "COMPREHENSIVE LOSS" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]", "terseLabel": "OTHER COMPREHENSIVE LOSS:" } } }, "localname": "ComprehensiveIncomeNetOfTaxAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for comprehensive income.", "label": "Comprehensive Income, Policy [Policy Text Block]", "terseLabel": "Other Comprehensive Income" } } }, "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r81", "r199" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Concentrations of Credit Risk" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r59", "r150" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Basis of Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r46", "r176" ], "calculation": { "http://jowayhealth.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "COST OF REVENUES" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfRestrictionsOnDividendsLoansAndAdvancesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure of Restrictions on Dividends, Loans and Advances Disclosure [Abstract]" } } }, "localname": "DisclosureOfRestrictionsOnDividendsLoansAndAdvancesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents": { "auth_ref": [ "r0", "r1", "r8", "r108" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as cash and cash equivalents attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents", "terseLabel": "Cash" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ScheduleofreconciliationofthedeconsolidationTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent": { "auth_ref": [ "r0", "r1", "r8", "r106", "r108" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Intangible Assets, Noncurrent", "terseLabel": "Intangible assets" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ScheduleofreconciliationofthedeconsolidationTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendPaymentsRestrictionsScheduleStatutoryCapitalAndSurplus1": { "auth_ref": [ "r213" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of statutory capital and surplus computed using prescribed or permitted statutory accounting practice.", "label": "Dividend Payments Restrictions Schedule, Statutory Capital and Surplus", "terseLabel": "Dividend payables" } } }, "localname": "DividendPaymentsRestrictionsScheduleStatutoryCapitalAndSurplus1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/SpecialDividendPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueFromRelatedParties": { "auth_ref": [ "r65", "r113", "r115", "r116", "r120", "r121", "r122", "r168", "r192", "r205" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "For an unclassified balance sheet, amounts due from related parties including affiliates, employees, joint ventures, officers and stockholders, immediate families thereof, and pension funds.", "label": "Due from Related Parties", "terseLabel": "Due from related party" } } }, "localname": "DueFromRelatedParties", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ReceivablefromRelatedPartyDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueToEmployeesCurrentAndNoncurrent": { "auth_ref": [ "r168", "r193", "r204" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amounts due to employees, not to include stockholders or officers.", "label": "Due to Employees", "terseLabel": "Unpaid principal balance in advance" } } }, "localname": "DueToEmployeesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueToRelatedPartiesCurrent": { "auth_ref": [ "r27", "r65", "r113", "r115", "r116", "r120", "r121", "r122", "r168" ], "calculation": { "http://jowayhealth.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).", "label": "Due to Related Parties, Current", "netLabel": "Total", "terseLabel": "Due to related parties", "verboseLabel": "Due from related party" } } }, "localname": "DueToRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedBalanceSheet", "http://jowayhealth.com/role/ScheduleofpayablesduetorelatedpartiesTable", "http://jowayhealth.com/role/ScheduleofreceivablefromrelatedpartyTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareBasicAndDiluted": { "auth_ref": [ "r75" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Basic and Diluted", "terseLabel": "Discontinued operations - Basic & diluted (in Dollars per share)" } } }, "localname": "EarningsPerShareBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAndDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic and Diluted [Abstract]", "terseLabel": "LOSS PER COMMON SHARE, BASIC AND DILUTED:" } } }, "localname": "EarningsPerShareBasicAndDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r77", "r78" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Basic and Diluted Earnings per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents": { "auth_ref": [ "r160" ], "calculation": { "http://jowayhealth.com/role/ConsolidatedCashFlow": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.", "label": "Effect of Exchange Rate on Cash and Cash Equivalents", "terseLabel": "EFFECT OF EXCHANGE RATE CHANGES ON CASH" } } }, "localname": "EffectOfExchangeRateOnCashAndCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A description of the principal activities of an investee accounted for under the equity method.", "label": "Equity Method Investment, Description of Principal Activities", "terseLabel": "Principal Activities" } } }, "localname": "EquityMethodInvestmentDescriptionOfPrincipalActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ScheduleofcompanyanditssubsidiariesTable" ], "xbrltype": "stringItemType" }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "auth_ref": [ "r104" ], "lang": { "en-us": { "role": { "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.", "label": "Equity Method Investment, Ownership Percentage", "terseLabel": "Ownership percentage", "verboseLabel": "Equity interest" } } }, "localname": "EquityMethodInvestmentOwnershipPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/OrganizationDetails", "http://jowayhealth.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ExcessStockSharesIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of excess stock shares of an entity that have been sold or granted to shareholders.", "label": "Excess Stock, Shares Issued", "terseLabel": "Shares available to shareholders" } } }, "localname": "ExcessStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/SpecialDividendPayableDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r157", "r158" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "terseLabel": "Fair Value of Financial Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_ForeignCurrencyExchangeRateTranslation1": { "auth_ref": [ "r162", "r163" ], "lang": { "en-us": { "role": { "documentation": "Foreign exchange rate used to translate amounts denominated in functional currency to reporting currency.", "label": "Foreign Currency Exchange Rate, Translation", "terseLabel": "Gains and losses from foreign currency transactions" } } }, "localname": "ForeignCurrencyExchangeRateTranslation1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ScheduleofgainsandlossesfromforeigncurrencytransactionsTable" ], "xbrltype": "pureItemType" }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "auth_ref": [ "r164" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "terseLabel": "Foreign Currency Translation" } } }, "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges": { "auth_ref": [ "r54" ], "calculation": { "http://jowayhealth.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) from the difference between the sale price or salvage price and the book value of an asset that was sold or retired, and gain (loss) from the write down of assets from their carrying value to fair value.", "label": "Gain (Loss) on Sale of Assets and Asset Impairment Charges", "negatedLabel": "General and administrative expenses" } } }, "localname": "GainLossOnSalesOfAssetsAndAssetImpairmentCharges", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r44", "r62", "r90", "r92", "r94", "r97", "r99", "r105", "r110", "r111", "r112", "r115", "r116", "r117", "r118", "r119", "r121", "r122", "r159" ], "calculation": { "http://jowayhealth.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "GROSS PROFIT" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperations": { "auth_ref": [ "r45", "r55", "r68", "r69", "r70", "r71", "r74", "r76", "r146" ], "calculation": { "http://jowayhealth.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 }, "http://jowayhealth.com/role/ConsolidatedIncomeStatement": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent.", "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent", "terseLabel": "Net loss from continuing operations", "totalLabel": "NET LOSS FROM CONTINUING OPERATIONS" } } }, "localname": "IncomeLossFromContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedCashFlow", "http://jowayhealth.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r41", "r90", "r92", "r94", "r97", "r99", "r189", "r195", "r198", "r209" ], "calculation": { "http://jowayhealth.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "LOSS BEFORE INCOME TAXES" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) from continuing operations per each basic and diluted share of common stock or unit when the per share amount is the same for both basic and diluted shares.", "label": "Income (Loss) from Continuing Operations, Per Basic and Diluted Share", "terseLabel": "Continuing operations - Basic & diluted (in Dollars per share)" } } }, "localname": "IncomeLossFromContinuingOperationsPerBasicAndDilutedShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "perShareItemType" }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax": { "auth_ref": [ "r2", "r3", "r4", "r5", "r6", "r10", "r11", "r142", "r206" ], "calculation": { "http://jowayhealth.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.", "label": "Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Loss from operations of discontinued component, net of taxes" } } }, "localname": "IncomeLossFromDiscontinuedOperationsNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r63", "r132", "r133", "r136", "r138", "r140", "r143", "r144", "r145" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "INCOME TAXES" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r64", "r72", "r73", "r89", "r131", "r139", "r141", "r210" ], "calculation": { "http://jowayhealth.com/role/ConsolidatedIncomeStatement": { "order": 3.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "INCOME TAXES" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r38", "r129", "r130", "r133", "r134", "r135", "r137" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxesPaid": { "auth_ref": [ "r52", "r57" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.", "label": "Income Taxes Paid", "terseLabel": "Income taxes paid" } } }, "localname": "IncomeTaxesPaid", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_IntercompanyForeignCurrencyBalanceByDescriptionAxis": { "auth_ref": [ "r161" ], "lang": { "en-us": { "role": { "documentation": "Information by name or description of the entity to which the long-term intercompany foreign balances of the entity relate.", "label": "Intercompany Foreign Currency Balance by Description [Axis]" } } }, "localname": "IntercompanyForeignCurrencyBalanceByDescriptionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ScheduleofgainsandlossesfromforeigncurrencytransactionsTable" ], "xbrltype": "stringItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r49", "r51", "r57" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Interest paid" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r25", "r62", "r105", "r159", "r175", "r191", "r202" ], "calculation": { "http://jowayhealth.com/role/ConsolidatedBalanceSheet": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r29", "r62", "r105", "r110", "r111", "r112", "r115", "r116", "r117", "r118", "r119", "r121", "r122", "r149", "r153", "r154", "r159", "r173", "r174", "r175" ], "calculation": { "http://jowayhealth.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "CURRENT LIABILITIES:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation": { "auth_ref": [ "r0", "r1", "r8", "r9", "r11", "r108" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Liabilities", "negatedLabel": "Liabilities" } } }, "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ScheduleofreconciliationofthedeconsolidationTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r50" ], "calculation": { "http://jowayhealth.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations": { "auth_ref": [ "r50" ], "calculation": { "http://jowayhealth.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r50", "r53", "r55" ], "calculation": { "http://jowayhealth.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations": { "auth_ref": [ "r50", "r53", "r55" ], "calculation": { "http://jowayhealth.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r11", "r33", "r35", "r39", "r42", "r55", "r62", "r67", "r68", "r69", "r70", "r71", "r72", "r73", "r74", "r90", "r92", "r94", "r97", "r99", "r105", "r110", "r111", "r112", "r115", "r116", "r117", "r118", "r119", "r121", "r122", "r156", "r159", "r196", "r207" ], "calculation": { "http://jowayhealth.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "totalLabel": "NET LOSS" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently Issued Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r47" ], "calculation": { "http://jowayhealth.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "OTHER LOSS, NET" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://jowayhealth.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "OPERATING EXPENSES" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r90", "r92", "r94", "r97", "r99" ], "calculation": { "http://jowayhealth.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "LOSS FROM OPERATIONS" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r13", "r155" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "ORGANIZATION" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/Organization" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "auth_ref": [ "r32" ], "calculation": { "http://jowayhealth.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "terseLabel": "Foreign currency translation adjustments" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r17", "r18", "r28", "r175" ], "calculation": { "http://jowayhealth.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Current", "terseLabel": "Other payables" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingExpense": { "auth_ref": [ "r48" ], "calculation": { "http://jowayhealth.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense related to nonoperating activities, classified as other.", "label": "Other Nonoperating Expense", "negatedLabel": "Other expenses" } } }, "localname": "OtherNonoperatingExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherReceivablesNetCurrent": { "auth_ref": [], "calculation": { "http://jowayhealth.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.", "label": "Other Receivables, Net, Current", "terseLabel": "Receivable from related party" } } }, "localname": "OtherReceivablesNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r19", "r123" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (in Dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r19", "r123" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r19", "r175" ], "calculation": { "http://jowayhealth.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock - par value $0.001; 1,000,000 shares authorized; no shares issued and outstanding" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt": { "auth_ref": [], "calculation": { "http://jowayhealth.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from long-term debt by a related party. Related parties, include, but are not limited to, affiliates, owners or officers and their immediate families, and pension trusts.", "label": "Proceeds from (Repayments of) Related Party Debt", "terseLabel": "Due to related parties" } } }, "localname": "ProceedsFromRepaymentsOfRelatedPartyDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r127", "r167", "r168" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/OrganizationDetails", "http://jowayhealth.com/role/ScheduleofpayablesduetorelatedpartiesTable", "http://jowayhealth.com/role/SpecialDividendPayableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r127", "r167", "r168", "r170" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r127" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party.", "label": "Related Party Transaction [Domain]" } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ScheduleofpayablesduetorelatedpartiesTable" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r127", "r167", "r170", "r177", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/OrganizationDetails", "http://jowayhealth.com/role/ReceivablefromRelatedPartyDetails", "http://jowayhealth.com/role/ScheduleofpayablesduetorelatedpartiesTable", "http://jowayhealth.com/role/ScheduleofreceivablefromrelatedpartyTable", "http://jowayhealth.com/role/SpecialDividendPayableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r165", "r166", "r168", "r171", "r172" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "RELATED PARTY TRANSACTIONS" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r22", "r126", "r128", "r175", "r201", "r211", "r212" ], "calculation": { "http://jowayhealth.com/role/ConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r60", "r61" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "label": "Revenue [Policy Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r40", "r62", "r87", "r88", "r91", "r95", "r96", "r100", "r101", "r102", "r105", "r110", "r111", "r112", "r115", "r116", "r117", "r118", "r119", "r121", "r122", "r159", "r198" ], "calculation": { "http://jowayhealth.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "terseLabel": "REVENUES" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockDescriptionOfTransaction": { "auth_ref": [ "r147", "r151", "r152" ], "lang": { "en-us": { "role": { "documentation": "Description of stock transaction which may include details of the offering (IPO, private placement), a description of the stock sold, percentage of subsidiary's or equity investee's stock sold, a description of the investors and whether the stock was issued in a business combination.", "label": "Sale of Stock, Description of Transaction", "terseLabel": "Sale of stock, description" } } }, "localname": "SaleOfStockDescriptionOfTransaction", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDividendPaymentRestrictionsTextBlock": { "auth_ref": [ "r214" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of statutory restrictions on the payment of dividends as prescribed by the National Association of Insurance Commissioners or state regulatory authorities.", "label": "Dividend Payment Restrictions [Text Block]", "terseLabel": "SPECIAL DIVIDEND PAYABLE" } } }, "localname": "ScheduleOfDividendPaymentRestrictionsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/SpecialDividendPayable" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r169", "r170" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ScheduleofpayablesduetorelatedpartiesTable" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.", "label": "Schedule of Related Party Transactions [Table Text Block]", "terseLabel": "Schedule of payables due to related parties" } } }, "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/RelatedPartyTransactionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r58", "r66" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/SummaryofSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.", "label": "Stock Issued During Period, Shares, Purchase of Assets", "terseLabel": "Shares on hold" } } }, "localname": "StockIssuedDuringPeriodSharesPurchaseOfAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ReceivablefromRelatedPartyDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r20", "r23", "r24", "r62", "r103", "r105", "r159", "r175" ], "calculation": { "http://jowayhealth.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "totalLabel": "Total stockholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "STOCKHOLDERS' EQUITY:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.", "label": "Substantial Doubt about Going Concern [Text Block]", "terseLabel": "GOING CONCERN" } } }, "localname": "SubstantialDoubtAboutGoingConcernTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/GoingConcern" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "SUPPLEMENTAL DISCLOSURES:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_TemporaryEquityForeignCurrencyTranslationAdjustments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Adjustments to temporary equity resulting from foreign currency translation adjustments.", "label": "Temporary Equity, Foreign Currency Translation Adjustments", "terseLabel": "Foreign currency translation adjustments" } } }, "localname": "TemporaryEquityForeignCurrencyTranslationAdjustments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r79", "r80", "r82", "r83", "r84", "r85", "r86" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_WarrantExercisePriceDecrease": { "auth_ref": [ "r125" ], "lang": { "en-us": { "role": { "documentation": "Per share decrease in exercise price of warrant. Excludes change due to standard antidilution provision.", "label": "Warrant, Exercise Price, Decrease", "terseLabel": "Exercise price (in Dollars per share)" } } }, "localname": "WarrantExercisePriceDecrease", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/OrganizationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).", "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted", "terseLabel": "WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING, BASIC AND DILUTED (in Shares)" } } }, "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "sharesItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2510-110228" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2473-110228" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r12": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "40", "Topic": "205", "URI": "http://asc.fasb.org/subtopic&trid=51888271" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318" }, "r13": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=109227538&loc=d3e44648-109337" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r145": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4613673-111683" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569655-111683" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4582445-111684" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r155": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6897108&loc=SL6897125-166521" }, "r164": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "830", "URI": "http://asc.fasb.org/topic&trid=2175825" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r172": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.10(3))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e957-107759" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.17)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.3)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6486098&loc=d3e24708-158529" }, "r214": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "505", "Topic": "944", "URI": "http://asc.fasb.org/subtopic&trid=4738323" }, "r215": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r216": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r217": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r218": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r219": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721523-107759" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "3B", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.13)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1012-107759" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r66": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" } }, "version": "2.1" } ZIP 50 0001213900-21-057191-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-21-057191-xbrl.zip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